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Abstract




Synthetic oligonucleotides and peptides have found wide applications in

industry and academic research labs. There are ~60 peptide drugs on the market and
over 500 under development. The global annual sale of peptide drugs in 2010 was
estimated to be $13 billion. There are three oligonucleotide-based drugs on market;
among them, the FDA newly approved Kynamro was predicted to have a $100
million annual sale. The annual sale of oligonucleotides to academic labs was
estimated to be $700 million. Both bio-oligomers are mostly synthesized on
automated synthesizers using solid phase synthesis technology, in which nucleoside
or amino acid monomers are added sequentially until the desired full-length sequence
is reached. The additions cannot be complete, which generates truncated undesired
failure sequences. For almost all applications, these impurities must be removed. The
most widely used method is HPLC. However, the method is slow, expensive, laborintensive, not amendable for automation, difficult to scale up, and unsuitable for high
throughput purification. It needs large capital investment, and consumes large
volumes of harmful solvents. The purification costs are estimated to be more than
50% of total production costs. Other methods for bio-oligomer purification also have
drawbacks, and are less favored than HPLC for most applications.
To overcome the problems of known biopolymer purification technologies,
we have developed two non-chromatographic purification methods. They are (1)
catching failure sequences by polymerization, and (2) catching full-length sequences



by polymerization. In the first method, a polymerizable group is attached to the
failure sequences of the bio-oligomers during automated synthesis; purification is
achieved by simply polymerizing the failure sequences into an insoluble gel and
extracting full-length sequences. In the second method, a polymerizable group is
attached to the full-length sequences, which are then incorporated into a polymer;
impurities are removed by washing, and pure product is cleaved from polymer. These
methods do not need chromatography, and all drawbacks of HPLC no longer exist.
Using them, purification is achieved by simple manipulations such as shaking and
extraction. Therefore, they are suitable for large scale purification of oligonucleotide
and peptide drugs, and also ideal for high throughput purification, which currently has
a high demand for research projects involving total gene synthesis.
The dissertation will present the details about the development of the
techniques. Chapter 1 will make an introduction to oligodeoxynucleotides (ODNs),
their synthesis and purification. Chapter 2 will describe the detailed studies of using
the catching failure sequences by polymerization method to purify ODNs. Chapter 3
will describe the further optimization of the catching failure sequences by
polymerization ODN purification technology to the level of practical use. Chapter 4
will present using the catching full-length sequence by polymerization method for
ODN purification using acid-cleavable linker. Chapter 5 will make an introduction to
peptides, their synthesis and purification. Chapter 6 will describe the studies using the
catching full-length sequence by polymerization method for peptide purification.




Chapter 1
Introduction to Oligodeoxynucleotides Purification


1.1 Oligodeoxynucleotides (ODNs)


Oligodeoxynucleotides

(ODNs)

1.1

are

short

single-stranded

deoxyribonucleic acid or DNA. They are comprised of four nucleosides
deoxyadenosine (dA), thymidine (dT), deoxycytidine (dC), and deoxyguanosine (dG).
Each nucleoside is comprised of a 2 -deoxyribose sugar and nucleobase such as
adenine, thymine, cytosine and guanine. The nucleosides with phosphate group are
known as nucleotides. Multiple nucleosides linked together by phosphate diester
linkages form ODN. Usually, ODN refers to deoxyribonucleic acids with lengths of
15 to 200 nucleotide units.



Figure 1.1. Structure of ODN



1.2 Applications of ODN


Synthetic ODNs encompass a wide range of applications in the area of
genomics, medical diagnosis, forensic science and nanotechnology.[1] Recently,
synthetic ODNs have been booming in therapeutics and antisense therapy.[2] The
antisense therapy is based on specific binding of ODN sequences on specific gene
sequence and is used to treat diseases caused by genetic disorders.[3] Currently, three
oligonucleotide based drugs are on the market. Kynamro is the newly approved drug
by FDA which was predicted to have a $100 million annual sale[4]. In academic lab,
the annual sale of oligonucleotide is $700 million [5]. More than 60 drugs based on
oligonucleotide are in various stages of preclinical and clinical testing for treating
diseases such as cancer, viral infection and diabetes. In addition synthetic ODNs have
been widely used as primers for DNA sequencing and polymerase chain reaction
(PCR).[6]
1.3 Synthesis


The most widely used method for ODN synthesis is the phosphoramidite
chemistry. Usually, the synthesis is carried out on a solid support. During synthesis
the first nucleoside is pre-anchored to the support, and nucleoside phosphoramidite
monomers are added sequentially one at a time. Each addition requires four steps,[7]
which is called a synthetic cycle. The four steps are detritylation, coupling, capping
and oxidation. At the end of synthesis, the ODNs are cleaved from the solid support




and fully deprotected. The following paragraphs give detailed description of the four
steps and the most widely used conditions for cleavage and deprotection.
1.3.1 Detritylation
This is the first step of ODN synthesis cycle. As shown in scheme 1.1, it
converts 1.2 to 1.3. The 5 -OH group of nucleoside phosphoramidite is protected with
the 4,4 -dimethoxytrityl (DMTr) group. Thus the growing chain of ODN contains
DMTr group at the 5 end. This group needs to be removed in each cycle before the
coupling step. This group is acid labile and is usually removed by 3% trichloroacetic
acid in dichloromethane. Once the DMTr group is removed, 5 -OH group 1.3 is
generated and the solid support is ready for the coupling step in the cycle.






Scheme 1.1. Oligodeoxynucleotide synthesis cycle using phosphoramidite chemistry




1.3.2 Coupling
After detritylation, the next step is coupling in which 1.3 reacts with
phosphoramidite monomer 1.4 to give 1.5 (Scheme 1.1). The nucleoside
phosphoramidite 1.4 and activator 1H-tetrazole or 4,5-dicyanoimidazole are delivered
to the synthesis column, which contains the solid support. The activator protonates
the diisopropylamino group of nucleoside phosphoramidite making it a better leaving
group. The free 5 -OH group readily displaces the leaving group and the phosphite
triester 1.5 is generated.
1.3.3 Capping
After coupling, the next step is capping. The coupling step cannot be 100%
complete. Some nucleosides with free 5 -OH group (1.6) will remain unreacted. If
they are not blocked right after coupling, they will continue to elongate in the next
synthetic cycles giving what is called deletion sequences. Deletion sequences are very
difficult to remove during purification. As a result, these 5 -OH groups are capped
with large excess of acetic anhydride to give the failure sequences 1.7.
1.3.4 Oxidation
After capping, an oxidation step is executed. The newly formed triester
linkage in 1.5 in the coupling step is unstable under next detritylation conditions,
which is acidic. It must be converted to the stable phosphate triester 1.8. The step is
achieved by treating with iodine in water in the presence of pyridine. After oxidation,
the cycle is completed, and this finishes addition of one nucleoside phosphoramidite



monomer, and the ODN grows one nucleotide longer. The synthesizer repeats the
cycles until the desire ODN length is reached.
1.3.5 Cleavage
In phosphoramidite chemistry, the succinyl linker connects 3 end of ODN to
the solid support. This linker is stable to all the reagents used during solid phase
synthesis. As the desired length of ODN is reached, the linker is usually cleaved with
concentrated ammonium hydroxide solution at room temperature. The cleavage
reaction can be carried out either on the synthesizer automatically or off the
synthesizer manually.
1.3.6 Deprotection
The exocyclic amino groups on the heterocyclic bases (A, C, and G) are
nucleophilic and should be protected thoughout the ODN synthesis. The most
commonly used protecting groups for A and C are benzoyl and for G isobutyryl.
These protecting groups can be removed with concentrated ammonium hydroxide
solution at 55 #C for 15 hours. In some cases, the Ultramild protecting groups are
used and are attached to the monomers. The Ultramild protecting group for A, C and
G are phenoxyacetyl, acetyl

and isopropyl phenoxyacetyl, respectively. These

protecting groups can be readily removed by concentrated ammonium hydroxide
solution at room temperature in 2 hours.
During synthesis, the phosphate groups are also protected. The mostly used
group is the 2-cyanoethyl group. The protecting groups are usually easy to remove.



They usually fall off during cleavage via a -elimination mechanism caused by a base
such as ammonia.
1.4 Impurities


The ODNs cleaved from the synthesizer and full deprotected contain
impurities. They must be removed before most applications. The impurities are
classified into three different types.
The first type is called truncated failure sequences. They are generated in each
synthetic cycle due to incomplete coupling of nucleoside phosphoramidite monomer.
The amount of failure sequences in crude ODN depends on the sequence, scale, and
length of ODNs. For example, in a normal 20-mer ODN synthesis, failure sequences
constitute 30-60% ODN content.[8] The failure sequences have similar physical
properties as the full-length ODN which make them difficult to be separated.
The second type of impurities is small organic molecules from the protecting
groups. These molecules are neutral. They are easy to remove from the negatively
charged full-length sequences. These small molecules are soluble in ethanol or nbutanol while the full-length ODNs are insoluble. Simple precipitation can remove
these small organic molecules.
The third types of impurities are deletion sequences, addition sequences and
sequences resulted from depurination. Deletion sequences are resulted from
incomplete capping and incomplete de-tritylation. Addition sequences are resulted
from premature de-tritylation. The deletion and addition sequences are very difficult



to remove. They should be minimized by careful tuning synthesis conditions. Based
on the above analysis, the major task of ODN purification is the removal of failure
sequences.
1.5 Current Purification Methods


Currently there are several known methods to purify ODN. They include
reversed-phase (RP) high performance liquid chromatography (HPLC), anionexchange HPLC, gel electrophoresis, fluorous affinity purification, RP cartridge
chromatography and biotin-avidin based affinity purification. The following
paragraphs describe the principle, advantages and disadvantages of these methods.
1.5.1 RP HPLC
The principle of this method is based on the hydrophobic interaction between
ODN and stationary phase. The stationary phase contains long hydrophobic chain.
More hydrophobic ODNs interact with the stationary phase more strongly and elute
slowly while less hydrophobic impurities move faster. The ODNs with fluorescent
dyes and DMTr groups are more hydrophobic which makes the purification easier.[6]
This method is very efficient and is most widely used in industrial processes. It can
separate ODNs of similar size on the basis of hydrophobicity. However, the ODNs
which form stable secondary structure is difficult to separate by RP HPLC because
the ODN elutes as a broad peak or multiple peaks. In addition the method needs
expensive instruments and columns. It also requires large volume of solvents and is

!


highly labor-demanding.[9] As a result, RP HPLC is difficult to scale up, and is
expensive for large-scale ODN purification.
1.5.2 Anion-Exchange HPLC
In anion-exchange HPLC, the stationary phase contains positively charged
functional groups. The mobile phase is usually 25 mM Tris/Cl, 1 mM EDTA and 25
mM Tris/Cl 1 mM EDTA, 1.0 M NaCl. ODN is negatively charged. It has rich
interaction with the stationary phase. The interactions are different for different ODN
sequences. As a result, they are eluted by the mobile phase with different rate.
Although this method can purify short ODN with good resolution, it needs expensive
instruments, column and large volume of solvents. It is also labor intensive. The
purified ODN needs further desalting because the eluent contains non-vaporizable
salts.
1.5.2 Gel-Electrophoresis
In gel-electrophoresis, an electrical field is applied across a gel. The ODN is
loaded at one side of the gel. Because ODN is negatively charged, it travels from high
potential end of the electrical field to the low potential end. Different ODNs have
different mass to charge ratios, and they travel with different speeds. As a result, they
are separated in the process. This method can produce ODN in high levels of purity
but is only suitable for very small scale purification.[6] It cannot be scaled up for
large scale purifications.

"


1.5.3 Fluorous Affinity Purification
During ODN synthesis, the full-length sequences are tagged with a molecule
containing multiple fluorine atoms. The failure sequences are not tagged. During
purification, the crude ODN solution is passed through a column containing
fluorinated stationary phase. Due to the strong attraction forces between fluorinated
molecules on the full-length sequences and the stationary phase, the full-length
sequences have a much longer retention time than the failure ones.[8] As a result, the
full-length sequences are easily separated from failure ones and other impurities. The
method can purify ODN in high levels of purity but it has disadvantages. It is
expensive to scale up and fluorous column is not reusable.
1.5.4 RP Cartridge
RP cartridge is a disposable column that contains C-18 alkyl group
functionalized silica gel. The surface of the silica gel is hydrophobic. During ODN
synthesis, the DMTr group on the full-length sequences is not removed. The failure
sequences and other molecules do not contain DMTr group. During purification, the
crude ODN solution is passed through the column. Due to strong hydrophobic
attraction, the full-length sequences are eluted much slower than the failure ones, and
the two are separated.[10] This method is cheap and convenient for short ODNs.
However, this purification method is not suitable for longer ODNs. The
hydrophobicity effect of the DMTr groups ultimately diminishes with increasing
ODNs size. This results in a less efficient purification process overall. Another




drawback of this method lies with the extremely susceptible characteristic of the 5 DMTr group which results in a general low yield.[8]
1.5.5 Biotin-Avidin Based Affinity Purification
The principle of this method is based on the interaction between biotin and
avidin. A biotin molecule is tagged with full-length ODN during the synthesis. The
full-length ODN with biotin binds with avidin while the failure sequences which lack
biotin tag are washed away. The desired ODN is cleaved from avidin
microspheres.[11-13] This method is convenient to purify small quantities of ODN.
However, it has disadvantages. It requires harsh conditions to cleave ODN from
avidin-biotin linkage and is expensive because of the high cost associated with avidin
which is not reusable.
1.6 Our Catching by Polymerization ODN Purification Methods


To overcome the problems of known ODN purification technologies, we have
developed two new methods. Both methods are based on a new concept which is
catching by polymerization. The following paragraphs briefly describe the principle
of the two methods and their advantages over known methods.
1.6.1 First Method: Catching Failure Sequences by Polymerization


The first method is called catching failure sequences by polymerization.
During automated synthesis, the failure sequences are capped with a phosphoramidite
that contain a polymerizable group. The full-length sequences are not capped with



this phosphoramidite. As a result, the failure sequences contain a polymerizable
group while the full-length sequences do not. During purification, the crude ODN is
subjected into a polymerization condition. The failure sequences are incorporated into
a polymer. The full-length sequences remain in solution. Extraction followed by
nBuOH precipitation gives pure ODN. The polymerizable group we used is the
methacrylamide group, which can be incorporated into a polyacrylamide gel. Four
capping phosphoramidites (1.11-1.14) have been tested so far. All of them worked
great. However 1.11-1.12 are preferred because they are easier to synthesize and
cheaper. Scheme 1.2 illustrates how to cap the failure sequences with a polymerizable
phosphoramidite while leaving the full-length sequences un-capped.

Figure 1.2. Capping reagents for catching failure sequences
As shown in Scheme 1.2, after the coupling step, the failure sequences 1.6 are
capped with polymerizable phosphoramidite 1.12. Instead of using acetic anhydride,
the polymerizable phosphoramidite 1.12 is delivered to the column right after the
coupling step. The failure sequences 1.6 react with 1.2 to give 1.15, which after the



oxidation step, becomes 1.16. The failure sequences 1.16 now contain a
methacrylamide polymerizable group. After synthesis, cleavage and deprotection, all
failure sequences are depicted as 1.17 which contains a polymerizable group while
full-length sequences 1.10 do not. The crude ODN is subjected into radical
polymerization conditions. N,N-Dimethylacrylamide is used as the polymerization
monomer and N,N-methylenebisacrylamide is used as a cross-linker. The
polymerization is initiated with ammonium persulfate (APS) and N,N,N,Ntetramethylethylenediamine (TMEDA). The failure sequences are incorporated into
the polyacrylamide gel 1.18 (scheme 1.3). The full-length ODN 1.10 remains in the
gel-matrix. The full-length ODN is extracted with water. At this stage, the full-length
sequence is still contaminated with small molecules which are resulted from
protecting groups. However, these small molecules are easily removed by
precipitation of ODN from NH4OH solution with nBuOH (Scheme 1.3). This
technology is useful to purify short ODNs because the failure sequences needs to be
capped in each synthesis cycle and the capping agent is more expensive than acetic
anhydride. We used this technology to purify different ODNs including short (20mer) and relatively longer ones (61-mer). This technology also works well to purify at
large scales. We tested 3 μmol purification, the results were excellent. The ODNs
purified by this method has high purity and good recovery yield ( 80%).






Scheme 1.2. Acrylation of failure sequences using 1.12 during ODN synthesis




Scheme 1.3. Catching failure sequences by polymerization
1.6.2 Second Method: Catching Full-length Sequences by Polymerization


The

second

method

is

called

catching

full-length

sequences

by

polymerization. In this method, the full-length sequences are tagged with a
polymerizable phosphoramidite. The failure sequences are capped with acetic
anhydride. Thus the full-length sequences have a polymerizable group while failure
sequences do not. The crude ODN is subjected to polymerization. The full-length
sequences are incorporated into a polymer. The failure sequences remain in the gelmatrix, which are removed by washing. The full-length ODN is cleaved from the gel



using 80% acetic acid followed by extraction. Pure ODN is obtained by nBuOH
precipitation from NH4OH. The polymerizable tagging agent 1.19 used to catch fulllength is used in our examples. It contains an alkyl trityl ether linkages, which is
readily cleavable under weekly acidic conditions. The polymerizable group is the
methacrylamide.

Figure 1.3. Polymerizable tagging phosphoramidite with an acid cleavable linker
Scheme 1.4 describes the procedure for tagging full-length sequences with a
polymerizable linker 1.19. During ODN synthesis, failure sequences are capped with
acetic anhydride in each synthesis cycle. At the end of synthesis, the full-length
sequence is tagged with the polymerizable phosphoramidite 1.19. The 5 end of fulllength ODN then contains a polymerizable group 1.20. After cleavage and
deprotection, the crude ODN contains a mixture of full-length ODN 1.21, which
contains a polymerizable group and the failure sequences, which do not contain a
polymerizable group.




Scheme 1.4. Tagging of full-length sequences during ODN synthesis

The crude ODN is subjected into radical polymerization conditions which are
the same as described for the first purification method. The full-length sequences are
 


incorporated into the polyacrylamide gel 1.24 (Scheme 1.5). The failure sequences
and other impurities remain in the gel-matrix. The failure sequences and other
impurities are washed away. The full length ODN is cleaved with 80% acetic acid.
The full-length ODN is further extracted with water. Pure ODN is obtained after
nBuOH precipitation from NH4OH.

Scheme 1.5. Purification of ODN by catching full-length
Using this technology, the polymerizable tagging agent is used only once at
the last synthetic cycle of ODN synthesis. So the method is suitable to purify longer
ODNs. In our examples, we used this technology to purify ODNs as long as (151
mer) and at scales as large as 50 μmol. The purity and recovery yields are very good.
We believe that the method can be further scaled up easily.
!


1.7 Advantages of Our New Purification Methods


Our new methods have significant advantages over all known ODN
purification technologies. They do not need any chromatography. Purification is
achieved by simple manipulations such as mixing, shaking, washing and extraction.
They do not require large volumes of solvents and expensive column. The
technologies use inexpensive materials and avoid expensive instrumentation. As a
result, they are suitable for large scale and high throughput purification. The ODNs
purified by the methods have high purity and good recovery yields. The technologies
use environmentally benign materials and save a substantial amount of energy, which
are usually needed for solvent evaporation using methods such as RP HPLC.
The advantages of our technologies over known are summarized in Table 1.1.

"


Table 1.1. Advantages of the our purification techniques over known ones a


Techniques

Our methods RP
HPLC

IX
HPLC

PAGE

Fluorous Biotinb
c
Avidin

RP
cartridge

Expensive instrument
Expensive column

No
No

Yes
Yes

Yes
Yes

Medium
No

No

No

Yes

Expensive materials

No

No

No

No

Yes

Scalability
High
throughput
purification
Desalting
Automation
Labor intensive
Harmful solvent
Waste to product ratio

Excellent
Yes

Medium
No

Medium
No

No
No

No
No

No
No

No
No

No
Yes
No
Minimal
0.1K/1
Low

No
No
Yes
Large
200K/1
High

Yes
No
Yes
Large
200K/1
High

No
No
Yes
Small
50K/1
Low

No
No
Medium
Small
0.5K/1
Low

No
Possible
Medium
Minimal
0.2K/1
Low

No
No
Medium
Medium
10K/1
High

-

Low

e

Energy demand
Environmental benign High
Product purity

i

98-100%

Purity dependence
on loading
Recovery yield
j

Purification time
Overall purification
k
cost

Low

f

Low

f

Low

g

d
d

Low

h

No
No
Yes

Yes
d

Yes

d
d

f

80100%
High

80100%
High

85100%
Low

90-100%

70-100%

No

80100%
High

No

High

80-99%
Fast

~70%
Slow

~65%
Slow

~50%
Slow

~80%
Fast

~80%
Medium

~60%
Fast

~15%

100%

~120%

~400%

~200%

~250%

~70%

Information is based on our experience. We tried best to be fair. b Refers to
fluorous affinity purification. c Refers to biotin-avidin affinity purification.
d
Refers to fluorous support, biotin and avidin, or C-18 silica. e Energy is needed
for solvent evaporation. f Large amount of harmful solvents. g Large amount of
acrylamide. h Fluorous materials are not environmental benign. i Purity is
dependent on batch scale for known techs but not so for MTU techs. j Solvent
evaporation time is not considered. k Relative to RP HPLC.
a

A comarision of different techniques for oligonucleotide purification is shown
in Table 1.2.




Table 1.2. Costs of different ON purification methods a


Cost
Electrophoresis
RP HPLC
Fluorous method
MTU methods
Saving over HPLC


0.2 μmol
(~1 mg)
$125 b
$45 b
$18 d
$9 e
80%

1 μmol
(~6 mg)
$425 b
$90 b
$22 d
$10 e
88%

10 μmol
(~60 mg)

1 mol
(~6 kg)

c

c

$150 b

c

c

c

$12 e
92%

$1,500 e
-

a

Based on 20-mer, which has a molecular weight of ~6 kg/mol.
Appromxiate Price.
c
No information on the web.
d
Price estimated from website; labor not included. 
e
Estimated number; labor not included; not accurate.
b



The specific details of new ODN purification methods are described in
subsequent chapters. Purification of ODN by catching failure sequences is described
in chapters 2 and 3. Chapter 2 describes the detailed investigation of this technology
while in chapter 3 we highlight the optimization and refinements of this technology
for practical use. In chapter 4 we describe the second method of purifications, which
is catching full-length ODN by polymerization. An acid-cleavable linker is used in
the examples.
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Abstract


Oligodeoxynucleotide (ODN) purification was achieved by capping failure
sequences with a polymerizable methacrylamide phosphoramidite during automated
synthesis, polymerizing the failure sequences into an acrylamide gel after cleavage
and deprotection, and extraction of full-length sequences with water. The details
regarding the technology including the capping efficiency of four polymerizable
phosphoramidites, optimal capping time, diffusion speeds of ODN from gels with
different cross-linking ratios to solution, and the efficiency of ODN extraction from
gel were investigated. In addition, the technology was tested for purification of a long
sequence and purification on larger scales. We also found that polymerization of
failure sequences in a centrifuge tube in air did not affect purification results. Finally,
we provided additional evidences that ODNs are stable under radical polymerization
conditions by complete digestion of ODN followed by reversed-phase HPLC analysis
of nucleosides.




2.1 Introduction


Applications such as total gene synthesis require the production of large
numbers of short ODNs within a short time with high efficiency.[1-3] An ideal
method to achieve this is through high throughput production. The high interest in
using oligonucleotides (ONs) as therapeutic agents to cure human diseases generates
a need for large quantities of ONs for preclinical research, clinical trial and patient
use. This requires to develop technologies for large scale production of ON.[4]
Currently, high throughput and large scale syntheses of ON are possible due to the
commercialization of oligonucleotide microarray technologies,[5] high throughput
automated solid phase synthesizer, [1], [6] and large scale synthesizer.[7] However,
the products contain impurities, which must be removed before the applications. The
impurities can be classified into three types. The first type is the truncated failure
sequences generated in each synthetic cycle due to incomplete coupling of nucleoside
phosphoramidite monomer. These failure sequences are capped usually with acetic
anhydride to prevent them from growing in subsequent synthetic cycles and
becoming the more difficult-to-remove deletion sequences. For a typical 20-mer
ODN synthesis, they usually consist of 30-60% ODN content depending on the scale
of synthesis, quality of reagents and solvents, and carefulness of the synthesizer
operator to minimize exposure of reagents and solvents to air.[8] Because failure
sequences have very similar physical properties as the desired full-length sequences,
this class of impurities is challenging to remove. The second type of impurities is
small organic molecules from protecting groups. These molecules are neutral, and
 


therefore are easy to remove from the negatively charged full-length sequences. The
third type impurities include deletion sequences, addition sequences, and sequences
resulted from depurination as well as other modifications during synthesis, cleavage
and deprotection. Deletion sequences can be resulted from incomplete capping, and
incomplete de-tritylation. Addition sequences can be resulted from premature detritylation. Deletion and addition sequences are most difficult to remove. Fortunately,
they only exist in minute quantities in crude ODN. In ODN production, it is best to
tune synthesis, cleavage and deprotection conditions to avoid the third type
impurities. As a result, the major task of ODN purification usually is the removal of
failure sequences from the full-length sequences.
Current methods for ODN purification include gel electrophoresis, ion
exchange HPLC, trityl-on reversed-phase (RP) HPLC, RP cartridge chromatography,
hydrophobic RP chromatography,[9] fluorous affinity purification,[8, 10] biotinavidin based affinity purification [11-13] and reaction-based solid phase extraction.
[14] The limitations of these methods in large scale ODN purification have been
discussed earlier.[15-17] For applications in high throughput purification, gel
electrophoresis and all chromatographic methods are not practical or highly
expensive, affinity purification methods may be expensive, and to our best
knowledge, reaction-based solid phase extraction methods have not been well
developed.
Recently, we communicated our preliminary results on the development of a
new ODN purification technology based on catching failure sequences by
polymerization.[16] Using this method, the failure sequences in crude ODN could be
!


simply removed by co-polymerizing them into an insoluble polymer, and pure ODN
could be obtained by simple extraction followed by nBuOH precipitation.[18] The
method does not require any chromatography, and purification is achieved with
simple manipulations such as mixing, shaking and extraction. As a result, it is
potentially useful for large scale and high throughput ODN purification. In this
article, we further report our detailed studies of the technology.
2.2 Results and Discussion


The working principle of the catching failure sequences by polymerization ODN
purification method is detailed in Scheme 2.1. The entity 2.1 represents two of many
n-mer ODNs on solid support (usually controlled pore glass, CPG) at the end of nth
synthetic cycle, at which time the 5-end DMTr (4,4-dimethoxytrityl) group is
removed (each cycle contains four steps: coupling, capping, oxidation and
detritylation). Coupling 2.1 with excess phosphoramidite monomer 2.2 in the
presence of an activator to generate (n+1)-mer is usually highly efficient, but it is
inevitable for small amount of n-mer to fail the coupling and therefore generating
failure sequences. The entity 2.3 represents one failure and one success sequences on
solid support. Repeated coupling of 2.3 with 2.2 to complete the reaction is not a
good option due to the expense of 2.2 and potential side reactions such as premature
detritylation. However, if the failure sequences were carried on to the next synthetic
cycles, they would become deletion sequences, which are highly challenging to
remove during purification. As a result, they are usually capped with acetic
anhydride. For using our catching failure sequences by polymerization ODN
"


purification technology, however, the capping agent is replaced with the
polymerizable methacrylamide phosphoramidite 2.4, and the resulting material is
depicted with 2.5. After oxidation and detritylation steps, 2.5 becomes 2.6. The
synthesis is continued and the capping failure sequences with 2.4 is performed in each
cycle.
After cleavage and deprotection, there are mainly three entities in the crude
product, the failure sequences that contain a methacrylamide group (2.7), the fulllength sequences that do not contain a methacrylamide group (2.8), and small
organics from protecting groups. The crude product is subjected into radical
polymerization conditions in the presence of additional polymerization monomer (e.g.
N,N-dimethylacrylamide) and a cross-linker (e.g. N,N-methylenebis(acrylamide)).
The failure sequences are incorporated into an insoluble polymer (2.9). The fulllength sequences (2.8) and small organics remain in solution and are extracted with
water. The small organics are neutral and soluble in nBuOH, while the full-length
sequences are anionic and insoluble in nBuOH. The two are separated by
precipitation of ODN 2.8 with nBuOH from a solution in concentrated NH4OH
(Scheme 2.1).




Scheme 2.1. The catching failure sequences by polymerization ODN purification
method
Capping Efficiency of Four Methacrylamide Phosphoramidites and Optimal
Capping Time
Previously, we used the methacrylamide phosphoramidite 2.10 as the reagent
for capping failure sequences.[16] In the present study, we synthesized three more
(2.11-2.13, Figure. 2.1). The capping efficiency of them and 2.10 were evaluated.
Compared with 2.10, compound 2.11 has an ether oxygen atom in the linker, which
may increase its solubility in polar organic solvents such as acetonitrile and have
better reaction kinetics during capping. Compound 2.12 has two ether oxygen atoms
in the linker and the linker is longer. These may offer benefits for reaction kinetics in
both capping and polymerization steps. Compound 2.13 has an even longer linker,
and in the linker, there is an amide bond. It was expected that the compound exist as a



solid at room temperature and therefore its purification and storage be more
convenient. Compound 2.11 was simply synthesized from amino alcohol 2.14 in two
steps in excellent yields (Scheme 2.2). The intermediate compound 2.15 is known,
[19] but we used a different procedure for its preparation (see experimental section).
Capping phosphoramidites 2.12-2.13 were prepared from 2.16, [20] and 2.18, [21]
respectively using the same procedures for preparing 2.11. The intermediate
compound 2.17 was known,[22] and 2.19 is new and was fully characterized.





Figure 2.1. Structures of polymerizable capping phosphoramidites.

Scheme 2.2. Synthesis of polymerizable capping phosphoramidites.



In our initial studies, during automated ODN synthesis, capping failure
sequences was performed after the oxidation step that oxidizes the newly formed
phosphite triester bonds in the success sequences.[16] As a result, after capping,
another oxidation step was needed to oxidize failure sequences. In the present study,
we planned to simplify the process by omitting the first oxidation step and to oxidize
the success and failure sequences in one single step. In addition, reduction of capping
delivery time and the concentration of capping solutions were also planned. To test
feasibility, the 20-mer ODN 2.20 was synthesized using a 0.15 M acetonitrile solution
of 2.11 for capping. After the coupling steps, without oxidation, the capping solution
was delivered to the synthesis column along with the activator 1H-tetrazole.


Figure 2.2. Labelling of ODNs




The delivery time and manner were about the same as in the coupling step except that
the reagents were delivered for two more times, and after each delivery a waiting step
was added. More specifically, the reagents were delivered to the synthesis column for
a total of four times (2.0 seconds, 1.5 seconds × 3). After each delivery the reagents
remained in the column for 90 seconds (Cycle 1 in supporting information). These
capping steps consumed less capping phosphoramidite compared with those used in
our initial studies, which were 2.5 seconds, 1.5 seconds × 3 with 0.2 M solution.[16]
After the capping steps, the column was washed with acetonitrile, and the synthesis
was allowed to proceed as normal.
The final detritylation, cleavage and deprotection were also carried out under
commonly used conditions. The crude product, which was labeled as 2.20(c2.11l)
(ODN labeling is summarized in Figure 2.2), was analyzed with RP HPLC (trace a,
Figure 2.3).
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Figure 2.3. RP HPLC profiles of ODN 2.20(c2.11l). (b) Crude ODN. (b) ODN
purified with catching by polymerization

The remaining crude 2.20(c2.11l) was subjected to radical acrylamide
polymerization conditions widely used for the preparation of gels in electrophoresis
experiments (Scheme 2.3).



Scheme 2.3. Purification of ODN 2.20 by polymerization of failure sequences

Briefly, the crude ODN, which mainly contained the full-length sequences
2.20, the failure sequences 2.21 and small organic molecules from protecting groups,
was mixed with a pre- prepared polymerization solution containing the
polymerization monomer N,N-dimethylacrylamide and the cross-linker N,Nmethylenebis(acrylamide). Polymerization was then initiated under a nitrogen
atmosphere with ammonium persulfate and N,N,N,N-tetramethylethylenediamine
(TMEDA).
The failure sequences were copolymerized into the acrylamide gel 2.22. The fulllength sequences (2.20) and small organics remained in solution, and were extracted



with water. After evaporation of volatiles and heating with concentrated NH4OH
briefly, the ODN was precipitated with nBuOH.[16] The purified 2.20(c2.11l) was
analyzed with RP HPLC (trace b, Figure. 2.3) and the purity was found to be 93%.
The recovery yield of the purification process was estimated to be 93% by dividing
the area of the peak at 19 minutes in trace b by that in trace a in Figure 2.3. The
results indicate that the new agent 2.11 with the simplified capping procedure is
capable of capping failure sequences completely. We also tested the capping agents
2.10, 2.12 and 2.13 under the same new ODN synthesis and catching by
polymerization purification conditions. All of them were found equally suitable for
the application. The RP HPLC profiles for ODNs 2.20(c2.10l), 2.20(c2.12l) and
2.20(c2.13l) are shown in supporting information. Their recovery yields and purity
are shown in Table 2.1.
In order to see if capping time could be further shortened and at the same time to
distinguish the efficiency of the four capping reagents, the above ODN synthesis
procedure was repeated with the capping conditions being changed from
phosphoramidite and activator delivering time of 2.0 seconds, 1.5 seconds × 3, and
waiting time of 90 seconds after each delivery to delivering time of 2.0 seconds, 1.5
seconds × 2, and waiting time of 30 seconds (Cycle 2 in supporting information).
After cleavage and deprotection, the four crude samples 2.20(c2.11s), 2.20(c2.10s),
2.20(c2.12s) and 2.20(c2.13s) were purified using the same procedure as described
above. The purified ODNs were analyzed with RP HPLC, and good purity and
recovery yields were found (Table 2.1). Because the delivery time of capping
reagents was almost the same as that of nucleoside phosphoramidite monomers in
 


typical coupling steps (2.0 seconds, 1.5 seconds), further shortening of capping time
was not pursued. All the four capping phosphoramidites (2.10-2.13) performed
equally well, and therefore any of them could be used for the catching by
polymerization technology. However, compounds 2.12-2.13 are relatively more
expensive to make. Compound 2.13 did not exist as a solid or foam at room
temperature as we hoped, and moreover, it was found more prone to oxidation during
purification. As a result, compounds 2.10-2.11 are preferred capping reagents for the
catching failure sequences by polymerization purification technology.

Table 2.1 ODN purity and recovery yielda
ODN

a

Purity

Recovery yield

2.20(c2.10l)

89%

92%

2.20(c2.11l)

93%

93%

2.20(c2.12l)

99%

72%

2.20(c2.13l)

100%

81%

2.20(c2.10s)

100%

82%

2.20(c2.11s)

100%

86%

2.20(c2.12s)

98%

95%

2.20(c2.13s)

94%

70%

2.23

92%

67%

2.20(c2.11ls)

94%

73%

2.20(c2.11dci)

100%

88%

Purity was calculated from the areas of ODN and impurity peaks in HPLC profile. Yield was calculated by dividing the area of

ODN peak in HPLC profile of purified sample by that in the profile of crude sample.
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Diffusion Speed of ODN From Gel and Extraction Efficiency
The diffusion speed of ODN from the acrylamide gel to solution is an important
factor to determine the efficiency of ODN extraction. The purification technology is
most useful if the diffusion speed is high and ODN can be extracted with high
efficiency and recovery yield. Our common sense was that gels with higher crosslinking ratio [the mole ratio of N,N-methylenebis(acrylamide) over N,Ndimethylacrylamide] would result in lower diffusion speed and extraction efficiency.
Gels with lower cross-linking ratio were expected to give better results. However, if
the cross-linking ratio is too low, the gel may be too soft and therefore difficult to
handle. We were interested to find a compromised point where the most common 20mer ODNs could be extracted with acceptable efficiency while the gel is hard enough
to be easily handled. From experiments on ODN purification with polyacrylamide gel
electrophoresis, it is known that gels with a cross-linking ratio of 1:25 are reasonably
hard and 20-mer ODNs can be extracted from them with acceptable efficiency and
yields. We therefore decided to start our experiments with this cross-linking ratio.

"


Table 2.2 Monitoring ODN diffusion from gels with different cross-linking ratios to
supernatanta
Entry

a

Time ODN Con.

% of

ODN Con.

% of

ODN Con.

% of

ODN Con.

% of

ODN Con.

% of

(min) (ng/μL)b

ODNb,g

(ng/μL)c

ODNc,g

(ng/μL)d

ODNd,g

(ng/μL)e

ODNe,g

(ng/μL)f

ODNf,g

1

10

47.7

66.0

29.9

47.5

32.7

45.0

27.1

39.9

25.8

39.3

2

20

53.3

73.7

37.8

60.1

40.9

56.3

36.0

53.0

34.7

52.9

3

30

54.7

75.7

43.4

69.0

49.5

68.2

42.0

61.9

37.7

57.5

4

40

58.6

81.1

48.6

77.3

53.4

73.6

46.9

69.1

42.8

65.2

5

50

64.6

89.3

50.9

80.9

56.7

78.1

50.5

74.4

47.0

71.7

6

60

65.1

90.0

54.6

86.8

59.2

81.5

53.3

78.5

50.0

76.2

7

70

66.4

91.8

56.0

89.0

64.2

88.4

56.1

82.6

53.3

81.3

8

80

67.6

93.5

58.0

92.2

64.6

89.0

59.7

87.9

56.0

85.4

9

90

68.6

94.9

59.6

94.8

67.2

92.6

59.9

88.2

58.6

89.3

10

100

70.9

98.1

61.2

97.3

68.0

93.7

64.0

94.3

59.8

91.2

11

110

71.7

99.2

62.0

98.6

70.6

97.3

66.2

97.5

65.4

99.7

12

120

72.3

100

62.9

100

72.6

100

67.9

100

65.6

100

Crude ODN containing 2.20 and 2.21 was copolymerized into gel. Water was added to extract 2.20. The concentration of 2.20

in the supernatant was monitored with UV over a two-hour period.
b-f

g

In supernatants of gel with cross-linking ratio of 1:2, 1:7, 1:15, 1:25, 1:50, respectively.

Calculated by dividing ODN concentration at a specific time by that after 120 min.

A portion of crude ODN 2.20(c2.11s), which contained 2.21, was subjected to
polymerization using a polymerization solution that had a mole ratio of cross-linker
over monomer of 1:25 (see details in Experimental section). Water was added to the
gel, and small aliquots of supernatant were taken out every 10 min and the
concentrations of ODN were determined with UV measurement. As shown in Table
2.2, after 10 min, the concentration of ODN in the supernatant had reached about
40% (entry 1) of the value at 2 h, at which time the diffusion was close to



equilibrium. For the concentration to reach 90% of equilibrium value, about 90 min
were required (entry 9). To find out how many times were needed to extract all or
most ODN from gel, after 2 h, the supernatant was removed completely (entry 12,
Table 2.2 and entry 1, Table 2.3). To the gel, water was added again, and after 2 h,
the supernatant was removed and its concentration was determined with UV
measurement (entry 2, Table 2.3). The extraction and UV measurement were repeated
for three additional times. As shown in Table 3, after two extractions, only about 3%
extractable ODN remained in the gel (entry 3). After three extractions, the value
lowered to 0.4% (entry 4). The results in Tables 2.2 and 2.3 indicate that ODN
2.20(c2.11s) can be efficiently extracted from gel that has a cross-linking ratio of 1:25
with water for three times in a total of 6 h.
Table 2.3 Extraction efficiency of ODN from gela

Time ODN Con.
Entry

a

% of

ODN Con.

% of

ODN Con.

% of

ODN Con.

% of

ODN Con.

% of

(h)

(ng/μL)b

ODNb,g

(ng/μL)c

ODNc,g

(ng/μL)d

ODNd,g

(ng/μL)e

ODNe,g

(ng/μL)f

ODNf,g

1

2

72.3

85.5

62.9

82.4

72.6

77.2

67.9

71.7

65.6

63.3

2

4

9.5

11.2

10.3

13.5

18.1

19.3

23.5

24.8

22.3

21.5

3

6

2.8

3.3

3.1

4.1

3.3

3.51

2.6

2.8

13.2

12.7

4

8

0.0

0.00

0.0

0.0

0.0

0.0

0.4

0.4

2.1

2.0

5

10

0.0

0.00

0.0

0.0

0.0

0.0

0.3

0.3

0.4

0.4

The experiments in Table 2.1 were continued by removing the supernatant after 2 h. Water was added to the gels again, and

supernatants were removed after 2 h. The extractions were repeated every 2 h for three additional times.
b-f

g

In supernatants of gel with cross-linking ratio of 1:2, 1:7, 1:15, 1:25, 1:50, respectively.

Calculated by dividing ODN concentration in each extract by that of the total amount of ODN extracted from the gel in the

same volume of water.




To find out if a gel with lower cross-linking ratio could offer higher diffusion
speed and better extraction efficiency, the above experiments were repeated with the
exception of using a polymerization solution that had a cross-linking ratio of 1:50. As
shown in Tables 2.2 and 2.3, the diffusion speed and extraction efficiency were not
better, which was contrary to our prediction. Instead, the data showed a slightly
slower diffusion speed and lower extraction efficiency although the differences were
small (e.g. 39.3% vs. 39.9% at 10 min entry 1, and 91.2% vs. 94.3% at 100 min entry
10, Table 2.2). Because gels with a higher cross-linking ratio gave slightly better
results, we repeated the experiments with a cross-linking ratio of 1:15 (Tables 2.2 and
2.3). According to the trend, the diffusion speed and extraction efficiency should
become better, which was indeed the case although the difference was small again.
For example, within 10 min, the concentration of ODN in the supernatant had reached
about 45% of equilibrium value (entry 1). For the concentration to reach 90% of
equilibrium value, about 80 min were required (entry 8). For extraction efficiency,
after three extractions, no more ODN was detectable in additional extracts (entry 4,
Table 2.3). We then further increased the cross-linking ratio to 1:7. The trends of
diffusion speed and extraction efficiency changes were the same. Within 10 min, the
concentration of ODN in the supernatant had reached 48% of equilibrium value (entry
1). For the concentration to reach 90% of equilibrium value, about 70 min were
needed (entry 7). When the cross-linking ratio was increased to 1:2, within 10 min,
the concentration reached 66% (entry 1), and the time for reaching 90% was reduced
to 60 min (entry 6). These results consistently show that the diffusion speed and ODN
extraction efficiency increase with increased cross-linking ratio of gel. This is



significant for the technology because gels with higher cross-linking ratios are harder
and therefore easier to handle.
It was quite surprising to find that the ODN diffusion speed and extraction
efficiency increase with cross-linking ratio. We had expected the contrary because
gels with higher cross-linking ratio have smaller pores and ODN molecules would be
more difficult to travel through them. Our explanation of the observed results is that
the ODN molecules were not totally in the gel even though this seemed impossible
because the gel with other contents including water and ODN looked like
homogenous. Instead, when the polymers grew, ODN molecules were expelled or
partially expelled out from the polymer matrix. With lower cross-linking ratio when
the pores in polymer were larger, a higher portion of ODN molecules was in the
polymer matrix, or all ODN molecules were not in the polymer matrix, but they could
diffuse into it with relatively high rates. These resulted in seemingly lower diffusion
speeds of ODN from gels to solution and lower extraction efficiency. With higher
cross-linking ratio when the pores in the polymer were smaller, a lower portion of
ODN molecules was in the polymer matrix, or all ODN molecules were not in the
polymer matrix, and they could only diffuse into it with low rates. These resulted in
seemingly higher diffusion speeds of ODN from gels to solution and higher extraction
efficiency.
Long Sequence Purification
For long sequence ODN purification, the catching failure sequences by
polymerization method requires significant amount of polymerizable capping
phosphoramidite, which is more expensive than acetic anhydride or phenoxyacetic



anhydride capping agents used in catching full-length sequences by polymerization
method.[15] We therefore recommended the catching full-length sequences by
polymerization method for long sequence purification.[16, 23] However, it is still
interesting to test the suitability of the catching failure sequences method for ODN
purification because it may be more convenient in certain applications such as high
throughput purification. The 61-mer ODN 2.23, which is a portion of the HIV
protease gene, was selected as the target. The synthesis was carried out on a 0.2 μmol
scale

using

the

procedure

with

shortened

capping

time.

Polymerizable

phosphoramidite 2.11 was used as the capping agent. In the coupling step, after
finishing phosphoramidite and activator delivery, an additional waiting of 30 seconds
was added to increase yields (Cycle 2 in supporting information with additional
waiting after coupling). The crude ODN was purified by catching failure sequences
by polymerization as we did for shorter sequences. RP HPLC analysis showed that
the ODN had good purity and recovery yield (Table 2.1 and supporting information).
The identity of purified ODN was confirmed with ESI-MS (supporting information).
Purification at Larger Scales
After investigation of the effect of several additional factors such as capping
agent storage time, radical scavenger, harsher deprotecting conditions, lower
concentration of capping solution, polymerization in air (see supporting information),
we decided to test the technology for larger scale purification. For this goal, ODN
2.20 was synthesized on a 1 μmol scale. The synthesis conditions were only slightly
different from those using shortened capping time described earlier, which was used
for 0.2 μmol synthesis. The standard 1 μmol synthesis cycle provided by



manufacturer of the synthesizer was modified. The steps for capping with acetic
anhydride were replaced with those for capping with polymerizable phosphoramidite.
The latter was achieved by delivering the solution of 2.11 in acetonitrile and activator
to the synthesis column in the same manner as in the coupling steps except that an
additional delivery was added and a waiting of 30 seconds was added after each
delivery (Cycle 3 in supporting information). At the end of synthesis, DMTr group
was removed, and cleavage and deprotection were performed. The crude ODN was
purified by catching failure sequences by polymerization using the same procedure
described earlier. The only differences were that the 1 μmol ODN was purified in one
batch, the volume of the polymerization solution was increased to 10 times of that
used in the general 0.05 μmol purification procedure, and the volume of extraction
water was slightly larger. The ODN, which is labeled as 2.20(c2.11ls), was found to
have good purity and recovery yield with RP HPLC (Table 2.1 and supporting
information). It is remarkable that even though the purification scale was increased
from 0.05 μmol to 1 μmol, which was 20 times, increasing the volume of
polymerization solution to 10 times was sufficient to catch all the failure sequences.
We further performed three 1 μmol syntheses simutaneously under conditions
that are more close to actual large scale ODN production. Specifically, 1H-tetrazole is
considered as an explosive and not recommended for large scale synthesis. Therefore,
4,5-dicyanoimidazole (DCI) was used as activator. To save phosphoramidite
monomers, their concentration was lowered from 0.1 M to 0.05 M. A 0.1 M solution
of 2.11 in acetonitrile was used for capping. With these modifications, ODN 2.20 was
synthesized under otherwise the same conditions for the synthesis of 2.20(c2.11ls).



According to trityl assay and RP HPLC analysis of crude ODN, the synthesis yields
were not significantly different from synthesis under conditions without the above
modifications. The 3 μmol ODN was purified in one batch under the same conditions
described for purification of 2.20(c2.11ls) and is labeled as 2.20(c2.11dci). RP HPLC
analysis indicated that the ODN was highly pure and had excellent recovery yield
(Table 2.1 and supporting information).
ODN Stability Under Radical Polymerization Conditions
A concern on the catching by polymerization purification technologies, which
involves copolymerization of ODN into polymer under free radical conditions, is the
potential damage of ODN under such conditions. Polymerization of ODN into
polyacrylamide gels under radical conditions is known in the literature.[24-26]
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Figure. 2.4 RP HPLC profiles of nucleosides from ODN enzymatic digestion essay.
(a) Nucleosides from ODN 2.20(c2.11s), which was purified with the catching by
polymerization technique. (b) Nucleosides from authentic ODN 2.20. (c) Nucleosides
from ODN 2.24. (d) Nucleosides from the mixture ODN 2.25. The peaks in a-b and d
correspond to dC, dG, dT and dA, respectively. Those in c correspond to dC, dG, 8oxo-dG, dT and dA, and 2-mercaptoethanol, respectively. The inconsistency of
retention times in c with those in a-b and d is caused by the use of a different column.
 

However, to our best knowledge, detailed study of ODN stability in the presence
of free radicals has not been reported. Certainly, RP HPLC analysis of ODNs purified
with the catching by polymerization technologies by comparing with authentic ODN
strongly supports that ODNs can survive such conditions. Another evidence of
stability comes from mass spectrometry, which consistently gave molecular mass
consistent with calculated values.  Further, we also subjected the nucleosides
guanosine, adenosine, thymidine and cytidine to free radical acrylamide
polymerization conditions, extracted them from the polymer, and analyzed them with
RP HPLC. No damaged nucleoside was detected. Among the four nucleosides,
guanosine oxidation is more common, and the oxidation product is 8-oxo-guanosine.
We compared the guanosine from the polymer with authentic 8-oxo-guanosine by coinjection into RP HPLC, the two were found to have different retention times, and no
8-oxo-guanosine was detected in the sample from polymer.[15] However, concerns
on ODN stability may still remain because this is so important an issue for
purification, especially for ODN drug purification. For RP HPLC analysis, if only one
of the 20 bases of a 20-mer ODN is damaged, and the physical properties of the
damaged nucleobase are not changed significantly, the analysis may not be able to
differentiate damaged ODN from authentic ODN. For mass spectrometry analysis, if
only a minute portion of ODN is damaged, the method may not be sensitive enough
for detection. For the experiments to test stability of nucleosides under radical
conditions, the reactivity of nucleosides in an ODN may not be the same as individual
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nucleosides. As a result, all the methods we used to support ODN stability under
radical conditions are not conclusive.
To obtain additional evidences on the stability of ODN under radical acrylamide
polymerization conditions, we used ion exchange HPLC to analyze one of our
samples purified with the catching failure sequences by polymerization process. It
was expected that ion exchange HPLC have different resolution on potentially
damaged ODNs than RP HPLC. To our satisfaction, we still did not found any
damaged ODN, and only one peak was observed (supporting information). We also
tried to find any impurity using RP HPLC by UV detecting at 210 nm instead of the
usually used 260 nm; again, only one peak was observed (supporting information).
Further, we performed an ODN enzymatic digestion essay to detect any damaged
nucleosides.[27] A portion of the ODN sample 2.20(c2.11s) purified with the
catching failure sequences by polymerization method was digested with Snake
Venom Phosphodiesterase (SVP) into nucleotides, which were dephosphorylated to
give nucleosides by Bacterial Alkaline Phosphatase (BAP). The neutral nucleosides
were then separated from the highly polar species including inorganic salts and
enzymes in the digestion mixture by precipitation of the latter materials by ethanol
from a sodium acetate buffer. The nucleosides were soluble in ethanol and remained
in the supernatant. The polar species were not soluble and were precipitated. The
nucleosides were analyzed with RP HPLC. As shown in Figure 2.4, only four peaks,
which correspond to the four natural nucleosides, were observed (trace a). No
additional peaks that correspond to any damaged nucleosides were detected. An
authentic ODN 2.20, which was from a commercial source and was purified with
"


preparative RP HPLC, was also subjected into the same digestion process. The
resulting HPLC profile of nucleosides (trace b) was exactly the same as that from
2.20(c2.21s). Another ODN (2.24), which is 2.20 with one dG being replaced with 8oxo-dG (Figure 2.2), was synthesized and purified by DMTr-on preparative RP
HPLC (see supporting information for crude and pure HPLC profiles and MALDITOF MS), and subjected to digestion.[28] The HPLC profile (trace c) showed five
peaks besides a peak from 2-mercaptoethanol indicating that the essay could detect
potentially damaged nucleosides. The relative retention times of the nucleosides
including 8-oxo-dG were consistent with literature values.[27, 28] To address the
concern that ODN damage may be dependent on the secondary structures resulted
from different sequences, a complex mixture of 20-mer ODN (2.25), which contained
419, theoretical sequences, were synthesized using a mixture of the four nucleoside
phosphoramidite monomers. The synthesis procedure with a shortened capping time
was used (Cycle 2 in supporting information), and the failure sequences were capped
with methacrylamide phosphoramidite 2.11. The crude ODN was subjected to the
general catching failure sequences by polymerization process (supporting
information). The resulting mixture of full-length sequences was subjected to the
same SVP digestion, BAP dephosphorylation, and RP HPLC analysis process (trace
d, Figure 2.4). Only four peaks were observed. To confirm that the peaks were from
ODN and not from SVP and BAP, the essay process was repeated without using any
ODN. No nucleoside peaks were observed (supporting information). The four peaks
in traces a-b and d correspond to dC, dG, dT and dA, respectively. The areas of them
are consistent with calculated values (supporting information). [27] These results



provide strong evidence that ODNs with different sequences are stable under the
radical acrylamide polymerization conditions. Further analysis to detect any minute
quantities of potentially damaged ODNs under the radical conditions is beyond the
scope of this study. Future directions would be to use the purified ODNs in molecular
biology experiments.
2.3 Experimental


General Methods
Reagents and solvents commercially available were used as received unless
otherwise noted. CH2Cl2 was distilled over CaH2 under a nitrogen atmosphere.
Reactions were carried out under nitrogen in oven-dried glassware. Thin layer
chromatography (TLC) was performed using TLC plates with silica gel 60F-254 over
glass support, 0.25 μm thickness. Flash column chromatography was carried out
using silica gel with particle size of 32 – 63 μm. 1H, 13C and 31P NMR spectra were
measured at 400, 100 and 162 MHz, respectively. HRMS was obtained using a TOF
mass analyzer. RP HPLC: A C-18 analytical column (5 μm diameter, 100 Å pore
size, 250 × 3.2 mm dimension) was used. Solvent A: 0.1 M triethylammonium
acetate, 5% acetonitrile. Solvent B: 90 % acetonitrile. Profiles were generated by
detection of absorbance of ODN at 260 nm using the following gradient system
unless indicated otherwise: solvent B (0%-45%) in solvent A over 60 min followed
by solvent B (45%-100%) in solvent A over 20 min at a flow rate of 0.5 mL/min. Ionexchange HPLC: An analytical Gen-Pak FAX (100 × 4.6 mm) column was used.
Solvent A: 25 mM Tris/Cl, 1 mM EDTA, pH 8.0. Solvent B: 25 mM Tris/Cl 1 mM



EDTA, 1.0 M NaCl, pH 8.0. The profile was generated by detection of absorbance of
ODN at 260 nm using the gradient system: solvent B (10%-75%) in solvent A over
30 min followed by solvent B (75%) in solvent A for 30 min at a flow rate of 0.5
mL/min. Succinic ester linked DMTr-dT-lcaa-CPG (1000 Å pore size) and 5-DMTr,
2-cyanoethyl phosphoramidites Pac-dA, benzoyl-dA, acetyl-dC, 4-isopropyl-Pac-dG,
isobutyryl-dG, dT and other commonly used reagents for solid phase ODN synthesis
were from commercial sources. The polymerization solution with a cross-linking
ratio of 1:25 was used in all cases unless otherwise noted. The solution could be
stored in a freezer at -20 ºC in dark for one month without affecting the results of
catching by polymerization purification. High resolution MS and elemental analysis
data for phosphoramidites were not collected due to their sensitivity to air and
moisture.
Methacrylamide 2.15
The compound is known, [19] but a different procedure was used for its
preparation. To a round-bottomed flask under a nitrogen atmosphere was added 2.14
(2.0 g, 19.0 mmol, 1.0 equiv), freshly distilled CH2Cl2 (60 mL), and saturated
Na2CO3 (60 mL). The mixture was cooled to 0 oC, and methacrolyl chloride (1.86
mL, 19.0 mmol, 1.0 equiv) was added via a syringe slowly with vigorous stirring.
After addition, the reaction was allowed to proceed overnight while warming to rt
gradually. The contents were then transferred into a separatory funnel. After
removing the organic layer, the aqueous layer was extracted with CH2Cl2 (50 mL ×
3). The combined organic phase was dried over anhydrous Na2SO4, and filtered.



Volatiles were removed under reduced pressure. The crude product was purified with
flash column chromatography (SiO2, CH2Cl2/CH3OH, 9:1) giving 2.15 as a colorless
oil (3.12 g, 18.0 mmol, 95%): Rf = 0.7 (SiO2, CH2Cl2/CH3OH, 9:1).
Phosphoramidite 2.11
An oven-dried round-bottomed flask containing 2.15 (0.5 g, 2.89 mmol, 1.0
equiv) and a magnetic stirring bar was evacuated and then refilled with nitrogen. The
evacuation and nitrogen-filling cycle was repeated for three times. Freshly distilled
CH2Cl2 (5 mL) was added via a syringe forming a light yellow solution. 2Cyanoethyl-N,N,N’,N’-tetraisopropylphosphoramidite (1.01 mL, 3.18 mmol, 1.1
equiv) and 1H-tetrazole (0.45 M solution in CH3CN, 7.07 mL, 3.18 mmol, 1.1 equiv)
were added slowly via syringes sequentially. After stirring at rt for 2 h, the reaction
mixture was concentrated to dryness using a flow of nitrogen. The residue was
purified with flash column chromatography (SiO2, hexanes/ethyl acetate/Et3N,
1:3:0.2) to give 2.11 as a colorless oil (0.98 g, 2.62 mmol, 90%): Rf = 0.7 (SiO2,
hexanes/ethyl acetate/Et3N, 1:3:0.2); 1H NMR (400 MHz, CDCl3)  6.29 (br s, 1H),
5.61 (s, 1H), 5.24 (s, 1H), 3.81-3.60 (m, 4H), 3.57-3.50 (m, 6H), 3.45-3.40 (m, 2H),
2.56 (t, J = 6.4 Hz, 2H), 1.88 (s, 3H), 1.18-1.04 (m, 12H);
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C NMR (100 MHz,

CDCl3)  168.6, 140.2, 119.6, 117.8, 71.2 (d, J = 7.6 Hz), 69.8, 62.9 (d, J = 16.7 Hz),
58.6 (d, J = 19.7 Hz), 43.2 (d, J = 12.1 Hz), 39.6, 24.8, 24.7 × 2, 24.66, 20.55, 20.47,
18.8; 31P NMR (162 MHz, CDCl3)  148.3.
Methacrylamide 2.17
The compound is known, [22] but a different procedure, which was the same
as that for the synthesis of compound 2.15, was used for its preparation. Reaction of



compound 2.16, [20] (1.3 g, 8.71 mmol, 1.0 equiv) with methacrolyl chloride (851
μL, 8.71 mmol, 1.0 equiv) in saturated Na2CO3 (40 mL) and CH2Cl2 (40 mL) gave
2.17 as a colorless oil after flash column chromatography purification (SiO2,
CH2Cl2/CH3OH, 9:1; 1.6 g, 7.37 mmol, 85%): Rf = 0.6 (SiO2, CH2Cl2/CH3OH, 9:1).
Phosphoramidite 2.12
The same procedure for the synthesis of phosphoramidite 2.11 was followed.
Thus compound 2.17 (500 mg, 2.30 mmol, 1.0 equiv), 2-cyanoethyl-N,N,N’,N’tetraisopropylphosphoramidite (0.80 mL, 2.53 mmol, 1.1 equiv) and 1H-tetrazole
(0.45 M in CH3CN, 5.60 mL, 2.53 mmol, 1.1 equiv) in CH2Cl2 (5 mL) gave
compound 2.12 as a colorless oil after flash column chromatography purification
(SiO2, hexanes/ethyl acetate/Et3N, 1:3:0.2; 0.85 g, 2.04 mmol, 88%): Rf = 0.7 (SiO2,
hexanes/ethyl acetate/Et3N, 1:3:0.2); 1H NMR (400 MHz, CDCl3)  6.33 (br s, 1H),
5.61 (s, 1H), 5.22 (s, 1H), 3.76-3.70 (m, 4H), 3.58-3.49 (m, 10H), 3.43-3.38 (m, 2H),
2.56 (t, J = 6.4 Hz, 2H), 1.86 (s, 3H), 1.10-1.07 (m, 12H);
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C NMR (100 MHz,

CDCl3)  168.5, 140.2, 119.6, 117.9, 71.4 (d, J = 7.6 Hz), 70.7, 70.4, 69.8, 62.8 (d, J
= 18.2 Hz), 58.6 (d, J = 18.2 Hz), 43.2 (d, J = 12.1 Hz), 39.5, 24.8, 24.7 × 2, 24.66,
20.5, 20.4, 18.8; 31P NMR (162 MHz, CDCl3)  149.5.
Methacrylamide 2.19
The same procedure for the synthesis of compound 2.15 was followed.
Reaction of 2.18[21] (2.0 g, 8.54 mmol, 1.0 equiv) with methacrolyl chloride (0.84
mL, 8.54 mmol, 1.0 equiv) in CH2Cl2 (80 mL) and saturated Na2CO3 (60 mL) gave
2.19 as a colorless oil (2.2 g, 7.28 mmol, 85%) after flash column chromatography
purification (SiO2, CH2Cl2/CH3OH, 9:1): Rf = 0.4 (SiO2, CH2Cl2/CH3OH, 9:1); 1H




NMR (400 MHz, CDCl3)  6.94 (br s, 1H), 6.80 (br s, 1H) 5.58 (s, 1H), 5.19 (s, 1H),
3.53-3.44 (m, 6H), 3.43-3.32 (m, 4H), 3.30-3.24 (m, 4H), 2.19 (t, J = 7.0 Hz, 2H),
1.81 (s, 3H), 1.74-1.66 (m, 2H); 13C NMR (100 MHz, CDCl3)  174.1, 169.1, 139.9,
120.1, 70.3, 69.92, 69.86, 61.7, 50.3, 39.6, 39.4, 33.4, 28.5, 18.7. HRMS (ESI,
[M+H]+) m/z calcd for C14H27N2O5 303.1914, found 303.1918.
Phosphoramidite 2.13
The same procedure for the synthesis of phosphoramidite 2.11 was followed.
Thus compound 2.19 (0.5 g 1.65 mmol, 1.0 equiv), 2-cyanoethyl-N,N,N’,N’tetraisopropylphosphoramidite (0.58 mL, 1.82 mmol, 1.1 equiv) and 1H-tetrazole
(0.45 M in CH3CN, 4.05 mL, 1.82 mmol, 1.1 equiv) in CH2Cl2 (5 mL) gave
compound 2.13 as a colorless oil after flash column chromatography purification
(SiO2, hexanes/ethyl acetate/Et3N, 1:3:0.2; 0.75 g, 1.49 mmol, 90%): Rf = 0.65 (SiO2,
hexanes/ethyl acetate/Et3N, 1:3:0.2); 1H NMR (400 MHz, CDCl3)  6.40 (br s, 1H),
6.22 (br s, 1H), 5.64 (s, 1H), 5.27 (s, 1H), 3.84-3.69 (m, 2H), 3.65-3.41 (m, 14H),
3.40-3.32 (m, 2H), 2.58 (t, J = 6.0 Hz, 2H), 2.24 (t, J = 7.4 Hz, 2H), 1.95-1.87 (m,
5H), 1.16-1.08 (m, 12H); 13C NMR (100 MHz, CDCl3)  172.8, 168.6, 140.2, 119.7,
118.0, 70.4, 69.9 (d, J = 18.3 Hz), 62.9 (d, J = 16.7 Hz), 58.4 (d, J = 19.8), 58.5, 45.5
(d, J = 6.0 Hz), 43.1 (d, J = 10.6), 39.5, 39.3, 33.1, 27.3, 24.8 × 2, 23.11, 23.04, 20.6,
20.3, 18.8; 31P NMR (162 MHz, CDCl3)  149.5.
Synthesis of ODN 2.20 Using Polymerizable Phosphoramidites 2.10-2.13 to Cap
Failure Sequences – The General ODN Synthesis Procedure
The synthesis using 2.11 as the capping agent is described as an example. The
phosphoramidite chemistry was used. CPG (1000 Å pore size) with a LCAA-succinyl



ester linkage was used as the solid support. The phosphoramidite monomers used
were Pac-dA-CE, Ac-dC-CE, i-Pr-Pac-dG-CE and dT-CE. For capping failure
sequences, a 0.15 M solution of 2.11 in dry acetonitrile (distilled under nitrogen or
from a commercial source) was placed on the 5th phosphoramidite position. The two
bottles normally used for storing Ac2O capping reagents were left empty. A new
synthetic cycle was created by copying the standard 0.2 μmol synthesis cycle into a
new file. The steps for capping failure sequences with Ac2O were deleted. After the
coupling steps, new steps for delivering 2.11 from the 5th bottle position and 1Htetrazole solution from the 9th position (i.e. the same activator for the coupling steps)
were added. These steps were the same as those in the coupling steps except that the
base was from the 5th bottle, the reagents were delivered for two additional times, and
after each delivery a waiting of 90 seconds was added. More specifically, the
solutions of 2.11 and 1H-tetrazole were delivered to column for 2.0 seconds, 1.5
seconds × 3, and after each delivery, the reagents remained in the column for 90
seconds. After capping, steps for washing the column with acetonitrile and oxidation
were added (Cycle 1 in supporting information). The synthesis was initiated using the
above reagents and cycle on a 0.2 μmol scale. In the last synthetic cycle, the 5-DMTr
group was removed. Cleavage and deprotection were carried out on the synthesizer
with concentrated NH4OH (900 min × 4) at rt. The synthesized ODN is labeled as
2.10(c2.11l). The same sequence was synthesized under the same conditions using
polymerizable phosphoramidites 2.10 and 2.12-2.13 as capping reagent giving
2.20(c2.10l), 2.20(c2.12l) and 2.20(c2.13l), respectively.



Purification of ODN 2.20 by Polymerization of Failure Sequences – The General
ODN Purification Procedure
Purification of 2.20(c2.11l) is described as an example. The ODN solution
from the synthesizer was divided equally into four portions and dried in centrifuge
tubes in a centrifugal vacuum concentrator. One portion was dissolved in 150 μL
water, 20 μL was injected into RP HPLC to generate trace a (Figure 2.3). The
remaining 130 μL solution was transferred into a 25 mL 2-necked round-bottomed
flask containing a magnetic stirring bar. The centrifuge tube was washed with water
(40 μL × 3), and the washes were transferred to the same flask. A polymerization
solution (250 μL, cross-linking ratio 1:25) was added via a pipette under positive
nitrogen pressure. The solution was gently stirred under a nitrogen flow at rt. After 5
min, the nitrogen flow was stopped but stirring was continued under a nitrogen
atmosphere. The polymerization reaction was then initiated with (NH4)2S2O8 (10%, 5
μL) and N,N,N,N-tetramethylethylenediamine (TMEDA, 5 μL), which were added
sequentially via a pipette and a syringe, respectively. A clear gel was formed within 5
min and stirring stopped automatically. The gel was allowed to stand for 1 h to ensure
complete polymerization.
The gel was broken into about 4 pieces with a clean spatula or preferably a knife
with a sharp blade that does not grind the gel into fine pieces. To the flask, sufficient
water that could cover all the gel (~3 mL) was added. The mixture was stirred or
shaken gently at rt for 3 h. The supernatant was separated from the gel. The gel was
further extracted with water (3 mL × 3) under the same conditions. After the volume
was reduced in a centrifugal vacuum concentrator, the extracts were filtered into one
 


1.5 mL centrifuge tube that has a spin filtration function. The extracts were
evaporated into dryness. To the residue, concentrated NH4OH (100 μL) was added.
The tube was closed. After vortexing and centrifuging briefly, it was kept for 25 min
on a heating block that was pre-heated to 80 oC. The solution was then cooled to rt,
and nBuOH (900 μL) was added. The tube was vortexed for 30 sec and centrifuged
for 8 min at 14.1 relative centrifugal forces. The supernatant was removed carefully
with a pipette. The residue was dried in a centrifugal vacuum concentrator shortly,
and then dissolved in 130 μL water. After vortexing and centrifuging shortly, 20 μL
was injected into RP HPLC to generate trace b (Figure 2.3). The recovery yield of the
catching by polymerization process was estimated to be 93% by dividing the area of
the peak at 19 min in trace b by that in trace a (Figure 2.3). Crude ODNs 2.20(c2.10l),
2.20(c2.12l) and 2.20(c2.13l) were purified using the same procedure, and their
recovery yields and purity are in Table 2.1. RP HPLC profiles are in supporting
information.
Synthesis of ODN 2.20 Using Polymerizable Phosphoramidites 2.10-2.13 to Cap
Failure Sequences with Shorter Capping Time
ODN 2.20 was synthesized again following the general ODN synthesis
procedure described earlier on a 0.2 μmol scale except that the capping time was
decreased from 2.0 seconds, 1.5 seconds × 3 deliveries and 90 seconds waiting after
each delivery to 2.0 seconds, 1.5 seconds × 2 deliveries and 30 seconds waiting after
each delivery (Cycle 2 in supporting information). The synthesized ODNs are labeled
as 2.20(c2.10s), 2.20(c2.11s), 2.20(c2.12s) and 2.20(c2.13s).
!


Purification of ODN 2.20 Synthesized Using Shorter Capping Time by
Polymerization of Failure Sequences
The general ODN purification procedure described earlier was used. The RP
HPLC profiles are in supporting information. The recovery yields and purity are in
Table 2.1.
Diffusion Speed of ODN From Acrylamide Gel and Extraction Efficiency
One fourth of the crude ODN 2.20(c2.11s) was subjected into the radical
acrylamide polymerization conditions in a 25 mL 2-necked round-bottomed flask as
described in the general ODN purification procedure. The polymerization solution
used in the procedure had a 1:25 cross-linking ratio between the cross-linker N,Nmethylenebis(acrylamide) and the polymerization monomer N,N-dimethylacrylamide.
After complete polymerization, the gel was broken into several pieces with a clean
spatula. Water (3 mL) was added to the gel, and the mixture was stirred gently with
magnetic stirring bar. The aliquots of supernatant (5 μL each) were taken out via a
pipette in every 10 min until 2 h. The ODN concentrations in the aliquots were
determined using a UV-Vis spectrophotometer at 260 nm (Table 2.2). At 2 h, all the
remaining supernatant were taken out and transferred into clean centrifuge tubes. The
ODN concentration in the supernatant was determined with UV. To the gel was added
water (3 mL) again and the mixture was gently stirred. After 2 h, the supernatant was
removed and the ODN concentration was determined with UV. The extraction and
ODN quantification process was performed for three more times (Table 2.3). The
ODN diffusion and extraction studies were repeated four more times using
polymerization solutions with a different cross-linking ratio. One with a ratio of 1:50
"


between N,N-methylenebis(acrylamide) and N,N-dimethylacrylamide, and the others
1:15, 1:7 and 1:2. The data were recorded in Tables 2.2 and 2.3.
Synthesis of Long Sequence ODN 2.23
The 61-mer ODN 2.23 was synthesized on a 0.2 μmol scale using
phosphoramidite 2.11 for capping failure sequences. The general synthesis procedure
with shorter capping time (Cycle 2 in supporting information) was used except that a
30 seconds additional waiting step was added after the coupling steps to increase
coupling yields.
Purification of ODN 2.23 by Polymerization of Failure Sequences
The general ODN purification procedure was used. The RP HPLC profiles
from crude and purified ODN 2.23 were generated using a different buffer A that
contained 10% urea under otherwise the same conditions described in the general
methods section (supporting information). Recovery yield and purity are in Table 2.1.
The purified 2.23 was analyzed with negative ESI MS using Waters’ Tofspec-2E,
calcd for C599H749N235O361P60 18875.1, found 18875.1. Image of the MS is included
in supporting information.
Synthesis of ODN 2.20 on a Larger Scale
The general ODN synthesis procedure was followed except that a different
synthesis cycle was used. To create the new cycle (Cycle 3 in supporting
information), the standard 1 μmol synthesis cycle provided by the manufacturer of the
synthesizer was copied into a new file. The steps for capping failure sequences with
Ac2O were deleted. After the coupling steps, new steps for delivering polymerizable
phosphoramidite 2.11 (0.15 M acetonitrile solution) from the 5th phosphoramidite



bottle position and 1H-tetrazole solution from the 9th position (i.e. the same activator
for the coupling steps) were added. These steps were the same as those in the
coupling steps except that the base was from the 5th bottle, one additional delivery of
reagents was added, and after each delivery a waiting of 30 seconds was added. More
specifically, the solutions of 2.11 and 1H-tetrazole were delivered to column for 2.5
seconds × 3, and after each delivery, the reagents remained in the column for 30
seconds. Other modifications of the cycle were the same as detailed in the general
synthesis procedure. The synthesis was performed using this new cycle at 1 μmol
scale following the conditions described in the general synthesis procedure. The ODN
is labeled as 2.20(c2.11ls)
Purification of 2.20(c2.11ls) by Polymerization of Failure Sequences
The general ODN purification procedure was followed. The 1 μmol ODN was
purified in one batch. The volume of the polymerization solution was 10 times of that
used in 0.05 μmol scale purification described in the general procedure. Extraction of
full-length sequences from gel was achieved by water (4 mL × 4). HPLC profiles are
in supporting information. Recovery yield and purity are in Table 2.1.
Synthesis of ODN 2.20 with DCI as Activator
ODN 2.20 was synthesized under the same conditions described for the
synthesis of 2.20(c2.11ls) except for the following modifications. DCI (0.25 M in
acetonitrile) instead of 1H-tetrazole was used as the activator for coupling and
capping. The concentration of phosphoramidite monomers was lowered from 1.0 M
to 0.05 M. Capping was performed using a 0.1 M acetonitrile solution of 2.11. The



synthesis was performed in three 1 μmol columns simultaneously. The ODN is
labeled as 2.20(c2.11dci).
Purification of 2.20(c2.11dci) by Polymerization of Failure Sequences
The 3 μmol ODN was purified in one batch following the procedure for the
purification of 2.20(c2.11ls). The volumes of the polymerization solution and
extraction solutions were increased proportionally (i.e. 3 times of those for the 1 μmol
2.20(c2.11ls) purification). The volumes of the polymerization initiators and the
reagents for ODN precipitation from NH4OH solution by nBuOH were not changed.
The RP HPLC profiles from crude and purified ODN 2.20(c2.11dci) including one
that was generated by UV detection at 210 nm from the purified ODN are included in
supporting information. Recovery yields and purity are in Table 2.1.
Synthesis of Mixture ODN 2.25
The general ODN synthesis procedure with a shorter capping time was
followed (Cycle 2 in supporting information). The synthesis was carried out on a 0.2
μmol scale using polymerizable phosphoramidite 2.11 for capping failure sequences.
To synthesize the mixture ODN, the solution of Pac-dA-CE, Ac-dC-CE, i-Pr-Pac-dGCE and dT-CE in 1:1:1:1 mole ratio was used as the phosphoramidite monomers in
the coupling steps in all synthesis cycles. The cycle was executed 20 times to give the
20-mer ODN mixture 2.25. At the end of synthesis, the DMTr group was removed.
The ODN were cleaved and deprotected with concentrated NH4OH at rt on
synthesizer.




Purification of ODN Mixture 2.25 by Polymerization of Failure Sequences
The general ODN purification procedure was used to remove failure
sequences. The RP HPLC profiles from crude and purified ODN 2.25 (only failure
sequences were removed; theoretically it still contained 419 sequences) are included in
supporting information. The recovery yield of the purification process was estimated
to be 78%.
ODN Stability Studies Through Nuclease Digestion Followed by RP HPLC
Analysis
To a 1.5 mL centrifuge tube, which contained 18 μg ODN 2.20 purified by
catching failure sequences by polymerization, was added 29 μL master mixture
solution containing 16.45 unit SVP (Worthington Biochemical Corporation), 0.4 unit
BAP (TaKaRa Bio Inc.), and 1× of BAP buffer. The tube was vortexed and
centrifuged briefly to mix thoroughly and to bring the master mixture to the bottom of
the tube. The mixture was then incubated at 37 ºC for 24 h. The digested ODN was
then prepared for RP HPLC analysis following reported procedure.[27] Briefly,
sodium acetate buffer (3 M, 4 μL) and ethanol (100 μL) were added into the tube.
The tube was then vortexed shortly and chilled on dry ice for 10 min. After
centrifuging for 5 min at 14.1 relative centrifugal force, the supernatant was carefully
transferred into another 1.5 mL centrifuge tube. To the tube was added ethanol (300
μL), and the contents were vortexed and chilled on dry ice again for 10 min. The tube
was centrifuged for 5 min, and the supernatant was transferred into a new 1.5 mL
centrifuge tube. After drying in a centrifugal vacuum concentrator, the nucleosides
were dissolved in water (30 μL). The sample (20 μL) was analyzed with RP HPLC



under the conditions described in the General section except that the gradient system
was changed to: solvent A (100%) for 5 min, solvent B (0%-10%) in solvent A over
30 min, followed by solvent B (10%-100%) in solvent A over 25 min. The resulting
profile is shown in Figure. 2.4 (trace a). The same ODN digestion and RP HPLC
analysis procedure was applied to a control ODN (18 μg) from a commercial source
purified with preparative RP HPLC (trace b), the mixture ODN 2.25 (33 μg, trace d),
and a blank control (supporting information). The control ODN 2.24 (9 μg) was
synthesized and digested following known procedure (trace c).[28]
Effect of One-Month Old Capping Agent on Purification
For the catching by polymerization purification technology to be practically
useful, it is important that capping phosphoramidites stored for a reasonable time
have a similar capping efficiency as freshly prepared ones. For this reason, we stored
compound 2.11 in a freezer under a nitrogen atmosphere at -20 ºC. After one month,
its acetonitrile solution was prepared and used for the synthesis ODN 2.20 for
capping failure sequences. The synthesis procedure with shortened capping time
(Cycle 2) was used. The crude ODN, which is labeled as 2.20(c2.11o), was purified
with the catching failure sequences by polymerization method. RP HPLC analysis
(see this supporting information) indicated that the purification results were the same
as with freshly prepared capping agents. The recovery yield of the purification
process was estimated to be 87%. The purity is 92%.
Effect of Radical Scavenger on Purification
For one time, when pure phosphoramidite 2.10, which was a thick oil, was
dried under high vacuum at room temperature overnight, it became a gel. The reason



is that under such conditions, the amount of oxygen, which serves as a radical
scavenger, was significantly reduced, and radical polymerization occurred. To avoid
premature radical polymerization, since then all capping phosphoramidites (2.102.13) were dried over drierite in a dessicator under a relatively low vacuum (achieved
using an oil pump for an appropriate time and then close the dessicator) at -20 ºC in a
freezer overnight. With the new drying method, we never met premature
polymerization problem again. In the case of the solution of the methacrylamide
phosphoramidites (2.10-2.13) in acetonitrile, premature polymerization never
occurred in our hands. They are stable for at least three days on a synthesizer or in a
freezer (-20 ºC) under nitrogen. Despite these favorable observations, potential users
of the technology may still be interested to know if the capping steps during ODN
synthesis are compatible with radical polymerization inhibitors in the capping
solution. To clarify, ODN 2.20 was synthesized using the procedure with shortened
capping time (Cycle 2). The solution of 2.11 (0.15 M) in acetonitrile with 500 ppm
2,6-di-tert-4-methylphenol was used for capping. The crude ODN was purified by
catching failure sequences in the usual way. RP HPLC analysis (see this supporting
information) revealed that the ODN, which is labeled as 2.20(c2.11i), was pure
indicating that the radical scavenger studied did not adversely affect the purification
results. The recovery yield of the purification process was estimated to be 97%. The
purity is 98%.




Effect of Harsher Deprotecting Conditions on Purification
In our studies so far, the exo-amino groups on adenine and guanine were
protected with phenoxyacetyl (Pac) and isopropyl-phenoxyacetyl (i -Pr-Pac) groups,
respectively. These groups along with the acetyl group on cytosine were removed
with concentrated NH4OH at room temperature after synthesis. This protecting
strategy has the advantage of avoiding deprotection under ammonia pressure in a
sealed vial at elevated temperature. In the less expensive and more commonly used
ODN synthesis methods, adenine and guanine are protected with benzoyl and
isobutyryl groups, respectively, and deprotection are usually achieved with
concentrated NH4OH at elevated temperature. Previously, we showed that the harsher
deprotecting conditions were compatible with the catching full-length sequences by
polymerization ODN purification technology (Y. Yuan et al, RSC Adv., 2012, 2,
2803). Here, we show that the conditions are also compatible with the catching failure
sequences method. The ODN 2.20 was synthesized on a 0.2 μmol scale using the
more commonly used protecting strategy (benzoyl for dA, isobutyryl for dG, and Ac
for dC). The synthetic cycle with shortened capping time described earlier (Cycle 2)
was used for the synthesis, and phosphoramidite 2.11 was employed for capping
failure sequences. At the end of synthesis, DMTr group was removed, and cleavage
was performed on the synthesizer with concentrated NH4OH (900 min × 4) at rt.
Deprotection was achieved by heating the concentrated NH4OH solution in a screw
capped vial at 65 ºC for 8 h. The ODN, which was labeled as 2.20(c2.11c), was
purified by catching failure sequences by polymerization as usual. RP HPLC analysis
showed that the ODN was pure (see this supporting information). The recovery yield



of the purification process was estimated to be 76%. The purity is 93%. The results
indicate that the catching failure sequences by polymerization purification method is
equally effective when protecting groups that require harsher deprotecting conditions
are used during ODN synthesis.
Capping with Lower Concentration Polymerizable Phosphoramidite Solution
In our preliminary communication, we used a capping solution with a
concentration of 0.2 M to cap failure sequences (S. Fang et al, Chem. Commun.,
2011, 47, 1345). In the present work, we reduced the concentration of capping
solution to 0.15 M. Good purification results were obtained in both cases. In the
coupling steps, the concentration of nucleoside phosphoramidite monomers we used
was 0.1 M. We were interested in further reducing the concentration of the capping
solution to this value. For the purpose, ODN 2.20 was synthesized using the
procedure with shortened capping time (Cycle 2). Capping failure sequences was
performed with a 0.1 M solution of 2.10. The resulting ODN, which is labeled as
2.20(c2.10lc), was purified by catching failure sequences by polymerization as usual.
RP HPLC analysis showed that the ODN was equally pure (see this supporting
information). The recovery yield of ODN was estimated to be 90%. The purity is
99%.
Purification by Polymerization in Air
So far in all of our studies, the polymerization step, in which failure sequences
were incorporated into a polyacrylamide gel, was performed under a nitrogen
atmosphere to minimize the chances of termination of polymerization by oxygen.
This may not be convenient for some applications such as high throughput
 


purification. Noting that excess initiators were used and cross-linking could connect
terminated polymer segments, we tested to perform the step in air in a 1.5 mL
centrifuge tube. A portion of ODN 2.20(c2.11s) in a centrifuge tube was simply
dissolved in water and polymerized by adding polymerization solution and initiators
to the tube directly. Interestingly, the polymerization speed was not found slower than
that under nitrogen atmosphere, and the gel was formed within 5 min. After waiting
for complete polymerization for 1 h, extraction of full-length sequences with water
was also carried out directly in the same tube. The remaining steps were the same as
in the general purification procedure. RP HPLC showed that the ODN was equally
pure (see this supporting information). The recovery yield was estimated to be 87%.
The purity is 100%. Polymerization under nitrogen in large scale purifications should
be quite convenient, and is not expected to add any significant cost to the process.
However, for high throughput purification, handling many samples at the same time
under a nitrogen atmosphere may require special equipment. Therefore, the results are
important for applying the technology in high throughput ODN purification.
2.4 Conclusion


Several details of the catching failure sequences by polymerization ODN
purification technology were investigated. We found that the four methacrylamide
phosphoramidites 2.10-2.13 were similarly effective for capping failure sequences in
the purification technique. However, because 2.10 and 2.11 are easier to prepare, they
are the best choices. The studies on the diffusion speeds of ODN from
polyacrylamide gel to solution indicate that extraction of ODN from gel is efficient.
!


Normally, three extractions will recover more than 90% ODN. Contrary to our
prediction, ODN extraction efficiency is higher in the case of gels with higher crosslinking. This is a favorable finding for the technology because gels with higher crosslinking are harder and easier to work with. The technology was successfully applied
for the purification of a long sequence and purification at a larger scale. Capping
failure sequences with older methacrylamide phosphoramidite and phosphoramidite
solution containing a radical scavenger were also studied and were found that they
have little adverse effects on the purification results. The more commonly used exoamino nucleobases protecting groups that require harsher conditions to remove were
tested in the ODN purification method. They were found equally compatible with the
technology as the more labile phenoxyacetyl protecting groups. Polymerization in air
is more convenient than under a nitrogen atmosphere. This is especially important for
high throughput purification. We demonstrated that it does not affect purification
results. Finally and most importantly, we provided further evidences to support that
ODNs are stable under free radical acrylamide polymerization conditions. This study
is most important in the context of ODN drug purification.
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Abstract


Purification of synthetic oligodeoxynucleotides (ODNs) is simply achieved by
capping failure sequences with a polymerizable phosphoramidite followed by
polymerization. In this article, the reduction of the amount of polymerization
monomer to drastically increase ODN extraction efficiency, the use of a centrifugal
filter unit to ease the extraction process and the notification of using fresh
phosphoramidite solutions are described. In addition, further evidence to support the
purity of ODN and discussions of ODN stability under radical polymerization
conditions are provided.




3.1 Introduction


Synthetic oligodeoxynucleotides (ODNs) have found wide applications in
areas such as molecular biology, synthetic biology and antisense drug
development.[1] Their syntheses have been automated. Large scale and high
throughput syntheses are both possible.[2-6] During synthesis, the first nucleoside is
attached to a solid support. Subsequent nucleosides are added sequentially to give the
full-length ODN. The coupling reactions are highly efficient, but cannot be 100%,
which inevitably generates failure sequences. These failure sequences are usually
capped with acetic anhydride to ease purification. At the end of synthesis, the ODN is
cleaved from support and fully deprotected. The product contains failure sequences
and small molecules besides full-length sequences, and has to be purified for most
applications and ideally for all applications. The small molecules are easy to remove
because they are neutral and ODNs are anionic. Removal of failure sequences is,
however, more difficult. Currently, the most widely used method is HPLC.
Drawbacks include high cost of instrument and column, labor intensiveness, and high
waste to product ratio. The method is difficult to automate, expensive to scale up, and
unsuitable for high throughput purification. Other methods have been developed to
solve the problems[7-13], but still have various shortcomings.[14]
We recently reported a catching failure sequences by polymerization method
for ODN purification.[14, 15] In this method, the failure sequences are capped with a
polymerizable phosphoramidite such as 3.1 (Figure 3.1). Purification is achieved by
copolymerization

with

N,N-dimethylacrylamide.
!



The

failure

sequences

are

incorporated into polymer. The full-length sequences and small molecules remain in
solution and polymer matrix. Extraction with water and nBuOH precipitation gives
pure ODN. In this letter, we report several highly important refinements of the
technology. In our initial procedure, large excess of polymerization monomer was
used. One refinement is to reduce this amount. This refinement drastically increased
the extraction efficiency of ODN from polymer. Previously, extraction of ODN was
accomplished by pipetting supernatant, which was inconvenient. The second
refinement is to carry out polymerization in a centrifugal filter unit and to perform
extraction by simple spins. Besides these refinements, further evidences to prove the
purity of ODN, and the explanation of the stability of ODN under radical
polymerization conditions are provided.
The greatly simplified procedure is demonstrated by the purification of the 20mer ODN 5-TCA TTG CTG CTT AGA CCG CT-3 (3.2). The ODN synthesis
procedure, which includes capping failure sequences by 3.1, was similar as previously
described.[15] Briefly, the synthesizer manufacturer (ABI 394) suggested 1 μmol
DNA synthesis cycle was copied to create a new cycle. The steps for capping with
acetic anhydride were replaced with those for capping with 1, which were achieved
by delivering 3.1 and activator to column. The delivery method was the same as the
coupling steps except that an additional delivery was added (2.5 seconds × 3) and
after each delivery a wait of 30 seconds was added. Following capping, three washes
(acetonitrile to column, 10 seconds; reverse flush, 6 seconds) were added. The
synthesis was set up as usual with 3.1 (0.1 M in acetonitrile)[15] being placed in
bottle 5. 4,5-Dicyanoimidazole (0.25 M in acetonitrile) was used as activator.
"


Because the catching by polymerization method can isolate full-length ODN from
very complex mixture, we lowered the concentration of phosphoramidite monomer
(Pac-dA, acetyl-dC, 4-isopropyl-Pac-dG, dT) solutions from the usually used 0.1 M
to 0.05 M (in acetonitrile). At the end of synthesis, detritylation was performed.
Cleavage and deprotection were carried out with concentrated NH4OH at room
temperature on synthesizer (15 min × 4, then 2 h). The solution was divided into four
portions and dried in 1.5 centrifugal tubes. One portion was dissolved in 600 μL
water, 20 μL was injected in to HPLC to give the crude profile (trace A, Figure 3.2).
Another portion of the crude 3.2 (~0.25 μmol) was dissolved in 50 μL water.
Short vortex and spin were performed to ensure complete dissolution and bring down
solution to bottom. To the solution was added 6 μL polymerization solution (0.37 M
N,N-methylenebisacrylamide and 3.7 M N,N-dimethylacrylamide) followed by a
short vortex and spin. The molar ratio of the polymerization monomer over ODN is
~100/1. The initiators (NH4)2S2O8 (5%, 5 μL) and TMEDA (0.66 M, 5 μL) were then
added. After a short vortex and spin, the mixture was transferred to the center of the
filter in a centrifugal filter unit (2 mL, pore size 7-20 μm, Aldrich) immediately in
one portion (Figure 3.1).[16]

!


Figure 3.1. The catching failure sequences by polymerization ODN purification
technology. (A) Working principle. (B) Picture of centrifugal filter units. (C)
Workflow: (a) To crude ODN in a centrifugal tube are added polymerization
monomer, cross-linker and initiators. After mixing, the contents are transferred to the
upper tube of a centrifugal filter unit. (b) The cap is closed and the mixture is allowed
to polymerize for 1 h. (c) The gel is cut into several pieces and the supernatant is
collected in the lower tube by spin. To the gel was added water. After standing at
room temperature for 10 min, spin again. The extraction is repeated two more times.
(d) The upper tube is removed, and the filtrate is evaporated to dryness. (e) To the
residue is added concentrated NH4OH, warmed for 15 min at 80 ºC in a heating
block. After cooling to room temperature, nBuOH is added. The mixture is vortexed
and then spun for 2 min. (f) The supernatant is removed by a pipette.
!
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Figure 3.2. HPLC profiles of ODN 3.2. Conditions: column, C-18, 5 μm, 100 Å, 250
× 3.20 mm; solvent A, 0.1 M triethylammonium acetate, 5% acetonitrile; solvent B,
90% acetonitrile; gradient, solvent B (0%-45%) in solvent A over 60 min; flow rate,
0.5 mL/min; detection, 260 nm.
It is suggested to close the bottom of the tube, but we found that the solution
would not leak even without closing. Care needs to be taken to transfer all contents
and to avoid splashing, which is easily achievable by manipulating the pipette with a
steady force as opposed to abrupt sucking and pushing. The unit was closed and the
mixture was allowed to polymerize for 1 hour. The gel was cut into about four pieces,
and the bottom of the upper tube was opened. The unit was spun for about 30
seconds, which separated the supernatant from gel. To the upper tube was added 50
μL water, which should cover all the gel. After standing for 10 minutes, the unit was
spun. The extraction was repeated two more times. The supernatants were evaporated
to dryness. To the residue, 100 μL concentrated NH4OH was added, and the mixture
!

was heated to 80 ºC for 15 minutes on a heating block (CAUTION: safety goggles
and face shield are needed for potential explosion). After cooling to room
temperature, 900 μL nBuOH was added. The mixture was vortexed shortly and spun
for 2 minutes. The supernatant was removed with a pipette. The white flake was pure
ODN. To determine purity and recovery yield, it was dissolved in 600 μL water, and
20 μL was injected into HPLC to give trace B (Figure 3.2). The ODN was 100%
pure. The recovery yield was estimated to be 97% by dividing the area of the peak at
15.5 minutes in trace B by that in trace A. To see if more ODN could be obtained
from the gel, the extraction and precipitation process was repeated. HPLC analysis
did not show any ODN (supporting information), which indicated that three
extractions in a time as short as 30 minutes were sufficient. We also performed a
blank control experiment in which no ODN was used. We did not see any residue.
HPLC analysis did not found any UV active material.
To confirm that the ODN peak in trace B does not contain any failure
sequences, we synthesized the 19-mer ODN 5-CAT TGC TGC TTA GAC CGC T-3
(3.3), which was identical to 3.2 except that the 20th base was not added. The ODN
was purified by catching by polymerization. Co-injection of 3.2 and 3.3 gave a
broadened peak. When a slower gradient was used, the two were well-resolved. With
the same slower gradient, 3.2 did not show any 19-mer failure sequence (supporting
information). Because 19-mer failure sequence is most difficult to resolve from the
full-length 20-mer sequence, it is conclusive that all failure sequences can be
removed by the catching by polymerization purification technique. Another potential
impurity in 3.2 may be the one from oxidation of dG to 8-oxo-dG, and this could not
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be detected by HPLC. We had described the synthesis of the same 20-mer sequence
of 3.2 with one dG being replaced with 8-oxo-dG 5-TCA TTG CT(8-oxo-dG) CTT
AGA CCG CT-3 (3.4), and its digestion to nucleosides. We found that 8-oxo-dG
could be detected by HPLC. In contrast, 8-oxo-dG could not be detected from
nucleosides from digesting 3.2.[15] In addition, we had subjected the G nucleoside
into the radical polymerization conditions and found that it was stable.[16] Here, we
provide further evidence that dG is stable under radical acrylamide polymerzation
conditions. When ODN 3.4, which contains 8-oxo-dG, was exposed to concentrated
NH4OH at elevated temperature, multiple peaks were observed in HPLC profile
(supporting information). This observation indicated that ODNs containing 8-oxo-dG
is unstable under such conditions. Because our purification procedure involves in
heating ODN in concentrated NH4OH, and HPLC analysis showed single peak, we
can conlude that ODNs purified with the catching by polymerization technology do
not contain 8-oxo-dG.
It is interesting to note that radicals can damage DNA.[17] Then, why is ODN
stable under the radical acrylamide polymerization conditions? To anwser this
question, we need to consider the fact that DNA damage is mostly caused by the
highly reactive hydroxyl radical. This radical is so reactive that it breaks carbonhydrogen bonds with little selectivity. The radical used to initiate the acrylamide
polymerization reaction is the sulfate radical, which was reported to be 3,000 times
less reactive than the hydroxyl radical.[18] In addition, under the polymerization
conditions used for purification, large excess of acrylamide is used. This acrylamide
could serve as a radical scavenger like vitamin E in the biological system. Once the
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sulfate radical is formed in the initiation stage of polymerization, it is quickly
converted to the carbon radical of acrylamide. This radical is stabilized by the amide
group through resonance, and may not be reactive enough to damage ODN, which
requires abstraction of hydrogen atom from a carbon-hydrogen bond or breaking
aromaticity of nucleoside bases by adding a radical to an aromatic ring.
For using the catching by polymerization method for ODN purification, one
very important lesson we learned in the past few years is that fresh nucleoside
phosphoramidite solutions need to be used for ODN synthesis. Otherwise, the purity
of product may be lower. For example, to reduce costs, in some of our previous
experiments, phosphoramidite solutions that were stored in a freezer under nitrogen in
jars containing Drierite over half a year were used. The ODNs purified by catching by
ploymerization were found contaminated with small amount of unidentifiable
impurities.[15] After realizing this, we always used phosphoramidite solutions
prepared within one week and found that ODN purity was consistently 100% after
purification by polymerization. Leaving the solutions on the synthesizer for one week
was found having no adverse effects on the purification results. It should be noted
that the phosphoramidites do not need to be freshly purchased. In fact, the ones we
used were usually stored in a freezer for more than six months.
The above refinements including using less acrylamide polymerization
solution, using a centrifugal filter unit, and using fresher phosphoramidite solutions
are critical for the catching by polymerization purification technology to be
practically useful. The resulted improvements are summarized in Table 3.1. For
example, in previous procedure, we used large excess of polymerization monomer.
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Therefore, we had to extract 0.25 μmol ODN from more than 500 μL gel.[14, 15] In
the improved procedure, we only used 6 μL monomer solution and the gel volume is
less than 20 μL. Importantly, we observed supernatant over the gel, which may
contain a large portion of ODN. In contrast, using previous procedure, there was only
one phase. Due to the reduced gel volume and the existence of supernatant, the
efficiency of ODN extraction is drastically improved. Previously, we had to be very
careful to suck up the supernatant by pipette during extraction.[14, 15] It was
inconvenient because gel fragments occasionally block pipette tip, and fine fragments
can be sucked up, which contaminate ODN. With a centrifugal filter unit, extraction
can be carried out by short spins.
3.2 Conclusion


In conclusion, several very important refinements of the catching failure
sequences by polymerization ODN purification technology are presented. These
refinements are critical for the technology to be practically useful. In addition, to
demonstrate the purity of ODN, we synthesized a 19-mer failure sequence and proved
that HPLC can resolve it from the 20-mer full-length sequence. The observation of
ODN that contains 8-oxo-dG is unstable under the purification conditions further
confirmed that ODN is stable under the acrylamide radical polymerization conditions.
The reasons for the stability are discussed. With these new results and findings, we
are now very confident that the catching by polymerization purification method is
highly convenient and highly reliable. We expect that it be widely used for small
scale, large scale, and high throughput purification.
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Table 3.1. Summary of advantages of improved procedure over previous procedure

Entry

Items

Previous procedure

Improved procedure

1

Polymerization
solution

250 μL

6 μL. Save monomers and reduce gel
volume

2

ODN solution

250 μL

50 μL

3

Gel volume

500 μL. Larger volume makes
extraction less efficient

< 20 μl. Smaller volume makes
extraction more efficient

4

Supernatant

No. All ODN in gel, difficult to
extract

Yes. Most ODN in supernatant, easier
to extract

5

Water for extraction

12 mL (3 mL x 4). Needs more time
to evaporate

0.15 mL (50 μL × 3). Needs less time
to evaporate

6

Extraction time

12 h (3 h x 4). Cannot finish in one
day

30 min (10 min × 3)

7

Extraction method

Pipetting supernatant. Difficult to
tip blockage by gel. Each extraction
takes ~ 20 min. Not suitable for
high throughput purification

Spin. Each extraction takes 10 sec.
Suitable for high throughput
purification

8

Extract

May contain gel, which needs
additional removal and reduces
recovery yield

No gel fragments, and very clean

9

Recovery yield

70-95%

>95%

10

ODN Purity

92-100%

100%. due to fresher
phosphoramidite solution
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Abstract


A methacrylation phosphoramidite containing a linker cleavable with acetic
acid was synthesized, and used for synthetic oligodeoxynucleotide (ODN)
purification. During automated synthesis, the full-length ODN was tagged with the
phosphoramidite. The failure sequences were not. In purification, the full-length
ODN was co-polymerized into a polyacrylamide gel, and the failure sequences and
other impurities were removed by washing. Pure ODN was cleaved from the gel with
acetic acid. Using the method, purification of sequences as long as 151-mer and at
scales as high as 50 jmol was demonstrated. The products have high purity and good
recovery yields. The method does not involve in any type of chromatography and
purification is achieved through simple manipulations such as shaking and filtration.
Compared with gel electrophoresis and HPLC purification methods, the new
technology is less labor-demanding and more amendable for automation, consumes
minimal amount of environmentally harmful organic solvents and requires little
energy for solvent evaporation. Therefore, it is ideal for high throughput purification
and large scale ODN-based drug purification as well as small scale purification.
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4.1 Introduction


Synthetic ODNs have found wide applications.[1-5] Important recent
examples include total gene synthesis for genome construction in synthetic biology
projects,[6-11] and oligonucleotide-based drug development.[12-16] Gene synthesis
requires hundreds of ODNs. In order for the synthetic genes to be affordable, the
ODNs should be produced in a high throughput fashion. Due to automated ODN
synthesis either using modern column-based synthesizers or microarray technologies,
large numbers of ODNs can be synthesized simultaneously.[6-11] For gene assembly,
it is crucial that the ODNs are highly pure. Currently, the ODNs are mostly purified
using gel electrophoresis or HPLC. However, using these technologies purification in
a highly parallel fashion is challenging, and high throughput ODN purification
remains a bottle-neck for gene synthesis and synthetic genome construction. For
oligonucleotide-based drug development, kilograms to metric tons of oligos are
needed for clinical trials and patient use after the drugs are marketed. This requires
large scale oligo production, which includes synthesis and purification. The
challenges for large scale oligo synthesis have been largely overcome,[12, 13] but
large scale purification remains a bottle-neck.[13-16] Currently, the most widely used
technology for large scale purification of oligonucleotide-based drugs is reversedphase (RP) HPLC. The method is expensive to scale up, consumes large volumes of
environmentally harmful organic solvents, and takes significant energy for solvent
evaporation. The waste to product mass ratio can be as high as 105:1.
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In order to overcome the challenges currently existed in high throughput and
large scale ODN purifications, we recently reported a new technology using the
concept of catching by polymerization.[17-21] In one instance, during automated
synthesis, the failure sequences were capped with acetic anhydride in each synthetic
cycle, and the full-length sequences were tagged with a polymerizable
methacrylamide group using a methacrylation phosphoramidite that contained a
cleavable linker. At purification, the crude product was simply subjected to
acrylamide polymerization conditions. The full-length sequences were copolymerized into the polyacrylamide gel, leaving the failure sequences and other
impurities in solution, which were removed by washing. The full-length ODN was
then cleaved from the polymer, and extracted with water. Highly pure ODN was
obtained with excellent recovery yields.[18] The new purification technology does
not involve any types of chromatography, and purification is achieved with simple
manipulations such as shaking and filtration. The waste to product mass ratio can be
as low as 1:1. As a result, the technology is highly suitable for high throughput and
large scale purification. However, in our earlier studies, the linker we used in our
methacrylation

phosphoramidite

for

tagging

full-length

sequences

was

a

diisopropylsilyl acetal function, and the highly toxic and corrosive hydrogen fluoride
had to be used for cleaving the full-length sequences from the polyacrylamide gel. In
addition, before cleavage the gel had to be dried under vacuum, which was energydemanding and time-consuming. Furthermore, the cleaving reaction was carried out
in DMF, which is expensive for large scale purification and difficult to evaporate due
to its high boiling point.[18] In this Paper, we report the synthesis of a new
"


methacrylation phosphoramidite, which contains a linker that can be readily cleaved
with the more environmentally benign 80% acetic acid, and its application in ODN
purification using the catching full-length sequences by polymerization approach. We
demonstrate that even for purification of sequences as long as 151-mer and at scales
as high as 50 jmol, the purification procedure requires little modification, and the
technology is still highly efficient.
4.2 Results and Discussion


Synthesis of Methacrylation Phosphoramidite 1
The phosphoramidite (4.1), which contains a polymerizable methacrylamide
group and an acid-labile alkyl trityl ether linker, was synthesized according to
Scheme 4.1. The commercially available 4-hydroxybenzophenone (4.2) was reacted
with methyl 6-bromohexanoate in the presence of potassium carbonate to give 4.3.
Compound 4.3 was treated with 4-methoxyphenylmagnesium bromide to give 4.4,
which was conveniently converted to 4.5 by simply heating with 2,2(ethylenedioxy)bis(ethylamine) in water. Under these conditions, mono-acylation was
favored over di-acylation, which is a common side reaction for mono-acylation of
symmetric diamines.[22, 23] Compound 4.5 was acylated with methacrolyl chloride
using DIEA as base to give 4.6. Converting 4.6 to 4.7 was achieved by first treating
4.6 with excess acetyl chloride. After removing volatiles, without purification, the
intermediate trityl chloride was used directly to react with thymidine in pyridine.
Product 4.7 was obtained in 77% isolated yield.[24] Phosphinylation of 4.7 using 2"


cyanoethyl N,N,N,N-tetraisopropylphosphordiamidite with diisopropylammonium
tetrazolide as activator gave compound 4.1 in 87% yield. All the reactions are simple,
and the reagents are inexpensive or can be replaced with cheaper ones. We expect
that the synthesis could be easily scaled up to kilograms.

Scheme 4.1. Synthesis of methacrylation phosphoramidite 1. Reagents and
conditions: (a) Br(CH2)5CO2CH3 (1.0 equiv), K2CO3 (4.0 equiv), acetone, reflux, 12
h, 85%; (b) p-H3COPhMgBr (3.0), -78 °C to rt, 4 h, 56%; (c) [CH2O(CH2)2NH2]2 (3.0
equiv), H2O, 85 C, 12 h, 75%; (d) methacrolyl chloride (1.0 equiv), DIEA (3.0 equiv),
CH2Cl2, 0 °C to rt, 12 h, 88%; (e) acetyl chloride, rt, 2 h; then thymidine (1.0 equiv),
pyridine, rt, 18 h, 77%; (f) (iPr2N)2PO(CH2)2CN (1.1 equiv), diisopropylammonium
tetrazolide (1.0 equiv), rt, 5 h, 87%.
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Purification at Small Scales
Table 4.1. ODN sequences
ODN

Length

4.8

20-mer

Sequences
5-T CAT TGC TGCT TAG ACC GCT-3

4.9

31-mer

5-T CGG ATT ATG TCG ATA TTA GGA GAA TGG TAT-3

4.10

37-mer

5-T ATA CCA TTC TCC TAA TAT CGA CAT AAT CCG TCG ATC-3

4.11

61-mer

5'-T AAA GCT ATA GGT ACA GTA TTA GTA GGA CCT ACA CCT
GTC AAG ATA ATG GTC CAG GTC GGT-3'

4.12

151-mer

5'-T CAA CAA AAT CAT TTT GCA CCA TGT GGA GCA CCT CCA
AAT AAC ACC TTT ATA ACC CAT GTG GCG TAA TCA TTG TTT
TCC ATC CTA GAA AGC TCA TAC AAT GCG TTT TTC ATG AGT
TTA TTT TCA TGC TCT AGT TTA GTC ATC TTC TTT TCT-3'

The 20-mer ODN sequence 4.8 (see Table 4.1 for ODN sequences) was used
to demonstrate the convenience of the new technology for the purification of short
ODNs on small scales. The ODN was synthesized on a 1 jmol scale under standard
conditions using phosphoramidite chemistry. The synthesizer manufacturer suggested
cycle was slightly modified so that the methacrylation phosphoramidite 4.1 could be
coupled to the 5-end of full-length sequences on the synthesizer automatically
(Figure 4.1). If one does not prefer to spend time on cycle modification, manual
coupling can also be used. For automated coupling, the standard cycle was copied to a
new file. After the coupling steps and before the capping steps, a 180 second waiting
step was inserted, and was set to be active only for base 5. The solution of 4.1 in
acetonitrile at the same concentration (0.1 M) as other standard phosphoramidite
monomers was attached to this bottle position. In the sequence, the nucleotide at the
5-end was edited to be 5, which in the example here incorporated the nucleotide dT
while tagging the ODN with a methacrylamide group. Except for these modifications,
"!


all other synthesis, deprotection and cleavage conditions were standard. Briefly, CPG
with a succinyl ester linker was used as solid support. The phosphoramidite
monomers were 5-DMTr 2-cyanoethyl benzoyl-dA, acetyl-dC, isobutyryl-dG, and
dT. Their 0.1 M solutions in acetonitrile were used for coupling with DCI as the
activator. Failure sequences were capped with acetic anhydride in each synthetic
cycle. At the end of synthesis, detritylation was not carried out as this would remove
the methacrylamide tag. Cleavage was carried out on the synthesizer with
concentrated ammonium hydroxide. Deprotection was achieved by heating the
ammonium hydroxide solution to 55 °C for 15 hours. After adding ~200 jL DIEA,
the solutions were divided into five equal portions, and evaporated to dryness under
vacuum. One portion was dissolved in 300 jL water, and 20 jL was injected into RP
HPLC to give trace a (Figure 4.2).
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Figure 4.1. The catching full-length sequences by polymerization ODN purification
technology. (A) Principle. (B) Workflow: (a) Add polymerization monomer and
initiators to crude ODN, and transfer to a centrifugal filter unit. (b) Wait for
polymerization. (c) Spin, add water, and spin. (d) Add 80% AcOH. (e) Spin, add
water, spin, evaporate filtrate, and precipitate with nBuOH. (f) Remove supernatant.
Once the full-length sequences were tagged with a methacrylamide group,
purification was very simple (Figure 4.1). To the second portion of the crude ODN
(~0.2 jmol), small amounts of water (50 jL), polymerization solution containing
N,N-dimethylacrylamide and N,N-methylenebis(acrylamide) (12 jL, see supporting
information for recipe), 5% ammonium peroxide (5 jL) and 0.66 M TMEDA
solutions (5 jL) were added sequentially. For convenient filtration during subsequent
washing, cleavage and extraction, before polymerization the solution was transferred



into the top compartment of a centrifugal filtering unit using a pipette. The solution
could stay above the filter disc even without stopping the bottom of the compartment.
The polymerization occurred quickly within 15 minutes, but it was allowed to
proceed for 1 hour to ensure completion (Figure 4.1). The full-length sequences were
covalently linked to polymer, and failure sequences remained in solution. The
polyacrylamide gel was loosened with a clean spatula, and water containing 5% Et3N
was added to wash away impurities including failure sequences and small molecules.
The wash was very convenient because the supernatant could be removed by a simple
spin. So, it was carried out for six times. A final wash with pure water was performed
to rinse away residue Et3N. To cleave the full-length sequences from the polymer,
minimum amount of 80% acetic acid that could cover the gel (120 jL) was added,
and the mixture was incubated for 5 minutes. The supernatant was removed by spin,
and the cleavage was repeated for two times. To extract remaining ODN, minimum
amount of water that could cover the gel (120 jL) was added, and the supernatant
was collected by spin. This was repeated for four times. The acetic acid and water
extracts were combined and evaporated to dryness. The residue was dissolved in 100
jL concentrated ammonium hydroxide and precipitated with 900 jl nBuOH. Pure
ODN 4.8 was dissolved in 300 jL, and 20 jL was injected into RP HPLC to give
trace b (Figure 4.2). As shown, the ODN was 100% pure. Because the theoretical
amount of ODN for generating traces a and b were equal, the recovery yield of the
purification process was easily determined to be 68% by dividing the area of the peak
in trace b at 19 minutes by that in trace a at 45 minutes.



To demonstrate the simplicity and effectiveness of the purification procedure
with more examples, the slightly longer ODNs 4.9 (31-mer) and 4.10 (37-mer) were
synthesized and purified. ODN 4.9 was synthesized at 1 jmol scale under the same
conditions described for 4.8, and 4.10 was synthesized at 10 μmol scale described in
the section of large scale purification. For cleavage and deprotection, we tested
different conditions. The mixture of concentrated ammonium hydroxide and
methylamine solutions at 1:1 volume ratio was used in both cases. This reagent
cleaved the ODN from CPG and removed all protecting groups at room temperature
in three hours, and therefore the procedure was more convenient. The purification
procedures were similar to that for purifying 4.8 with only slight modifications (see
experimental section). Both ODNs were obtained in 100% purity, and the recovery
yields were high. RP HPLC profiles are in supporting information.
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Figure 4.2. RP HPLC profiles of ODNs; (a) crude 4.8 (b) pure 4.8 (c) crude 4.10 (d)
pure 4.10 (e) crude 4.12 (f) pure 4.12


Purification at Larger Scales
A major application of the technique is the purification of ODNs on large
scales, which is important for large scale ODN-based drug production. To
demonstrate the suitability of our method for this purpose, we decided to carry out a
purification on a 50 jmol scale using ODN 4.10 as the example. The ODN was
synthesized in five 10 jmol columns with 1000 Å CPG. The same procedure and
reagents for synthesizing 4.8 were used except that the synthesis cycle was modified
from 10 jmol cycle. According to trityl essay before the cycle for attaching 4.1, the
average yield of 36-mer for the five synthesis was 50%. Cleavage and deprotection
were achieved using the mixture of concentrated ammonium hydroxide and
methylamine. RP HPLC analysis of the crude indicated that only about 50% of the
36-mer intermediate was successfully methacrylated with 4.1 (trace c, Figure 4.2). As
a result, the synthesis yield of the 37-mer was 25%. In the future, the synthesis should
be improved by increasing coupling time and capping time, and by coupling 4.1 for
one more time or allowing it to proceed longer. These modifications are expected to
give higher synthesis yield. For purification, the crude ODN was dissolved in 1.25
mL water in a 25 mL round-bottomed flask, and polymerization was carried out using
as little as 1.25 mL polymerization solution. The gel was transferred into a 15 mL
Büchner funnel with a sintered glass disc and broken into several pieces with a
spatula. Washing failure sequences and other impurities were simply achieved using
water containing Et3N followed by water. The wash was convenient because the
solutions could be easily removed by applying vacuum. Cleaving the full-length



sequences from gel was achieved under the same conditions in small scale
purifications with only a slightly larger volume of 80% AcOH (~4 mL). Extraction of
full-length sequences and precipitation with nBuOH were also very convenient (see
experimental section). Pure ODN 4.10 was obtained as nice white cotton-like fluffy
fibers (see picture in supporting information). The weight was 98 mg, which
corresponds to a 70% recovery yield of the purification process. RP HPLC analysis
showed that the ODN was 100% pure (trace d, Figure 4.2). The images 1H NMR are
in supporting information.
Long Sequence Purification
Another important application of the technique is long ODN purification,
which is especially important for total gene synthesis. Because long ODNs can
usually assume secondary structures and the hydrophobicity of DMTr group becomes
less distinctive as the length increases, they are challenging to purify with other
methods including trityl-on RP HPLC. Because our catching by polymerization
technology attaches the full-length sequences to a polymer gel covalently, in
principle, there is no limit on the length of ODN that can be purified using the
method. To demonstrate the power of the technique, the 61-mer 4.11 and the 151-mer
4.12 were synthesized and purified. ODN 4.11 was synthesized on 1 jmol scale using
the conditions for 4.9 on 1000 Å CPG. ODNs 4.12 was synthesized on 0.2 jmol scale
using 2000 Å CPG. To increase recovery yield and capping efficiency, additional
coupling and capping times were added in the synthetic cycle (see experimental
section). In addition, before the synthesis, the CPG was subjected to the capping



conditions for 20 minutes. All other conditions were the same as for the synthesis of
4.8 (see experimental section). The synthesis yields as indicated by trityl assay before
the last cycle for coupling 4.1 were 83% (for 4.11) and 22% (for 4.12). Cleavage and
deprotection were achieved using the mixture of concentrated ammonium hydroxide
and methylamine. Purification was carried out at 0.2 jmol (for 4.11) and 0.04 jmol
(for 4.12) scales. Polymerization was achieved under the same conditions described
for 4.8 using the same amount of polymerization reagents even though the
purification scales and sequence lengths were different. For washing failure
sequences from gel, the same conditions for 4.9 were used for 4.11. For the longer
ODNs 4.12, 3.0 M NaOAc was used to increase washing efficiency. The residue
NaOAc was removed by washing with 1% Et3N and water sequentially. Cleavage of
ODN from gel, extraction and nBuOH precipitation were carried out under the same
conditions described for 4.8. Recovery yields were determined to be 83% (for 4.11)
and 50% (for 4.12) by comparing areas of pure and crude HPLC peaks. All ODNs
were 100% pure. The crude and pure HPLC profiles for 4.12 are shown in Figure 4.2.
Those for 4.11 are in supporting information.
Reagent Mass Considerations
A major advantage of the catching by polymerization purification technology
compared to the most widely used RP HPLC is the low waste to product ratio. In the
above purification processes, for small scale purifications including 0.2 jmol scale
purification of 20-mer 4.8, 0.2 jmol scale purification of 31-mer 4.9, 0.2 jmol scale
purification of 61-mer 4.11, and 0.04 jmol scale purification of 151-mer 4.12, we



consistently used 12 jl polymerization solution [3.7 M N,N-dimethylacrylamide and
0.37 M N,N-methylenebis(acrylamide)]. The molar ratio of polymerization
monomers [moles of N,N-dimethylacrylamide and N,N-methylenebis(acrylamide)]
over the nucleotides in the ODNs (moles of ODN times the number of nucleosides)
were 12.2 (for 0.2 jmol 4.8), 7.9 (for 0.2 jmol 4.9), 4.0 (for 0.2 jmol 4.11), and 8.1
(for 0.04 jmol 4.12). For the 1 jmol scale purification of 37-mer 4.10, 24 jl
polymerization solution was used, the molar ratio was 2.6. For the 50 jmol
purification of 37-mer 4.10, 1.25 mL polymerization solution was used, and the molar
ratio was 2.8. Our guideline is that the molar ratio of polymerization monomer over
nucleotides in the ODN should be equal to or slightly higher than 2.5. If we assume
that an ODN contains equal numbers of the four nucleotides, the mass ratio of
polymerization monomers over ODN is around 0.83, which means that purification of
one gram of ODN requires less than one gram of polymerization monomers. Molar
ratio lower than 2.5 is not suggested because the full-length sequences may not be
caught completely and the polymerization may not be efficient due to diluted
polymerization monomer concentration. For small scale purification of short
sequences, when the molar ratio of 2.5 is used, the volume of polymerization solution
may be too tiny for convenient manipulation. As a result, a larger ratio is suggested.
In our examples, 12 jL polymerization solution was consistently used in the
purification of 4.8 (0.2 jmol), 4.9 (0.2 jmol), 4.11 (0.2 jmol), and 4.12 (0.04 jmol).
For larger scale purification, molar ratio much higher than 2.5 is not recommended
even though the polymerization monomers are inexpensive. With large amount of gel,
 


extraction of ODN after washing failure sequences requires relatively more water,
which consumes energy for evaporation.
Besides the mass ratio of polymerization monomers over ODN, there are other
mass ratios that need to be decided although these ratios are not critical for the
success of purification. In all the above purification examples, the molar ratio of N,Ndimethylacrylamide over N,N-methylenebis(acrylamide) was set to be 10:1. Other
ratios could also be used, but ratios higher than 40:1 give gels that are too soft for
convenient handling and ratios lower than 5:1 may reduce ODN extraction efficiency.
For the volume of water used to dissolve ODN before adding polymerization
solution, it can also be varied but should not be too far away from our examples. The
ones we used ranged from one (50 jmol purification of 4.10) to four (0.2 jmol
purification of 4.8) times of that of polymerization solution. The initiators are usually
more than enough even though only 5 jl of each were used in most of our examples.
For the 50 jmol purification of 4.10, we used 10 jl of each to ensure efficient
polymerization. The molar ratio of TMEDA over ammonium persulfate was set to be
3:1 in our examples, but this is not a requirement. For washing failure sequences from
gel, we used water containing bases such as Et3N and, NaOAc followed by pure
water. Adding bases can ensure the stability of the trityl alkyl ether linkage for
anchoring full-length sequences to gel and is expected to increase washing efficiency.
The volume of the washing solutions can be large because the solutions are
inexpensive and not harmful to environment, and do not require evaporation. For
cleaving and extraction full-length sequences from gel, minimum amount of 80%
!


AcOH and water that can cover gel should be used. Efficiency should not be achieved
using large amount of solutions, instead it should be achieved through repetitions.
Minimizing the total volume is important for saving time and energy for evaporation.
4.3 Experimental Section


General Procedures
All reagents and solvents were used from commercial sources as received
unless otherwise indicated. Dry THF and CH2Cl2 were from Innovative Technology’s
PureSolv™ system. Dry pyridine was obtained from distillation over CaH2 under
nitrogen. All reactions were carried in oven-dried glassware under nitrogen. 1H,
and
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C

P NMR spectra were measured on a Varian UNITY INOVA spectrometer at

400, 100 and 162 MHz, respectively. High resolution mass spectra were obtained on
an Agilent Q-TOF system using a dual electrospray ionization source. MALDI-TOF
mass spectrometry experiments were performed on Waters’ Tofspec-2E. ODNs were
synthesized on an ABI 394 solid phase synthesizer. RP HPLC was carried out using
the JASCO LC-2000Plus System with the pump PU-2089Plus Quaternary Gradient;
detector UV-2075Plus; column C-18 analytical (5 μm diameter, 100 Å, 250 × 4.6
mm); solvent A, 0.1 M triethylammonium acetate, 5% acetonitrile; and solvent B, 90
% acetonitrile. Profiles were generated by detection of absorbance of ODN at 260 nm
using the gradient system, solvent B (0%-45%) in solvent A over 60 min followed by
solvent B (45%-100%) in solvent A over 20 min at a flow rate of 1 mL/min unless
otherwise noted. In all purification examples, the solution that contains 3.7 M N,Ndimethylacrylamide and 0.37 M N,N-methylenebis(acrylamide), which had a cross"


linking ratio of 10:1, was used as the polymerization solution for catching full-length
sequences. Solutions of 5% (NH4)2S2O8 and 0.66 M TMEDA were used as
polymerization initiators.
Compound 4.3
Compound 4.2 (5.0 g, 25.24 mmol, 1.0 equiv), methyl 6-bromohexanoate (4.1
mL, 25.24 mmol, 1.0 equiv) and K2CO3 (14.0 g, 100.96 mmol, 4.0 equiv) was
charged to a round-bottomed flask. About 80 mL of acetone was added which was
previously passed through anhydrous sodium sulfate. The mixture was refluxed for
overnight. After cooling to rt, the mixture was concentrated under reduced pressure to
remove acetone. The remaining contents were transferred into a separatory funnel and
partitioned between ethyl acetate and water. The organic phase was dried over
anhydrous Na2SO4, filtered and the filtrate was concentrated to dryness under reduced
pressure and the residue was recrystallized between ethyl acetate and hexane giving
pure 4.3 as a white solid. (7.0 g, 21.44 mmol, 85%): Rf = 0.5 (Hexane/EtOAc, 3:1);
1

H NMR (400 MHz, CDCl3)  7.80-7.71 (m, 4H), 7.56-7.51 (m, 1H) 7.47-7.43 (m,

2H), 6.93-6.90 (m, 2H), 4.02 (t, J = 7.2 Hz, 2H), 3.66 (s, 3H), 2.34 (t, J = 7.2 Hz 2H),
1.86-1.79 (m, 2H), 1.74-1.66 (m, 2H), 1.55-1.49 (m, 2H);
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C NMR (100 MHz,

CDCl3)  195.7, 174.1, 162.9, 138.5, 132.8, 132.0, 130.2, 129.9, 128.4, 114.2, 68.1,
51.7, 34.1, 29.0, 25.8, 24.8.




Compound 4.4
Compound 4.3 (5.0 g, 15.31 mmol, 1.0 equiv) in a round-bottomed flask was
stored over Drierite under vacuum in a dessicator overnight. The flask was then
connected to a nitrogen atmosphere via a Schlenk manifold. Freshly distilled THF (60
mL) was added. After cooling to -78 °C, the solution of 4-methoxyphenymagnesium
bromide in THF (0.5 M, 92 mL, 45.95 mmol, 3.0 equiv) was added slowly via a
syringe. After addition, the mixture was allowed to warm up to rt gradually. After a
total of 4 h, the reaction was quenched with water, and THF was evaporated under
reduced pressure. The remaining contents were transferred into a separatory funnel
and partitioned between ethyl acetate and 5% NaHCO3. The organic phase was dried
over anhydrous Na2SO4, filtered and the filtrate was concentrated to dryness under
reduced pressure. The product was purified with flash column chromatography (SiO2,
hexanes/EtOAc/Et3N, 3:1:0.2) giving 4.4 as a thick oil (3.7 g, 8.52 mmol, 56%): Rf =
0.4 (hexanes/EtOAc/Et3N, 3:1:0.4); 1H NMR (400 MHz, CDCl3)  7.30-7.15 (m,
9H), 6.84-6.40 (m, 4H) 3.91 (t, J = 6.4 Hz 2H), 3.71 (s, 3H), 3.61 (s, 3H), 3.49 (br s,
1H), 2.30 (t, J = 7.2 Hz 2H), 1.78-1.63 (m, 4H), 1.51-1.46 (m, 2H); 13C NMR (100
MHz, CDCl3)  174.3, 158.8, 158.3, 147.9 139.9, 139.8, 129.5, 128.1, 128.0, 127.2,
113.9, 113.3, 81.6, 67.8, 55.4, 51.7, 34.1, 29.2, 25.9, 24.9; HRMS (ESI, [M+Na]+)
m/z calcd for C27H30NaO5 457.1991, found 457.1989.
Compound 4.5
Compound

4.4

(3.0

g,

6.91

mmol,

1.0

equiv),

2,2-

(ethylenedioxy)bis(ethylamine) (3.1 mL, 20.73 mmol, 3.0 equiv) and water (700 μL )



was charged to a round-bottomed flask. The mixture was stirred under nitrogen at 85
°

C overnight. After cooling to rt, the mixture was concentrated and the residue was

purified by flash column chromatography (SiO2, Et2O/MeOH/Et3N, 3:2:0.2) giving 5
as a thick oil (2.85 g, 5.18 mmol, 75%): Rf = 0.5 (Et2O/MeCN/MeOH/Et3N, 5:2:2:1);
1

H NMR (400 MHz, CDCl3)  7.24-7.08 (m, 9H), 6.80-6.70 (m, 4H) 6.39 (br s, 1H),

3.86 (t, J = 6.4 Hz 2H), 3.71 (s, 3H), 3.53-3.46 (m, 6H), 3.39-3.34 (m, 4H), 2.75-2.65
(m, 4H), 2.10 (t, J = 7.2 Hz 2H), 1.74-1.58 (m, 4H), 1.44-1.37 (m, 2H);
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C NMR

(100 MHz, CDCl3)  173.3, 158.6, 158.1, 147.9 140.1, 139.9, 128.4, 128.0, 127.9,
126.9, 113.7, 113.2, 81.3, 72.8, 70.3, 70.2, 70.1, 67.8, 55.4, 41.5, 39.3, 36.5, 29.2,
25.9, 25.6, HRMS (ESI, [M+H]+) m/z calcd for C32H43N2O6 551.3121, found
551.3126.
Compound 4.6
To an oven-dried round-bottomed flask under nitrogen was added 4.5 (2.7 g,
4.91 mmol, 1.0 equiv), dry CH2Cl2 (40 mL) and DIEA (2.6 mL, 14.73 mmol, 3.0
equiv). After cooling to 0 °C, methacrolyl chloride (479 μL, 4.91 mmol, 1.0 equiv)
was mixed with 10 mL CH2Cl2 then added via an addition funnel slowly with
vigorous stirring. After addition, the reaction flask was disconnected from the
nitrogen manifold and connected to air through a Drierite tube. The mixture was then
stirred at rt overnight. The contents were transferred into a separatory funnel and
partitioned between 10% Na2CO3 and CH2Cl2. The organic phase was dried over
anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure. The
crude

product

was

purified

by

flash




column

chromatography

(SiO2,

hexanes/EtOAc/Et3N, 1:5:0.2) giving 6 as a colorless oil (2.65 g, 4.29 mmol, 87%):
Rf = 0.3 (hexanes/EtOAc/Et3N, 1:5:0.6); 1H NMR (400 MHz, CDCl3)  7.25-7.08 (m,
9H), 6.80-6.72 (m, 4H) 6.34 (br s, 1H), 6.12 (br s, 1H), 5.64 (s, 1H), 5.27 (s, 1H),
3.88 (t, J = 6.4 Hz, 2H), 3.74 (s, 3H), 3.56-3.35 (m, 12H), 2.14 (t, J = 6.4 Hz, 2H),
1.90 (s, 1H), 1.76-1.58 (m, 4H), 1.50-1.40 (m, 2H);
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C NMR (100 MHz, CDCl3) 

173.2, 168.7, 158.7, 158.2, 147.7 140.1, 139.8, 139.7, 129.4, 128.0, 127.9, 127.1,
119.8, 113.8, 113.3, 81.5, 70.4, 70.3, 70.1, 69.9, 67.8, 55.3, 39.5, 39.3, 36.7, 29.2,
25.9, 25.6, 18.8; HRMS (ESI, [M+Na]+) m/z calcd for C36H46N2NaO7 641.3203,
found 641.3209.
Compound 4.7
Compound 4.6 (2.0 g, 3.23 mmol, 1.0 equiv) in a round-bottomed flask was
stored in a dessicator over Drierite under vacuum overnight. Thymidine (782.8 mg,
3.23 mmol , 1.0 equiv) in a round-bottomed flask was dried in the same way. The
flasks were connected to a Schlenk manifold under nitrogen and the contents were
further dried through multiple cycles of evacuation and nitrogen filling. To the flask
containing compound 4.6, acetyl chloride (4 mL) was added, and the mixture was
stirred at rt for 2 h. Most of acetyl chloride was evaporated by a nitrogen flow or
under vacuum. Freshly distilled hexane from the Innovative Technology’s
PureSolv™ system was added to precipitate the product. The hexane was removed by
syringe or cannula. The residue was washed with hexane one more time, and then
dried under vacuum for 1 h. Freshly distilled pyridine 10 mL was added, and the
solution was transferred via a cannula to the flask containing thymidine. The reaction



mixture was stirred at rt overnight. Volatiles were evaporated under reduced pressure.
The residue was transferred into a separatory funnel and partitioned between ethyl
acetate and 10% Na2CO3. The organic phase was dried over anhydrous Na2SO4 and
filtered. Volatiles were removed under reduced pressure. The product was purified
with flash column chromatography (SiO2, EtOAc/MeOH/Et3N, 9.5:0.5:0.2) giving 4.7
as a white foam (2.1 g, 2.50 mmol, 77%): Rf = 0.4 (EtOAc/MeOH/Et3N, 9:1:0.1); 1H
NMR (400 MHz, acetone-d6)  7.62 (s, 1H), 7.49-7.46 (m, 2H), 7.36-7.20 (m, 6H),
6.89-6.86 (m, 5H), 6.36 (t, J = 6.0 Hz, 1H), 5.69 (s, 1H), 5.29 (s, 1H), 4.59 (br s, 1H),
4.06-4.01 (m, 2H), 3.96 (t, J = 6.0 Hz, 2H), 3.76 (s, 3H), 3.56-3.30 (m, 16H), 2.382.28 (m, 2H), 2.18 (t, J = 7.2 Hz, 2H), 1.95 (s, 3H), 1.89 (s, 1H), 1.45 (s, 3H), 1.191.36 (m, 2H); 13C NMR (100 MHz, Acetone-d6)  172.6, 168.0, 163.7, 159.0, 158.7,
158.5, 150.6, 145.2, 140.8, 135.9, 130.3, 128.3, 128.0, 127.0, 118.6, 113.8, 113.3,
110.2, 86.7, 86.5, 84.6, 71.8, 70.3, 70.2, 69.9, 69.5, 67.6, 64.1, 59.9, 54.9, 40.5, 39.4,
39.1, 35.9, 25.7, 25.5, 20.1, 18.2, 13.8; HRMS (ESI, [M+H]+) m/z calcd for
C47H59N4NaO11 865.4000, found 865.3998.
Phosphoramidite 4.1
An oven-dried round-bottomed flask containing 4.7 (0.7 g, 0.83 mmol, 1.0
equiv) was evacuated then refilled with nitrogen. The evacuation and nitrogen-filling
cycle was repeated for three times. Freshly distilled CH2Cl2 (3 mL) was added via a
syringe. 2-Cyanoethyl-N,N,N’,N’-tetraisopropylphosphoramidite (292.2 μL, 0.92
mmol, 1.1 equiv) and diisopropyl ammonium tetrazolide (142.2 mg, 0.83 mmol, 1.0
equiv) were added sequentially. After stirring at rt for 5 h the mixture was



concentrated to dryness with a nitrogen flow. The residue was purified by flash
column chromatography (SiO2, EtOAc/Et3N, 9.5:0.5) to give 6 as a white foam (0.75
g, 0.72 mmol, 87%): Rf = 0.5 (EtOAc/acetone/Et3N, 7:3:0.1); 1H NMR (400 MHz,
acetone-d6)  7.62 (m, 1H), 7.50-7.47 (m, 2H), 7.38-7.10 (m, 6H), 6.91-6.87 (m, 5H),
6.36 (m, 1H), 5.69 (s, 1H), 5.29 (s, 1H), 4.76 (br s,1H), 3.98-3.80 (m, 2H), 3.78 (s,
6H), 3.6-3.20 (m, 8H), 2.75 (t, J = 6.0 Hz 2H), 2.61 (t, J = 6.4 Hz, 2H) 2.53-2.44 (m,
2H), 2.18 (t, J = 7.2 Hz, 2H), 1.90 (s, 3H), 1.86-1.60 (m, 4H), 1.48-1.47 (m, 6H),
1.27-1.14 (m, 12H); 13C NMR (100 MHz, Acetone-d6)  172.4, 167.9, 163.7, 159.1,
158.6, 150.6, 145.1, 140.8, 130.4, 128.4, 128.0, 127.1, 118.5, 113.9, 113.4, 110.5,
94.6, 86.8, 85.5, 84.6, 73.8, 70.4, 70.2, 69.9, 69.6, 67.8, 63.6, 58.9, 54.9, 43.3, 43.2,
39.4, 39.1, 35.9, 25.8, 25.5, 24.3, 20.0, 18.3, 11.6; 31P NMR (160 MHz, acetone-d6) 
149.3, 149.2, LRMS (ESI, [M+Na]+) m/z calcd for C55H75N6NaO12P 1065.5, found
1065.4
Procedure for Small Scale ODN Purification
ODN Synthesis
The 20-mer ODN 4.8 was used as an example. Its synthesis was carried out on
a 1 jmol scale under standard conditions using phosphoramidite chemistry. The
synthesizer manufacturer suggested 1 jmol synthetic cycle was copied to a new file.
After the coupling steps and before the capping steps, a 180 second waiting step was
inserted, and was set to be active only for base 5. The 0.1 M solution of 4.1 in dry
acetonitrile was attached to bottle position 5. The volume should be around 600 jL,
which was needed for running the bottle exchange cycle, the begin cycle, as well as



the coupling steps in one cycle. When editing sequence, the dT at the 5-end was
input as 5. CPG with a long chain alkylamine succinyl ester linker and a glass pore
size of 500 Å was used as solid support. The 5-DMTr 2-cyanoethyl benzoyl-dA,
isobutyryl-dG, acetyl-dC, and dT phosphoramidites (0.1 M acetonitrile solutions)
were used as coupling monomers. The 0.25 M DCI solution in acetonitrile was used
as activator. Failure sequences were capped with Ac2O in each synthetic cycle. At the
end of synthesis, detritylation was not carried out as this would remove the
methacrylamide tag. Cleavage was carried out on the synthesizer with concentrated
NH4OH. Deprotection was achieved by heating the solution to 55 °C for 25 h. After
cooling to rt, 200 jL DIEA was added. The solution was divided into 5 equal
portions, and evaporated to dryness under vacuum. One portion (~0.2 μmol) was
dissolved in 300 μL water, 20 μL was injected into RP HPLC to generate trace a
(Figure 4.2).
Polymerization
To the second portion (~0.2 μmol) of ODN in a centrifuge tube was added 50
μL water. The tube was vortexed and spun shortly for efficient dissolution.
Polymerization solution [12 μL, 44.4 jmol N,N-dimethylacrylamide, 4.4 jmol N,Nmethylenebis(acrylamide)], and initiators (NH4)2S2O8 (5%, 5 jL, 1.1 jmol) and
TMEDA (0.66 M, 5 jL, 3.3 jmol) were added sequentially. The mixture was
vortexed and spun briefly, and then transferred immediately into the top compartment
of a centrifugal filter unit. The bottom of the compartment could be stopped with a
cap or parafilm, but the solution will not pass through the filter disc even without



stopping. Care needs to be taken to transfer all solution to the center of the filter disc,
which can be achieved with steady releasing and pushing the pipette. Washing the
residue solution to the compartment is not recommended. The solution was allowed
to stand at rt with the cap of the unit closed. A gel was formed in ~15 min, but the
polymerization was allowed to continue for 1 h.
Washing
The gel was loosened with a clean spatula, and water containing 5% Et3N
(~200 μL) was added. After 3 min, the liquid was removed with a spin. The washing
was repeated for 7 times with the last wash using pure water.
Cleavage and Extraction
A minimum amount of AcOH solution (80%) that could cover the gel (~120
jL) was added. After 5 min, the liquid was collected with a spin. The procedure was
repeated for two more times. A minimum amount of water that could cover the gel
(~120 μL) was added, and the extract was collected with a spin. The extraction was
repeated for four times. The extracts including those of AcOH solution and water
were combined and evaporated to dryness. To the residue, concentrated NH4OH (100
μL) was added. After a short vortex, the closed tube was heated at 80 oC for 15 min.
The tube was cooled to rt, and nBuOH (900 μL) was added. The mixture was
vortexed for 30 sec and centrifuged for 3 min at 14.1K. The supernatant was carefully
removed with a pipette, and the residue, which was the pure ODN, was dried under
vacuum to evaporate residue nBuOH. The ODN was dissolved in 300 μL water,
 


vortexed, and spun, and 20 μL was injected into RP HPLC to generate traces b
(Figure 2). The recovery yield of the ODN was determined to be 68% by dividing the
area of the peak in trace b at 19 minutes by that in trace a at 45 minutes.
The 31-mer ODN 4.9 was synthesized under the same conditions as describe
for 4.8 except that cleavage and deprotection were achieved using a mixture of
concentrated NH4OH and MeNH2 solutions (1:1 v/v) at rt for 3 h. The ODN was
purified at 0.2 jmol scale using the same procedure and the same amount of reagents
for purifying 4.8. The RP HPLC traces for crude and pure ODNs are in supporting
information. The recovery yield of purification was determined to be 71% by
comparing areas of peaks in the HPLC profiles of pure and crude ODN. The 37-mer
ODN 4.10 was also purified at 1 jmol scale using the same procedure with slightly
different amount of reagents: 50 jL water for dissolving crude ODN, 24 jL
polymerization solution for catching full-length sequences, 5 jL (NH4)2S2O4 and
TMEDA solutions for initiating polymerization, and minimum amount of solutions
that could cover gel for washing failure sequences and for cleavage and extraction.
RP HPLC profiles for crude and pure ODN are in supporting information. Recovery
yield was determined to be 83% by comparing areas of peaks in the HPLC profiles of
pure and crude ODN.
Procedure for Large Scale Purification
The 37-mer ODN 4.10 was used as an example. Its synthesis was achieved in
five 10 jmol columns with 1000 Å CPG. The same procedure and reagents for
synthesizing 4.8 were used except that a different synthetic cycle was used. The
!


standard 10 jmol synthesis cycle was copied into a new file. After the coupling steps
and before the capping steps, a 180-second waiting step was inserted, and was set to
be active only for base 5. Approximately, a total of 5.9 mL of 0.08 M solution of 4.1
was used for tagging full-length sequences. According to trityl essay before the cycle
for attaching 4.1, the average yield of 36-mer for the five synthesis was 50%.
Cleavage and deprotection were achieved under the same conditions for 4.9. DIEA
(~500 jL) was added to minimize the possibility of premature tag cleavage during
evaporation. RP HPLC analysis of the crude indicated that only about 50% of the 36mer intermediate was successfully methacrylated with 4.1 (trace c, Figure 2). As a
result, the synthesis yield of the 37-mer was 50%. For purification, the crude ODN
was dissolved in 1.25 mL water in a 25 mL round-bottomed flask, which was flushed
with nitrogen. Polymerization solution (1.25 mL) and initiator solutions (10 jL each)
were added sequentially. The flask was hand-shaken briefly, and polymerization was
allowed to proceed at rt for 1 h. The gel was transferred into a 15 mL Büchner funnel
with a sintered glass disc and broken into several pieces with a spatula. Water (~4
mL) containing 5% Et3N was added to the gel. After 3 min, vacuum was applied and
the liquid was removed. The washing was repeated for 4 times. The gel was further
washed with water (~4 mL) containing 1% Et3N for 4 times without waiting between
the washes, and finally, the gel was washed with pure water (~ 4 mL). For cleaving
full-length sequences, 80% AcOH (~4 mL) was added into the funnel. After 5 min,
vacuum was applied and the extract was collected in a centrifuge tube placed in the
filter flask. The procedure was repeated for two times. The gel was further washed
with water (4 mL × 5) without waiting between washes. The extracts including AcOH
"


solution and water were combined and evaporated to dryness under vacuum. The
residue was dissolved in 1 mL concentrated NH4OH and heated at 80 ºC for 15 min.
After cooling to rt, 9 mL nBuOH was added, and the mixture was vortexed for 30 sec
and centrifuged for 3 min. The supernatant was removed, and the residue was dried
under vacuum. Pure ODN was obtained as white cotton-like fluffy fibers (see picture
in supporting information). The weight was 98 mg, which corresponds to a 70%
recovery yield of the purification procedure. A portion of the ODN was dissolved in
water, and analyzed with RP HPLC (trace d, Figure 2), which indicated 100% purity.
The images of 1H NMR of the pure ODN are in supporting information.
Procedure for Long Sequence Purification
The sequences 4.11 (61-mer) and 4.12 (151-mer) were used to demonstrate
the power of the technique for purification of long ODN sequences. ODN 4.12 is used
for the description of the procedure. The ODN was synthesized at 0.2 jmol scale
under similar conditions described for 8 with slight modifications. The standard 0.2
jmol (instead of 1 jmol) synthetic cycle was used to create the new cycle. After
coupling and capping steps, additional waiting steps of 45 sec and 30 sec were added,
respectively. CPG with a pore size of 2000 Å was used as solid support. Before
synthesis, the capping solutions were manually delivered to fill the column, and the
mixture was allowed to stand at rt for 20 min. The CPG was then washed with
acetonitrile. All other conditions were the same as for 4.8. The synthesis yield before
the last cycle was 22% according to trityl essay. The ODN was cleaved and
deprotected using the mixture of concentrated NH4OH and MeNH2 (1:1 v/v) at rt for



3 h. About 200 jL DIEA was added, and the solution was divided into five equal
portions, which were evaporated to dryness under vacuum. One portion was dissolved
in 150 jL water, and 20 jL was injected into RP HPC to generate trace e (Figure
4.2). A second portion was used for purification. The polymerization step including
reagent volumes were exactly the same as for 4.8. In the washing step, 3.0 M NaOAc
(200 jL × 6 with 3 min waiting between the washes), water containing 1% Et3N (200
jL × 1) and pure water (200 jL × 1) were used, sequentially. Cleavage, extraction,
and precipitation were carried out under the same conditions for 4.8. The pure ODN
was dissolved in 150 μL water, and 20 μL was injected into RP HPLC (flow rate 2
mL/min, column temperature 55 °C) to give trace f. The recovery yield of the
purification process was determined to be 50% by comparing the area of peaks of
crude trace (37 min) with that of pure one (18 min).
The sequence 4.11 was synthesized at 1 jmol scale under the conditions for
4.9 using 1000 Å CPG. Purification was carried out at 0.2 jmol scale under the same
conditions described for 4.9. The recovery yield was determined to be 83% by
comparing the area of peaks of crude trace (40 min) with that of pure one (20 min).
HPLC images of 11 and 13 are in supporting information.
4.4 Conclusion
A new methacrylation phosphoramidite that contains a linker cleavable with
acetic acid solution has been synthesized, and used for the purification of ODN using
the catching full-length sequences by polymerization approach. The simplicity,
convenience, and suitability of the technology with the new linker for small scale



purification, large scale purification and long sequence purification have been
demonstrated. Because acetic acid solution is much more environmentally benign
than the previously used hydrogen fluoride for the same purpose, we believe that the
work described in this paper will promote wide adoptions of the ODN purification
technology in academic labs, biotechnology companies and pharmaceutical industry.
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Chapter 5
Introduction to Peptide Purification
5.1 Peptides


Peptides are short polymers of amino acids monomers. The amino acids are
linked together by amide bonds from a dehydration reaction between a carboxylic
group of one amino acid and amino group of another amino acid. A general structure
of peptides is shown in Figure 5.1 (5.1). Depending on the number of amino acid
monomers, peptides are classified as dipeptides, tripeptides, tetrapeptides and so on.
Peptides with 10 or less number of amino acid are known as oligopeptides while the
longer peptides (more than 100 amino acids) are called proteins. The carboxylic end
of a peptide is termed as its C-terminal and amino end is N-terminal.



Figure 5.1. Peptide structure
5.2 Applications of Peptides


Synthetic peptides have a wide range of application in therapeutics,
biochemistry, molecular biology and immunology.[1] One of the most important
applications of peptides is to use as medicine. There are about 60 peptide drugs on the
market and more than 500 are in different stages of clinical and pre-clinical trials. It is
estimated the global annual sale of peptide drugs in 2010 to be $13 billion [2].
Peptide drugs have several advantages over traditional small molecule drugs. They



usually have high affinity, and selectivity to biological targets, and therefore have
high potency and low toxicity. Another reason for low toxicity of peptide drugs is
because the degradation products of peptide drug are amino acids, which are known
non-toxic molecules in the nature.[3] Currently, peptide based drugs are used to treat
different types of cancer, cardiovascular diseases and other diseases. They are also
used as vaccines for immunization against hepatitis A and B, insulin for diabetes and
some growth hormones.[4] It is estimated that the annual sale of peptide drugs is 20
billion USD in 2012, which is about 2% of total drug product. Currently, the annual
growth rate of peptide based drug sale is 7.5-10%.[5]
5.3 Peptide Synthesis
Peptides are synthesized by coupling of the carboxylic group of one amino
acid with the amino group of another amino acid. Two types of methods are
commonly used. One is solution-phase synthesis. This method is classical. It needs
intensive labor to purify intermediate products. It is still widely used. However, the
most commonly used method, which is the second method, is solid-phase synthesis.
This method was first developed by Bruce Merrifield in 1963.[6] Using this method,
the first amino acid is anchored to a solid support, usually polystyrene beads. Peptides
are assembled by stepwise addition of amino-protected amino acid monomers.
Because the desired peptide intermediates are anchored to the solid support, after
each reaction during the multiple step synthesis, excess reagents and side products are
conveniently removed by simple washing. As a result solid-phase synthesis is rapid
and can be automated. Nowadays, solid support with first amino acid being attached
 


is commercially available. Scheme 5.1 illustrates the typical solid phase peptide
synthesis cycle that are responsible for attaching one amino acid to the nascent
peptides on solid support. The cycle consists of three steps which are deprotection,
coupling and capping. They are described in following paragraphs.



Scheme 5.1. Synthesis cycle of solid-phase peptide synthesis.
5.3.1 Side-Chain Functional Group Protection
!


Some amino acids contain a side chain functional group. They have to be
protected during the peptide synthesis. These protecting groups should remain intact
throughout the synthesis and must be readily removable after synthesis. Most
commonly used side chain protecting groups are tert-butyloxycarbonyl (Boc), trityl,
benzoyloxymethyl and tert-butylether. Nowadays, side-chain protected amino acids
are commercially available.
5.3.2 Deprotection
This is the first step of a peptide synthesis cycle. As shown in scheme 5.1, in
this step, 5.2, which is the first amino acid anchored to solid support with its amino
group being protected with a Fmoc group, is converted to 5.3. The Fmoc group is an
abbreviation of 9-fluorenylmethoxycarbonyl group. This step is usually achieved with
the mild base piperidine, usually a 20% solution in dimethyl formamide (DMF). The
acid-labile protecting group used for side chain protection are all stable under the
conditions. Fmoc is the most widely used amino protecting group. Besides the Fmoc
group, the Boc group which is an abbreviation of tert-butyloxycarbonyl is also widely
used. Boc group is removed under acidic conditions. The side chain protecting groups
are also removed under acidic conditions but this needs harsher conditions. After this
step, the amino group in 5.3 is free of protecting group and the solid support is now
ready for the next step, which is coupling.

"


5.3.3 Coupling
The second step in a peptide synthesis cycle is coupling. As shown in scheme
5.1, this step couples 5.3 with the Fmoc-protected amino acid monomer 5.4 to give
5.5. This step requires activation of carboxylic group of the amino acid 5.4. Most
commonly used coupling reagents include N,N'-dicyclohexylcarbodiimide (DCC)
5.12 and diisopropylcarbodiimide (DIC) 5.13. Recently, O-(7-azabenzotriazol-1-yl)N,N,N ,N -tetramethyluronium hexafluorophosphate (HATU) 5.14 O-(benzotriazol-1yl)-N,N,N ,N -tetramethyluronium hexaflurophosphate (HBTU) 5.15 are widely used
because these reagents reduce racemization.[7] These coupling reagents form highly
reactive intermediates with the carboxylic acid group of amino acid monomer (5.4),
which react with 5.3 to form the peptide bond in 5.5.



Figure 5.2. Example peptide coupling reagents




5.3.4 Capping
The third step in a peptide synthesis is capping. The coupling step is usually
very efficient but it may be incomplete. The unreacted amino group in 5.3 if not
capped, can participate in the coupling reactions in the next synthesis cycle. This
generates deletion sequences. Deletion sequences are very difficult to remove during
purification. To solve the problem, the unreacted amino groups are capped with large
excess of acetic anhydride right after each coupling step to give 5.7. Products 5.7 are
called failure sequences. They cannot participate in next coupling reactions.
The synthesizer repeats the steps deprotection, coupling and capping, which is
responsible to add one amino acid in each synthesis cycle until desired length of
peptide is obtained.
5.3.5 Cleavage and Deprotection
Once the peptide synthesis is complete, the product is cleaved from solid
support. Cleavage is usually achieved with an acid. In the example we shown in
chapter 6, we used the 2-chlorotrityl linker to anchor nascent peptides to solid
support. The cleaving agent is 1.0% solution of trifluoroacetic acid (TFA) in
dichloromethane. Under these conditions, side chain protecting groups are not
removed. To remove side chain protecting group, usually the TFA cocktail containing
81.5% TFA, 1.0% triisopropylsilane, 5.0% water, 2.5% ethane dithiol, 5.0%
thioanisole and 5.0% phenol is used. This cocktail is much more acidic and can
remove all side chain protecting groups. Because the side products of the deprotection



reactions include highly reactive cationic species, the cocktail contains scavengers,
which prevents reactive cationic species from reacting with deprotected peptides.
5.4 Impurities


After synthesis, cleavage and deprotection, the crude peptide contains the
desired full-length sequence and impurities including failure sequences. The
impurities are divided into different classes. They have to be removed before most of
the applications.
The first type of impurities is the failure sequences. They are generated from
incomplete coupling of amino acid monomer during synthesis. Incomplete removal
of Fmoc group in the deprotection step in a synthesis cycle also results in failure
sequences.[8] Because the failure-sequences have similar physical properties as the
full-length peptides, they are difficult to remove. The major challenge of peptide
purification is to remove the failure-sequences.
The second type of impurities include deletion and addition sequences. The
deletion sequences are resulted from incomplete capping. The unreacted amino group
can couple with amino acid in the next synthesis cycle. The deletion sequence lacks
one or more amino acids in the peptide chain. The addition sequences are resulted
from premature removal of Fmoc group. The addition sequences have at least one or
more amino acids. Both deletion and addition sequences are challenge to remove
during purification. The best strategy is to minimize their quantity to close to zero by
tuning the reaction conditions during synthesis.



The third type of impurities is small organic molecules from side chain
protecting groups. These impurities can be removed easily by precipitation with cold
diethyl ether from TFA solution. The peptides are not soluble in cold ether, and are
precipitated. The small organic molecules are soluble in ether, and remain in solution.
Other impurities include diasteromers which are resulted from racemization.
Some impurities are generated from modification of functional groups.[9] These
impurities should be minimized by tuning the condition during synthesis, cleavage
and deprotection. They are challenging to remove using any purification methods.
5.5 Current Methods of Purification


Currently, several methods are extensively studied for peptide purification.
These methods include reversed-phase (RP) HPLC, fluorous affinity purification,
polyacrylamide gel-electrophoresis, size-exclusion chromatography, and ionexchange chromatography. The principles of the methods have been introduced in
Chapter 1. When they are applied to peptide purification, advantages and
disadvantages similar to ODN purification exist. Briefly the disadvantages include
high labor demand, unamenable for automation, requiring expensive instrument and
column consuming large volumes of harmful organic solvents, expensive to scale up,
and harmful to environment.
5.6 Our Peptide Purification Method


To overcome the problems associated with known peptide purification
methods, we developed a simple and convenient method for peptide purification. This



method utilizes the same principle as discussed in previous chapters for ODN
purification, which is catching by polymerization.

In this method, a compound

containing polymerizable methacrylamide group and a cleavable linker (5.16) is
attached to the amino terminus of full-length peptide. The failure sequences are not
tagged with the compound. During purification, the crude product is subjected to
polymerization. The full-length sequences are incorporated into polymer. The failure
sequences are removed by washing. The full-length sequences are then cleaved from
the polymer. The compound we used for the application is 5.16. It contains a
methacrylamide polymerizable group and an acid-cleavable linker. The following
paragraph explains how to tag the full-length sequence while leaving failure
sequences free of the methacrylamide tag.

Figure 5.3. Polymerizable linker
As shown in Scheme 5.2, at the end of peptide synthesis, the full-length
peptide on solid support (5.9) is reacted with the polymerizable tagging agent 5.16 to
give 5.17. The failure sequences on the solid support 5.8 do not react because their
amino groups are capped with acetic anhydride in capping step. The peptide including
full-length sequences and failure sequences are cleaved from the solid support. The




cleavage reagent we used is 1% TFA. The linker shown in 5.16 and side chain
protecting groups are stable under this condition.



Scheme 5.2. Acrylation of full-length peptide by polymerizable linker 5.16



After peptide synthesis and cleavage, the crude peptide mainly contains the
methacrylamide-tagged full-length sequence 5.18, the failure sequences 5.11 and
other impurities. It is subjected into a polymerization mixture containing N,Ndimethylacrylamide 5.19 and N,N-methylenebisacrylamide 5.20. The polymerization
reaction

is

initiated

with

ammonium

persulfate

(APS)

and

N,N,N,N-

tetramethylethylenediamine (TMEDA). The full-length peptide 5.18 is incorporated
into the polymer gel 5.21. The failure sequences 5.11 and other impurities remain in
solution. The failure sequences and other impurities are washed away. The full-length
peptide is cleaved with TFA cocktail solution, which also removes the side chain
protecting groups. The full-length peptide is further extracted with TFA. Small
molecule impurities are removed by precipitation of peptides with diethyl ether from
the TFA solution. The small molecules are in solution. The peptide is not soluble in
ether and is precipitated.

Scheme 5.3. The catching full-length sequence by polymerization peptide
purification method




5.7 Advantages of Our New Peptide Purification Method


Our new peptide purification method has significant advantages over all
known purification methods. The method does not involve any chromatography and
purification is achieved through simple manipulation such as mixing, shaking,
filtration and extraction. It does not need any expensive reagents, instruments and
column. Therefore it is highly suitable for large scale purification including large
scale peptide based drug purification.
The advantages of our technology to purify ODN are presented in Table 1.1
and Table 1.2 of chapter 1. The tables can be used to compare the advatages of our
technology for peptide purification.
The detailed information on peptide purification using the catching full-length
sequence by polymerization method is presented in Chapter 6.
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Abstract


During automated solid phase peptide synthesis, failure sequences were
capped with acetic anhydride. After synthesis, a polymerizable methacrylamide tag
was attached to the full-length sequences. Peptide purification was then achieved by
polymerizing the full-length sequences, washing away impurities, and cleaving the
peptide product from the polymer




6.1 Introduction


Synthetic peptides have wide applications. For example, there are 65 therapeutic
peptides on the market and around 270 peptides in clinical trials.[1, 2] Peptides are
mostly synthesized on a solid support by stepwise addition of amino-protected amino
acid (aa) monomers. Each synthetic cycle accomplishes the addition of one aa. It
usually consists of three steps, which are coupling, capping and deprotection. Excess
reagents and side products in each step are removed by washing. After synthesis, the
product is cleaved from the support and fully deprotected. Besides the desired fulllength peptide, the major impurities in the crude product include failure sequences
and small molecules from side chain protecting groups. The latter can usually be
removed by precipitation with cold diethyl ether from a trifluoroacetic acid (TFA)
solution. However, the failure sequences have physical properties similar to those of
full-length peptide, and cannot be removed in the process.
Currently, the first industrial choice for peptide purification is reversed-phase (RP)
HPLC. However, it has limitations. For example, in the manufacture of enfuvirtide,
which is a 36-aa peptide used to treat HIV infection, RP HPLC is the primary tool for
purification. When a linear solid phase synthesis method was used, the purity of the
crude product was 30-40%, which is acceptable considering the length of the
synthesis and the convenience of the procedure. Unfortunately, the product had to be
purified by a complicated procedure involving difficult, low-concentration, low


throughput, and two-pass HPLC.[3] To ease purification, later a combined solid phase
and solution phase synthesis method was developed, and the purity of product was
improved to ~75%. However, the purification was not much easier. The product was
loaded in multiple portions onto a column for preparative HPLC.[3] In general, the
disadvantages of HPLC for large scale purification include high capital costs on
instrument and column, labor intensiveness, high energy demand for solvent
evaporation, and inability to resolve peptides with multiple higher order structures.
Most importantly, HPLC consumes large volumes of harmful solvents, which results
in high waste to product ratios, usually more than 1,000. Other methods for peptide
purification include fluorous affinity purification,[4-10] antigen-antibody affinity
purification,[11, 12] covalent capture with a solid matrix,[13-15] and lipophilic tag
assisted chromatography.[16] All these methods are extensively studied, but are still
not ideal for large scale peptide drug purification.
6.2 Results and Discussion


Recently, we reported a catching by polymerization strategy for purification of
oligodeoxynucleotides (ODN).[17-19] In one method, at the end of automated
synthesis, a polymerizable methacrylamide group is attached to the full-length
sequence. ODN purification is then achieved by polymerizing the full-length
sequences, washing away failure sequences and other impurities, and cleaving
product from the polymer.[17] The method avoided many drawbacks associated with
chromatography and other known methods, and could be used for large scale and high




throughput ODN purification. Here we report our results on using the strategy for
synthetic peptide purification.
To demonstrate feasibility, compound 6.1, which contains an acid-labile linker and
a reactive 4-nitrophenyl carbonate function, was designed. Because we planned to use
the commercially available 2-Cl-trityl polystyrene resin as the solid support for
peptide synthesis, the linker must be stable in 1% TFA, which are the conditions for
cleaving peptides from the resin.[3, 20-23] However, the linker must be readily
cleavable under more acidic conditions to obtain good recovery yield in the
purification process. These goals were achieved by careful tuning the electron density
of the benzene ring in the linker. The molecule was also designed to be easy to
synthesize. As shown in Scheme 1, 4-hydroxybenzyl alcohol was alkylated with
methyl chloroacetate to give 6.2,[24] which was reacted at room temperature with
2,2-(ethylenedioxy)bis(ethylamine) to give 6.3.[25] Methacrylation of 6.3 gave
compound

6.4,

which

was

converted

to

6.1

by

reacting

with

4-

nitrophenylchloroformate. The synthesis did not use any expensive and highly
reactive reagents, and is expected to be readily scalable.




Scheme 6.1. Synthesis of compound 6.1

Since peptide synthesis and purification are much more complicated than
ODN, at the beginning of the project, we used the short 6-aa peptide 6.5 (LWTRFA)
to demonstrate the feasibility of the concept. The 2-Cl-trityl polystyrene resin
preloaded with Ala was selected as the solid support. The Fmoc-protected Phe,
Arg(Pbf), Thr(tBu), Trp(Boc) and Leu were used as aa monomers. Synthesis was
carried out on an automated synthesizer. In the coupling steps, only 2.1 equivalents of
monomers were used, which was lower than the amounts usually suggested by
manufacturers of peptide synthesizers. The lowered amount was expected to generate
more failure sequences and to better show the effectiveness of the new purification
method. After coupling, failure sequences were capped with excess acetic anhydride.
The steps for removing Fmoc protecting group were normal. After assembling the
sequence, the full-length peptide was reacted with compound 6.1 in the presence of a
base at room temperature overnight to give 6.6 (see Scheme 6.2). The failure
sequences (6.7) could not react because they were capped with acetic anhydride. The



crude product, which mainly contained 6.6 and 6.7, were cleaved from the resin using
1% TFA to give full-length peptide 6.8 and failure sequences 6.9. Under these
conditions, the side chain protecting groups and the 4-hydroxybenzyl alcohol linker
were stable.[3] The mixture was analysed with RP HPLC (trace a, Figure 6.1). The
full-length peptide appeared at 61 minutes. To generate a control HPLC profile, a
portion of the crude was treated with a TFA cocktail containing 81.5% TFA, 1.0%
triisopropylsilane (TIPS), 5.0% water, 2.5% ethane dithiol (EDT), 5.0% thioanisole,
and 5.0% phenol to globally remove protecting groups and to cleave the
methacrylamide tag. After Et2O precipitation, the crude product was analysed with
RP HPLC (trace b). The fully deprotected full-length peptide (6.5) appeared at 23
minutes.

 


Scheme 6.2. Peptide cleavage from resin and purification by catching full-length
sequence by polymerization
Another portion of the crude containing 6.8 and 6.9 (with side chain
protecting groups and methacrylamide tag not removed) was subjected to
polymerization under typical polyacrylamide gel formation conditions [N,Ndimethylacrylamide, N,N-methylenebis(acrylamide), (NH4)2S2O8, TMEDA]. The
full-length peptide 6.8 was incorporated into the polymer 6.10. The failure sequences
6.9 and other impurities remained in solution (Scheme 6.2). The gel was washed
!


extensively with solvents such as water, DMF and MeCN to remove impurities. Fulllength peptide was then cleaved from the gel and fully deprotected by
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Figure 6.1. RP HPLC profiles of peptides. (a) Crude 6-aa peptide containing fulllength sequences 6.8 and failure sequences 6.9, the side chain protecting groups and
the methacrylamide tag on 6.8 were on; (b) crude peptide with side chain protecting
groups and methacrylamide tag removed; (c) peptide 6.5 purified using the catching
full-length sequences by polymerization approach.
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treating with the TFA cocktail described above. At this stage, the peptide was still
contaminated with small molecules from side chain protecting groups and the
cocktail. Removing them was achieved by precipitation of peptide with cold Et2O.
The pure peptide 6.5 was analysed with RP HPLC (trace c, Figure 6.1). The purity of
the peptide was more than 98%. The recovery yield of the purification process was
estimated to be 66% by comparing the areas of the peaks at 23 minutes in traces b and
c. The identity of the peptide was confirmed with ESI-MS and NMR (see Supporting
Information).
To further demonstrate the effectiveness of the purification technique, the 16-aa
peptide 6.11 (KNRWEDPGKQLYNVEA), which is a peptide derived from human
C3d and carries the LYNVEA CR2 binding sequence,[26] was synthesized under
similar conditions described for 6.5. Fmoc aa Glu(OtBu), Val, Asn(Trt), Tyr(tBu),
Leu, Gln(Trt), Lys(Boc), Gly, Pro, Asp(OtBu), Trp(Boc) and Arg(Pbf) were used as
the monomers. To further increase the difficulty of the purification task, the amount
of aa monomers was lowered to 1.5 equivalents. The purification process was exactly
the same. The RP HPLC profiles for the crude peptide with the methacrylamide tag
and side chain protecting groups on, that with tag and protecting groups removed, and
purified full-length peptide are included in Supporting Information. The purity of the
peptide (6.11) is more than 96%. The recovery yield was estimated to be 73%. The
identity of 6.11 was confirmed with ESI MS and NMR.
The catching by polymerization peptide purification method has significant
advantages over other techniques. Compared with chromatographic methods such as



HPLC and lipophilic tag assisted purification,[16] the method does not need any
expensive instrument, column, or large volumes of harmful solvents. Compared with
RP cartridge, fluorous and antigen-antibody affinity purification methods,[4-12] the
method does not require a disposable column. Compared with the methods using
covalent capture,[13-15] the method does not need a functionalized solid matrix.
Importantly, using the method, purification is achieved by simple manipulations such
as shaking, washing, extraction and precipitation. As a result, it is expected to be
particularly useful for large scale peptide drug purification. Some drugs need to be
purified for more than one time, and ideally, each time uses a different purification
technique. The catching by polymerization method may be an excellent choice for
initial removal of large quantities of failure sequences. This is predicted to be
particularly useful for the purification of peptide sequences that have inherently low
coupling yields in certain cycles. Furthermore, due to the ease of removal of failure
sequences using the method, it is possible for drug manufacturers to reduce the
equivalents of aa monomers and their activators during synthesis. The re-balance of
reagent costs and purification costs will provide new opportunities to lower the
overall expenses of drug production.
6.3 Experimental Section


General Experimental
All reactions were performed in oven-dried glassware under a nitrogen
atmosphere using standard Schlenk techniques. Reagents and solvents available from
commercial sources were used as received unless otherwise noted. Pyridine and



CH2Cl2 were distilled over CaH2 under nitrogen. Thin layer chromatography (TLC)
was performed using plates with silica gel 60F-254 over glass support, 0.25 μm
thickness. Flash column chromatography was performed using silica gel with particle
size 32-63 μm. 1H and

13

C NMR spectra were measured at 400 and 100 MHz,

respectively on a Varian 400 MHz spectrometer. Chemical shifts () were reported in
reference to solvent peaks (residue CHCl3 at  7.24 ppm for 1H and CDCl3 at  77.00
ppm for 13C, and residue CHD2OD at  3.31 ppm for 1H and CD3OD at  49.00 ppm
for

13

C). ESI-MS for small molecules were obtained on an Agilent Q-TOF System;

those for peptides were obtained on a Thermo Finnigan LCQ Advantage
spectrometer. H-Ala-2-Cl-Trt polystyrene resin (1% DVB cross-linking, 100-200
mesh, ~0.56 mmol/g loading for the synthesis of 6.5 and ~0.80 mmol/g for 6.11),
Fmoc

protected

amino

acids,

N-hydroxybenzotriazole

(HOBt·H2O),

N,N'-

diisopropylcarbodiimide (DIC), piperidine, and N,N-diisopropylethylamine(DIEA)
were purchased from AAPPTec (Louisville, USA). RP HPLC was performed on a
JASCO LC-2000Plus System: pump, PU-2089Plus Quaternary Gradient; detector
UV-2075Plus. RP analytical columns XBridgeTM, C18, 5.0 jm diameter, 3.0 mm ×
250 mm (for 6-amino acid peptide 6.5); and XBridgeTM, C18, 5.0 jm diameter, 4.6
mm × 150 mm (for 16-amino acid peptide 6.11) were used. Solvent A: 0.05%
trifluoroacetic acid (TFA) in water. Solvent B: 0.05% TFA in acetonitrile. All profiles
were generated by detection of absorbance of peptide at 214 nm using the linear
gradient solvent system: solvent B (0%-15%) in solvent A over 9 min followed by
solvent B (15%-100%) in solvent A over 71 min at flow rates of 1.0 mL/min (4.6 mm
× 150 mm column) and 0.5 mL/min (3.0 mm × 250 mm column).



Synthesis and Characterization of Compounds
Compound 6.3
To a round-bottomed flask under a nitrogen atmosphere was added 6.2 (2.48
g, 12.64 mmol, 1.0 equiv.), water (1 mL) and 2,2’-(ethylenedioxy)bis(ethylamine)
(5.6 mL, 38 mmol, 3.0 equiv.). The reaction mixture was stirred for 5 h at rt. The
crude was loaded onto a flash chromatography column (SiO2). Eluting with the
solvent mixture Et2O/MeOH/MeCN/Et3N (v/v/v/v 5:2:2:1) gave 6.3 as a sticky solid
(2.78 g, 8.89 mmol, 70%): Rf = 0.32 (Et2O/MeOH/MeCN/Et3N, 5:2:2:1); 1H NMR
(400 MHz, CD3OD)  7.28 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 8.4 Hz, 2H), 4.51 (s, 2H),
4.47 (s, 2H), 3.65-3.43 (m, 10H), 2.75 (t, J = 5.2 Hz, 2H);

13

C NMR (100 MHz,

CD3OD)  169.9, 157.3, 135.1, 128.5, 114.6, 72.4, 70.1, 69.2, 67.2, 63.5, 40.8, 38.8;
HRMS (ESI) calcd for C15H25N2O5 [M+H]+ m/z 313.1763, found 313.1762.
Compound 6.4
To a round-bottomed flask under a nitrogen atmosphere was added 6.3 (4.5 g,
14.41

mmol,

1.0

equiv.),

freshly

distilled

CH2Cl2

(100

mL),

N,N-

diisopropylethylamine (7.5 mL, 43.23 mmol, 3.0 equiv.), and methacrolyl chloride
(1.34 mL, 13.69 mmol, 0.95 equiv.). The reaction mixture was stirred at rt overnight.
The contents were transferred into a separatory funnel and extracted with EtOAc (50
mL × 3). The combined organic phase was dried over anhydrous Na2SO4, and
filtered. Volatiles were removed under reduced pressure. The crude product was
purified by flash column chromatography (SiO2, EtOAc/acetone, 7:3) giving 6.4 as a



light yellow oil (4.53 g, 11.91 mmol, 82%): Rf = 0.24 (EtOAc/acetone, 7:3); 1H NMR
(400 MHz, CDCl3)  7.25 (d, J = 8.8 Hz, 2H), 6.95 (br s, 1H), 6.82 (d, J = 8.8 Hz,
2H), 6.36 (br s, 1H), 5.63 (s, 1H), 5.26 (s, 1H), 4.56 (s, 2H), 4.39 (s, 2H), 3.59-3.36
(m, 12H), 2.88 (br s 1H), 1.88 (s, 3H); 13C NMR (100 MHz, CDCl3)  168.7, 168.6,
156.8, 140.1, 135.4, 128.8, 119.8, 114.8, 70.4, 70.3, 69.9, 69.8, 67.7, 64.6, 39.5, 38.9,
18.8; HRMS (ESI) calcd for C19H28N2NaO6 [M+Na]+ m/z 403.1845, found 403.1844.
Compound 6.1
To a round-bottomed flask under a nitrogen atmosphere was added 6.4 (1.1 g,
2.89 mmol, 1.0 equiv.), freshly distilled CH2Cl2 (100 mL), freshly distilled pyridine
(1.16 mL, 14.45 mmol, 5.0 equiv.), and 4-nitrophenyl chloroformate (728.2 mg, 3.61
mmol, 1.25 equiv.). The reaction mixture was stirred at rt for 1 h. The contents were
transferred into a separatory funnel and partitioned between sat. NH4Cl and CH2Cl2
(50 mL). The aqueous phase was further extracted with CH2Cl2 (50 mL × 2). The
combined organic phase was dried over anhydrous Na2SO4 and filtered. Volatiles
were removed under reduced pressure. The crude product was purified by flash
column chromatography (SiO2, EtOAc/acetone, 7:3) giving 6.1 as a light yellow solid
(1.37 g, 2.51 mmol 86%): Rf = 0.37 (EtOAc/acetone, 7:3); m.p. 81.2 ºC; 1H NMR
(400 MHz, CDCl3)  8.24 (d, J = 9.2 Hz, 2H), 7.42-7.32 (m, 4H), 6.92 (d, J = 8.8 Hz,
2H), 6.25 (br s, 1H), 5.66 (s, 1H), 5.28 (s, 1H), 5.21 (s, 2H), 4.48 (s, 2H), 3.58-3.46
(m, 12H), 1.91 (s, 3H);

13

C NMR (100 MHz, CDCl3)  168.6, 168.1, 157.9, 155.7,

152.6, 145.6, 140.2, 131.1, 128.1, 125.5, 121.9, 119.8, 115.2, 70.7, 70.5, 70.4, 70.0,




69.9, 67.6, 39.5, 38.9, 18.8; HRMS (ESI) calcd for C26H31N3NaO10 [M+Na]+ m/z
568.1907, found 568.1903.
Peptide Synthesis, Acrylation and Cleavage
Peptide Synthesis:
The 6-amino acid peptide 6.5 (H2N-LWTRFA-CO2H) was synthesized on an
automated solid phase synthesizer using the Fmoc protecting strategy. The 2-ChloroTrityl-Ala-H polystyrene resin (with 1% DVB cross-linking, 0.56 mmol/g loading,
0.39 mmol, 0.70 g) was swollen by soaking in CH2Cl2 (25 mL) at rt for 45 min. The
solvent was removed. The resin was washed with DMF for 3 times and finally the
DMF was removed. Coupling was then carried out. To the amino acid tube on the
synthesizer containing Fmoc-Phe-OH (2.1 eq, 0.84 mmol, 0.32 g) and HOBt·H2O
(2.1 eq, 0.84 mmol, 0.13 g) was added DMF (3.5 mL). The mixture was dissolved by
bubbling nitrogen. After 5 min, DIC (2.1 eq, 0.84 mmol) in 3.5 mL DMF was added.
Pre-activation of the amino acid was proceeded at rt for 20 min. The mixture
containing the activated ester was added to the reaction flask containing the resin.
Coupling was allowed to proceed at rt for 60 min. The reagents were removed. The
resin was washed with DMF (10 mL × 4). Capping failure sequences was then
performed. First a solution of DIEA (1.5 M) in DMF, and then the solution of Ac2O
(1.0 M) also in DMF were delivered to the reaction flask. The ratio of the volumes of
the two solutions was approximately 1:1, and the total volume of the two solutions
was approximately 10 mL, which could cover the entire resin. The mixture was
allowed to react at rt for 30 min. The reagents were removed and the resin was



washed with DMF (10 mL ×2). The process was repeated for three more times under
the same conditions with the exception of reducing the capping time from 30 min to
15 min. The resin was washed with DMF (10 mL × 4). Removal of Fmoc group was
then carried out. A solution of piperidine in DMF (20%, 10 mL) was delivered to the
reaction flask, and the mixture was allowed to react at rt for 3 min. The reagents were
removed. The process was repeated for two more times. The resin was washed with
DMF (10 mL × 4 times). This completed one synthesis cycle, in which one amino
acid was added to the elongating peptide. The synthesis cycle was repeated with the
Fmoc amino acid monomers Arg(Pbf), Thr(tBu), Trp(Boc) (120 min for coupling),
and Leu sequentially. At the end of the synthesis, the Fmoc group was removed.
Acrylation of the Full-Length Peptide
The solutions of compound 6.1 (3.1 eq, 1.23 mmol, 0.67g) in DMF (2.0 mL),
and DIEA (10%) in DMF (2.0 mL) were combined, and then added to the resin
manually via a pipette. The reaction was allowed to proceed at rt overnight. The resin
was filtered, and washed with DMF (2.0 mL × 4) and CH2Cl2 (2.0 mL × 4), and then
dried under vacuum. The thoroughly dried resin (0.95 g) was stored at -20 ºC under
inert atmosphere.
Cleaving the Peptide From the Resin and HPLC Analysis of Crude Peptide
A portion of the resin (0.12 g) was swollen in CH2Cl2 (3.0 mL) at rt for 45
min. The solvent was removed with a pipette, and the resin was treated with a
solution of 1% TFA in CH2Cl2 (1.0 mL) at rt. After 30 min, the mixture was filtered.



The resin was washed with 1% TFA in CH2Cl2 (200 μL × 2). To the combined
solution was added Et2O (12 mL). The mixture was vortexed and spun briefly to
bring down contents to the bottom of the tube, and cooled to -70 ºC. After 1 h, the
mixture was centrifuged for 3 min (at ~10 ºC). The supernatant was removed with a
pipette. The residue was washed with cold Et2O (1 mL × 3, -70 ºC). After washing,
residue Et2O was allowed to evaporate in air. The crude product (26.7 mg), which
contained the full-length sequences 6.8, failure sequences 6.9 and other impurities,
was obtained as an amorphous solid. A portion (10 mg) was dissolved in 60%
CH3CN (1.0 mL). From the solution, 20 μL was injected into RP HPLC to generate
trace a (Figure 6.1). From the remaining solution (980 μL) was drawn 100 μL, and
evaporated to dryness in a centrifugal vacuum concentrator. The residue was treated
with a TFA cocktail (100 μL), which contained 81.5% TFA, 1.0% triisopropylsilane
(TIPS), 5.0% water, 2.5% ethane dithiol (EDT), 5.0% thioanisole, and 5.0% phenol,
at rt for 100 min. To the solution was added Et2O (900 μL). The mixture was
vortexed and spun briefly, and cooled to -70 ºC. After 1 h, the mixture was
centrifuged for 3 min (at ~10 ºC). The supernatant was removed with a pipette. The
residue was washed with cold Et2O (1 mL × 3, -70 ºC). Residue Et2O was allowed to
evaporate in air. The solid was dissolved in 100 μL 50% CH3CN, 20 μL was injected
into RP HPLC to generate trace b (Figure 6.1).

 


Purification by Catching Full-Length Sequences by Polymerization
Catching Full-Length Peptide by Polymerization
Purification was carried out with the side chain protected peptide to avoid side
reactions between peptide and acrylamide. An additional benefit is that protected
peptide must be soluble at least in the solvent in which it is synthesized. This will
ensure that other peptides could be purified using the method. Thus, from the above
remaining solution (~880 μL) of crude peptide containing 6.8 and 6.9 with side chain
protected, 100 μL was transferred into a 25 mL 2-necked round bottomed flask. To
the same flask, 150 μL CH3CN, 270 μL water, and 520 μL polymerization solution,
which

contained

N,N-dimethylacrylamide

(1.69

M)

and

N,N-

methylenebis(acrylamide) (0.068 M) in DMF, were added. The mixture was stirred
using a magnetic stirring bar while a gentle nitrogen flow passed over the liquid
surface. After 5 min, a solution of (NH4)2S2O8 (10%, 5 μL) and TMEDA (3.5 μL)
were added sequentially via a pipette and a syringe, respectively, under positive
nitrogen pressure. The solution was stirred gently under nitrogen at rt for 1 min to
mix the materials, and then stirring was stopped. The mixture was allowed to stand
under nitrogen. The gel 6.10 was formed within 30 min. To ensure complete
polymerization, the gel was left under nitrogen for 2 h or longer.
Removing Failure Sequences and Other Impurities by Washing
To the flask containing the gel was added 3 mL water via a pipette. The flask
was moved onto an orbital shaker and shaken at rt for 2 h. The supernatant was
!


removed with a pipette. The gel was further washed with water (3 mL × 2, 2 h each
time), DMF (3 mL × 3, 2 h each time), 50% CH3CN (3 mL × 3, 2 h each time), and
CH3CN (3 mL × 3, 2 h each time) to ensure complete removal of failure sequences
and other impurities. The gel 6.10 was then dried under vacuum.
Cleaving Full-Length Peptide From Gel and Global Peptide Deprotection
To the flask containing gel 6.10 was added 2.0 mL TFA cocktail (81.5% TFA,
1.0% TIPS, 5.0% water, 2.5% EDT, 5.0% thioanisole, and 5.0% phenol) via a pipette.
The flask was gently shaken at rt for 100 min. The supernatant, which contained the
full-length peptide 6.5 and small molecules from side chain deprotection, was
transferred to a 45 mL centrifuge tube using a pipette. The gel was further washed
with the TFA cocktail (2.0 mL, 1 h), pure TFA (2.0 mL, 2 h; 1.0 mL × 3, 1 h each
time) to ensure complete extraction of full-length sequences. The last extract was
concentrated and precipitated with Et2O at -70 ºC, and analyzed with HPLC. No
peptide was detected, which indicates that the extraction process could be simplified.
All other extracts were combined into the same 45 mL centrifuge tube, and
concentrated to about 2.5 mL with a flow of nitrogen. To the solution was added Et2O
(22.5 mL). The mixture was vortexed and spun briefly to bring down contents to the
bottom of the tube, and cooled to -70 ºC. After 1 h, the mixture was centrifuged for 3
min (at ~10 ºC). The supernatant was removed with a pipette. The residue was
washed with cold Et2O (1 mL × 3, -70 ºC). After washing, residue Et2O was allowed
to evaporate in air. The solid, which was the pure fully deprotected peptide 6.5, was
dissolved in 100 μL 50% CH3CN, 20 μL was injected into RP HPLC to generate
"


trace c (Figure 6.1). Occasionally, small impurities were observed in HPLC profiles.
These were caused by small molecules that were not completely removed by the
precipitation process. We were able to remove them by re-dissolving the peptide in a
minimum amount of 50% CH3CN followed by evaporation in a centrifugal vacuum
concentrator. The recovery yield of the catching by polymerization purification
process was estimated to be 66% by comparing the area of the peak at 23 min in trace
c with that in trace b. The identity of the peptide was established with ESI-MS using a
50% acetonitrile solution, calcd for [M+H]+ m/z 793.9, found 793.5. The image of the
spectrum is shown in this Supporting Information. To obtain sufficient peptide for
NMR experiment, the purification was repeated with peptides cleaved from 26.5 mg
of resin, which theoretically contains 10.9 μmol peptide. The product was obtained as
a white powder (5.5 mg, 6.9 μmol, 63% combined yield for synthesis and
purification). 1H NMR (400 MHz, 50% CD3CN in D2O)  7.98 (d, J = 7.2 Hz, 1H,
H-1, see following structure for proton assignment), 7.79 (d, J = 8 Hz, 1H, H-2),
7.71-7.58 (m, 6H, H-3), 7.55 (t, J = 8 Hz, 1H, H-4), 7.46 (t, J = 8 Hz, 1H, H-5), 5.10
(t, J = 7.6 Hz, 1H, H-6), 4.96 (m, 1H, H-7), 4.80-4.40 (buried in solvent peak, 2H, H8), 4.26 (t, J = 7.6 Hz, 1H, H-9), 3.70-3.20 (m, 7H, H-10), 2.20-1.85 (m, 3H, H-11),
1.78-1.63 (m, 7H, H-12), 1.37 (d, J = 6.4 Hz, 3H, H-13), 1.30-1.20 (m, 6H, H-14).




Figure 6.2. The 6-aa peptide 6.5 and proton numbering for NMR signal assignment

Purification of the 16-Amino Acid Peptide 6.11
The 16-amino acid peptide 6.11 (H2N-KNRWEDPGKQLYNVEA-CO2H)
was synthesized using Fmoc amino acid monomers Glu(OtBu), Val, Asn(Trt),
Tyr(tBu), Leu, Gln(Trt), Lys(Boc), Gly, Pro, Asp(OtBu), Trp(Boc) and Arg(Pbf),
under the similar conditions on the same resin with a loading of 0.80 mmol/g, and
using 1.5 equivalents amino acid monomers and activating agents in the coupling
steps. The catching by polymerization purification process was exactly the same as
described for purification of peptide 6.5. The RP HPLC profiles for the crude peptide
with the methacrylamide tag and side protecting groups on, the crude peptide with tag
and protecting groups removed, and full-length peptide purified with the catching
full-length sequences by polymerization approach are shown in this Supporting



Information. The recovery yield of the purification process was estimated to be 73%
by comparing the area of the peak at 17 min in the HPLC profiles of purified and
crude peptide. The image of ESI MS for the purified peptide, calcd for [M+2H]2+ m/z
974.5, found 974.3, are shown in this Supporting Information. To obtain sufficient
peptide for NMR experiment, the purification was repeated with peptides cleaved
from 85.4 mg of resin, which theoretically contains 12.6 μmol peptide. The product
was obtained as a white powder (16.9 mg, 8.7 μmol, 69% combined yield for
synthesis and purification). 1H NMR (400 MHz, 50% CD3CN in D2O)  7.97 (d, J = 8
Hz, 1H, H-1, see following structure for proton assignment), 7.80 (d, J = 8.4 Hz, 1H,
H-2), 7.60-7.40 (m, 5H, H-3), 7.13 (d, J = 8.0 Hz, 2H, H-4), 5.20 (t, J = 7.2 Hz, 1H,
H-5), 5.04 (t, J = 6.8 Hz, 2H, H-5), 4.97 (t, J = 8.4, 1H, H-5), 4.88-4.85 (m, 1H, H-5),
4.75-4.44 (buried in solvent peak, 6H, H-6), 4.34 (t, J = 6.0 Hz, 1H, H-6), 4.26 (br s,
2H, H-7), 4.16-4.08 (m, 2H, H-6), 3.70-1.60 (m, 58H, H-8), 1.30 (d, J = 6.0 Hz, 3H,
H-9), 1.27 (d, J = 6.0 Hz, 3H, H-9), 1.23 (d, J = 6.0 Hz, 3H, H-9), 1.17 (d, J = 6.0 Hz,
3H, H-9).

Figure 6.3. The 16-aa peptide 6.11 and proton numbering for NMR signal
assignment



6.4 Conclusion


In conclusion, we have successfully developed a new method for peptide
purification. The method used a concept that is completely different from any
previously reported peptide purification techniques. It is easy to use and readily
scalable, and gives peptides with good purity and recovery yields. Adapting the
method for purification of several peptide drugs such as Bivalirudin (20 aa),[27]
Ziconotide (25 aa),[28] Thymalfasin (28 aa),[29] Enfuvirtide (36 aa)[30] and
Pramlintide (39 aa)[31] is underway.
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Chapter 7
Future Research Plan


Synthetic ODNs and peptides have wide applications in therapeutics,
genomics and forensic science. In the previous chapters, we described the novel
technologies for ODN and peptide purification. We used catching by polymerization
approach to purify these biooligomers. The result of the technology is satisfactory. In
future, our efforts may be directed to extend the catching failure sequences by
polymerization approach to peptide purification, using the catching-full length
sequence by polymerization approach to purify peptides of much longer sequences
and specific drugs at large scales, using the catching by polymerization methods to
purify RNA, phosphorothioates, and other modified nucleic acids, and adopt the
technologies for high throughput purification of ODNs.
7.1 For Peptide Purification


7.1.1 Catching Failure Sequences by Polymerization
In chapter 6, we discussed the purification of peptide by polymerizing fulllength sequences. Despite the satisfactory result, the peptide must be cleaved from the
gel during purification. We proposed a purification method by catching failure
sequences which does not need a cleavage step. Failure sequences are capped right
after each synthetic cycle by suitable reagents containing polymerizable group. We
designed two capping reagents; the first one is methacrylic anhydride 7.1. The second
reagent is the pentafluro compound 7.2.
"


Figure 7.1. Proposed capping reagents
The failure sequences will be capped with 7.1 or 7.2 during automated synthesis.
After cleavage, they will be polymerized leaving full-length peptide in solution,
which will be extracted with suitable solvents. Small molecules will be removed by
precipitation of the full-length sequences from a TFA solution with cold ether. The
peptides, which normally carry positive charges under these conditions, are not
soluble in ether, while small molecules, which are neutral, are soluble in ether.
7.1.2 Purification of Longer Sequences and at Large Scale
We purified peptides that contain 6 and 16 amino acids by the catching fulllength sequence by polymerization approach. In this method, a polymerizable tag is
attached only once at the end of the amino terminus so it is suitable for longer peptide
purification. We will use the method to purify peptides that have more than 30 amino
acids. We will also use the technique to purify specific peptide durgs such as
Bivalirudin,[1] Ziconotide,[2] Thymalfasin,[3] Enfuvirtide,[4] and Pramlintide[5].
Further, we will use the method to purify at scales that can afford gram quantities of
pure peptides.

 


7.2 For ODN and RNA Purification


7.2.1 RNA Purification
Purification of oligoribonucleotides is also highly important because of their
wide applications in medicine and biology. RNA purification is more challenging due
to the ubiquitous enzyme known as RNAse. We propose the purification of
oligoribonucleotide using the catching by polymerization ODN purification
technologies. Both technologies of ODN purification can be used to purify
oligoribonucleotide by slight modification of the current methods.
7.2.2 Longer Sequence Purification, Large Scale Purification and High
Throughput Purification
In chapter 4, we discussed the purification of a 151 mer ODN by catching
full-length sequence polymerization. We propose to purify even longer ODNs such as
those that are as long as 200 mer. This method is suitable to purify longer ODNs
because tagging with an expensive polymerizable phosphoramidite is only required at
the end of synthesis. Because of the high demand for pure ODN in industrial scales,
we propose to test the suitability of the technology to purify ODNs at gram scales.

 


7.2.3 Purification of Phosphorothioates
Phosphorothioates

have

increasing

applications

in

therapeutics.

In

phosphorothioates 7.4, the oxygen atom in the phosphate backbone is replaced with a
sulfur atom. This structure change makes the ODN more resistant to enzymatic
hydrolysis (Figure 7.2).[6] The delivery of this modified ODN to the interior of cell is
more efficient than normal ODN. Because of the applications of phosphorathioates,
we propose to purify phosphorothioates by the catching polymerization approach.

Figure 7.2. Phosphodiester and phosphorothioate linkages





 


References and Notes

1.

Warkentin, T.E., A. Greinacher, and A. Koster, Bivalirudin. Thrombosis and
Haemostasis, 2008, 99(5): p. 830-839.

2.

Miljanich, G., Ziconotide: neuronal calcium channel blocker for treating
severe chronic pain. Current Medicinal Chemistry, 2004, 11(23): p. 30293040.

3.

Ciancio, A. and M. Rizzetto, Thymalfasin in the treatment of hepatitis B and
C. Annals of the New York Academy of Sciences, 2010, 1194(1): p. 141-146.

4.

Lazzarin, A., B. Clotet, D. Cooper, et al., Efficacy of enfuvirtide in patients
infected with drug-resistant HIV-1 in Europe and Australia. New England
Journal of Medicine, 2003, 348(22): p. 2186-2195.

5.

Younk, L.M., M. Mikeladze, and S.N. Davis, Pramlintide and the treatment of
diabetes: a review of the data since its introduction. Expert Opinion on
Pharmacotherapy, 2011, 12(9): p. 1439-1451.

6.

Skerra, A., Phosphorothioate primers improve the amplification of DNA
sequences by DNA polymerases with proofreading activity. Nucleic Acids
Research, 1992, 20(14): p. 3551-3554.

 


Appendix A
Supporting Information for Chapter 2

Synthetic Oligodeoxynucleotide Purification by Capping Failure
Sequences with a Methacrylamide Phosphoramidite Followed by
Polymerization

 


Figure A.1. 1H NMR of compound 2.11
 


Figure A.2. 13C NMR of compound 2.11

 


Figure A.3. 31P NMR of compound 2.11






Figure A.4. 1H NMR of compound 2.12
 !


Figure A.5. 13C NMR of compound 2.12  "


Figure A.6. 31P NMR of compound 2.12
!


Figure A.7. 1H NMR of compound 2.13
!


Figure A.8. 13C NMR of compound 2.13
!


Figure A.9. 13P NMR of compound 2.13
!


Figure A.10. 1H NMR of compound 2.15
!


Figure A.11. 13C NMR of compound 2.15
!


Figure A.12. 1H NMR of compound 2.17

!


Figure A.13. 13C NMR of compound 2.17
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Figure A.14. 1H NMR of compound 2.19
!!


Figure A.15. 13C NMR of compound 2.19
!"


Figure A.16. ESI MS of compound 2.19

"


Figure A.17. LC MS of ODN 2.23 (continued next page)

"


Figure A.17. LC MS of ODN 2.23 (continued)

"


Figure A.18. MALDI-TOF MS of ODN 2.24
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Figure A.19. RP HPLC profile of crude ODN 2.20(c2.10l)
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Figure A.20. RP HPLC profile of ODN 2.20(c2.10l) purified by catching by
polymerization
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Figure A.21. RP HPLC profile of crude ODN 2.20(c2.12l)
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Figure A.22. HPLC profile of ODN 2.20(c2.12l) purified by catching by
polymerization
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Figure A.23. RP HPLC profile of crude ODN 2.20(c2.13l)
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Figure A.24. RP HPLC profile of ODN 2.20(c2.13l) purified by catching by
polymerization
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Figure A.25. RP HPLC profile of crude ODN 2.20(c2.10s)
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Figure A.26. RP HPLC profile of ODN 2.20(c2.10s) purified by catching by
polymerization
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Figure A.27. RP HPLC profile of crude ODN 2.20(c2.11s)
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Figure A.28. RP HPLC profile of ODN 2.20(c2.11s) purified by catching by
polymerization
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Figure A.29. RP HPLC profile of crude ODN 2.20(c2.12s)
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Figure A.30. RP HPLC profile of ODN 2.20(c2.12s) purified by catching by
polymerization
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Figure A.31. RP HPLC profile of crude ODN 2.20(c2.13s)
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Figure A.32. RP HPLC profile of ODN 2.20(c13s) purified by catching by
polymerization
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Figure A.33. RP HPLC profile of crude ODN 2.23
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Figure A.34. RP HPLC profile of ODN 2.23 purified by catching by polymerization
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Figure A.35. RP HPLC profile of crude ODN 2.20(c2.11o)
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Figure A.36. RP HPLC profile of ODN 2.20(c2.11o) purified by catching by
polymerization
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Figure A.37. RP HPLC profile of crude ODN 2.20(c2.21i)
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Figure A.38. RP HPLC profile of ODN 2.20(c2.11i) purified by catching by
polymerization
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Figure A.39. RP HPLC profile of crude ODN 2.20(c2.11c)
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Figure A.40. RP HPLC profile of ODN 2.20(c2.11c) purified by catching by
polymerization
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Figure A.41. RP HPLC profile of crude ODN 2.20(c2.11lc)
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Figure A.42. RP HPLC profile of ODN 2.20(c2.11lc) purified by catching by
polymerization
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Figure A.43. RP HPLC profile of ODN 2.20 purified by catching by polymerization;
the polymerization step was carried in air in a centrifuge tube
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Figure A.44. RP HPLC profile of crude ODN 2.20(c2.11ls)
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Figure A.45. RP HPLC profile of ODN 2.20(c2.11ls) purified by catching by
polymerization
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Figure A.46. RP HPLC profile of crude ODN 2.20(c2.11dci) purified at 3 μmol scale
using the catching failure sequences by polymerization method
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Figure A.47. RP HPLC profile of ODN 2.20 (c2.11dci) purified at 3 μmol scale
using the catching failure sequences by polymerization method
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Figure A.48. RP HPLC profile of ODN 2.20(c2.11dci) purified at 3 μmol scale using
the catching failure sequences by polymerization method; the profile was generated
by UV detection at 210 nm
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Figure A.49. Ion-exchange HPLC analysis of ODN 2.20. The conditions described in
the general methods section were used. For analysis, 20 μL solution from the
remaining ODN 2.20 (c2.12s) solution in the purification by catching failure
sequences by polymerization experiment following the general ODN purification
procedure was injected into HPLC.

Abs (260 nm)

80

CrudeCrude
ODNODN
2.2424

60
40
20
0
0

10

20

30

40
Time

Figure A.50. RP HPLC profile of crude ODN 2.24
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Figure A.51. RP HPLC profile of pure ODN 2.24
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Figure A.52. RP HPLC profile of crude ODN mixture 2.25



60

[min.]

Abs (260 nm)

80

b

60

Pure ODN 24

Pure ODN 2.25

40
20
0
0

10

20

30

40

50

60

[min.]

Time

Absorbance (260 nm)

Figure A.53. RP HPLC profile of ODN 2.25 that went through catching by
polymerization
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Figure A.54. RP HPLC profile of nucleosides from ODN enzymatic digestion essay
for ODNs that do not contain 8-oxo-dG—the blank control
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Figure A.55. RP HPLC profile of nucleosides from ODN enzymatic digestion essay
for ODN that contain 8-oxo-dG—the blank control; the peak at 11 minutes is resulted
from 2-mercaptoethanol added to prevent oxidation of 8-oxo-dG




Table A.1. Nucleoside peak areas in HPLC profiles of SVP and BAP digested ODNs
20

ODN

Authentic 20

24

dC

dG

dT

dA

dC

dG

dT

dA

dC

dG

dT

dA

8OxodG

Number
of base

6

4

7

3

6

4

7

3

6

3

7

3

1

Calcd
relative
area*

6.0

6.4

8.5

6.3

6.0

6.4

8.5

6.3

6.0

4.8

8.5

6.3

-

Meaured
relative
area

6.0

7.1

7.8

5.7

6.0

7.0

7.5

5.6

6.0

5.3

7.6

6.3

1.1

Base

* Calculated based on the relative nucleoside extinction coefficients of dC/dG/dT/dA
1.0:1.6:1.2:2.1 from Current Protocols in Nucleic Acid Chemistry, Unit 10.6, DOI:
10.1002/0471142700.nc1006s01.
Table A.2. Recipes for the preparation of polymerization solutions
Cross-linking
ratio

N,N-Methylenebis(acrylamide)

N,N-Dimethylacrylamide
Water (mL)

Mass (mmol)

Weight (mg)

Mass (mmol)

Volume (μL)

1:50

0.169

26.05

8.44

870

5

1:25

0.337

52.1

8.44

870

5

1:15

0.563

86.8

8.44

870

5

1:7

1.207

186.1

8.44

870

5

1:2

4.225

651.3

8.44

870

14*

* More water had to be added to dissolve the materials.




Table A.3. ODN synthetic cycles using polymerizable phosphoramidite as capping
agent

Cycle 1 — 0.2 μmol synthesis, the general ODN synthesis procedure
ODN synthetic cycle using polymerizable phosphoramidite as the capping agent
Synthesizer: standard ABI 394 solid phase synthesizer; 4-column 8-base instrument
Polymerizable capping agent: 0.15 M solution of capping phosphoramidite in
acetonitrile, placed at the bottle 5 position
The bottles for normal Ac2O capping agents are empty
Activator for the capping phosphoramidite: from the same bottle for the coupling
steps
Synthesis scale: 0.2 μmol
Column used: column 2; functions for other columns are not shown
Step number

Function number

Function name

Step time

1.
2.

106
64

Begin
18 To waste

3.0

3.
4.
5.

42
2
1

18 To column
Reverse flush
Block flush

10.0
8.0
4.0

6.
7.

101
142

Phos Prep
Column 2 on

3.0

8.
9.

111
58

Block vent
Tet to waste

2.0
1.7

10.
11.
12.

33
34
33

B+Tet to column
Tet to column
B+Tet to column

2.0
1.0
1.5

13.
14.

43
143

Push to column
Column 2 off

15.
16.
17.

103
64
42

wait
18 To waste
18 To column

25.0
3.0
10.0

18.

2

Reverse flush

8.0




19.
20.

1
101

Block flush
Phos Prep

4.0
3.0

21.
22.

142
111

Column 2 on
Block vent

2.0

23.
24.
25.

58
35
34

Tet to waste
5+Tet to column
Tet to column

1.7
2.0
1.0

26.
27.

103
35

Wait
5+Tet to column

90.0
1.5

28.
29.

103
35

Wait
5+Tet to column

90.0
1.5

30.

103

Wait

90.0

31.
32.

35
103

5+Tet to column
Wait

1.5
90.0

33.
34.

43
103

Push to column
Wait

30.0

35.
36.
37.

64
42
4

18 To waste
18 To column
Flush to waste

4.0
8.0
4.0

38.
39.

42
2

18 To column
Reverse flush

8.0
5.0

40.
41.
42.

42
2
1

18 To column
Reverse flush
Block flush

8.0
5.0
3.0

43.
44.

41
64

15 To column
18 To waste

8.0
4.0

45.
46.
47.

1
103
41

Block flush
Wait
15 To column

3.0
10.0
8.0

48.
49.

64
1

18 To waste
Block flush

4.0
3.0

50.
51.

103
42

Wait
18 To column

10.0
15.0

52.

4

Flush to waste

4.0




53.
54.

42
2

18 To column
Reverse flush

10.0
5.0

55.
56.

42
2

18 To column
Reverse flush

10.0
5.0

57.
58.
59.

1
105
64

Block flush
Start detrityl
18 To waste

3.0

60.
61.

42
2

18 To column
Reverse flush

10.0
5.0

62.
63.

1
167

Block flush
If monitoring

3.0

64.

44

19 To column

25.0

65.
66.

40
135

14 To column
Monitor triyls

3.0

67.
68.

40
136

14 To column
Monitor noise

25.0

69.
70.
71.

40
137
42

14 To column
Stop monitor
18 To column

10.0

72.
73.

2
168

Reverse flush
If not monitoring

8.0

74.
75.
76.

40
3
40

14 To column
Trityl flush
14 To column

6.0
5.0
6.0

77.
78.

103
3

Wait
Trityl flush

5.0
5.0

79.
80.
81.

40
103
3

14 To column
Wait
Trityl flush

6.0
5.0
5.0

82.
83.

40
103

14 To column
Wait

6.0
5.0

84.
85.

3
42

Trityl flush
18 To column

5.0
10.0

86.

3

Trityl flush

8.0




4.0

10.0

87.
88.

169
42

End monitoring
18 To column

8.0

89.
90.

2
1

Reverse flush
Block flush

5.0
4.0

91.

107

End

Note: Bottle 5—polymerizable capping phosphoramidite; bottle 14—detritylation
solution; bottle 15—oxidation solution; bottle 18—acetonitrile; bottle 19—
dichloromethane; B—base or phosphoramidite; Tet—tetrazole or activator.
Table A.4. Cycle 2 — 0.2 μmol synthesis, the general ODN synthesis procedure with
shortened capping time
ODN synthetic cycle using polymerizable phosphoramidite as the capping agent
Synthesizer: standard ABI 394 solid phase synthesizer; 4-column 8-base instrument
Polymerizable capping agent: 0.15 or 0.1 M solution of polymerizable
phosphoramidite in acetonitrile, placed at the bottle 5 position
The bottles for normal Ac2O capping agents are empty
Activator for the capping phosphoramidite: from the same bottle for the coupling step
Synthesis scale: 0.2 μmol
Column used: column 2; functions for other columns are not shown

Step number

Function number

Function name

Step time

1.
2.

106
64

Begin
18 To waste

3.0

3.
4.

42
2

18 To column
Reverse flush

10.0
8.0

5.
6.
7.

1
101
142

Block flush
Phos Prep
Column 2 on

4.0
3.0

 


8.
9.

111
58

Block vent
Tet to waste

2.0
1.7

10.
11.

33
34

B+Tet to column
Tet to column

2.0
1.0

12.
13.
14.

33
43
143

B+Tet to column
Push to column
Column 2 off

1.5

15.
16.

103
64

wait
18 To waste

25.0
3.0

17.
18.

42
2

18 To column
Reverse flush

10.0
8.0

19.

1

Block flush

4.0

20.
21.

101
142

Phos Prep
Column 2 on

3.0

22.
23.

111
58

Block vent
Tet to waste

2.0
1.7

24.
25.
26.

35
34
103

5+Tet to column
Tet to column
Wait

2.0
1.0
30.0

27.
28.

35
103

5+Tet to column
Wait

1.5
30.0

29.
30.
31.

35
103
43

5+Tet to column
Wait
Push to column

1.5
30.0

32.
33.

103
64

Wait
18 To waste

30.0
4.0

34.
35.
36.

42
4
42

18 To column
Flush to waste
18 To column

8.0
4.0
8.0

37.
38.

2
42

Reverse flush
18 To column

5.0
8.0

39.
40.

2
1

Reverse flush
Block flush

5.0
3.0

41.

41

15 To column

8.0

!


42.
43.

64
1

18 To waste
Block flush

4.0
3.0

44.
45.

103
41

Wait
15 To column

10.0
8.0

46.
47.
48.

64
1
103

18 To waste
Block flush
Wait

4.0
3.0
10.0

49.
50.

42
4

18 To column
Flush to waste

15.0
4.0

51.
52.

42
2

18 To column
Reverse flush

10.0
5.0

53.

42

18 To column

10.0

54.
55.

2
1

Reverse flush
Block flush

5.0
3.0

56.
57.

105
64

Start detrityl
18 To waste

4.0

58.
59.
60.

42
2
1

18 To column
Reverse flush
Block flush

10.0
5.0
3.0

61.
62.

167
44

If monitoring
19 To column

25.0

63.
64.
65.

40
135
40

14 To column
Monitor triyls
14 To column

66.
67.

136
40

Monitor noise
14 To column

10.0

68.
69.
70.

137
42
2

Stop monitor
18 To column
Reverse flush

10.0
8.0

71.
72.

168
40

If not monitoring
14 To column

6.0

73.
74.

3
40

Trityl flush
14 To column

5.0
6.0

75.

103

Wait

5.0

"


3.0
25.0

76.
77.

3
40

Trityl flush
14 To column

5.0
6.0

78.
79.

103
3

Wait
Trityl flush

5.0
5.0

80.
81.
82.

40
103
3

14 To column
Wait
Trityl flush

6.0
5.0
5.0

83.
84.

42
3

18 To column
Trityl flush

10.0
8.0

85.
86.

169
42

End monitoring
18 To column

8.0

87.

2

Reverse flush

5.0

88.
89.

1
107

Block flush
End

4.0

Note: Bottle 5—polymerizable capping phosphoramidite; bottle 14—detritylation
solution; bottle 15—oxidation solution; bottle 18—acetonitrile; bottle 19—
dichloromethane; B—base or phosphoramidite; Tet—tetrazole or activator.
Table A.5. Cycle 3 — 1.0 μmol synthesis
ODN synthetic cycle using polymerizable phosphoramidite as the capping agent
Synthesizer: standard ABI 394 solid phase synthesizer; 4-column 8-base instrument
Polymerizable capping agent: 0.15 M solution of polymerizable phosphoramidite in
acetonitrile unless otherwise noted in the article, placed at the bottle 5 position
The bottles for normal Ac2O capping agents are empty
Activator for the capping phosphoramidite: from the same bottle for the coupling step
Synthesis scale: 1.0 μmol
Column used: column 2; functions for other columns are not shown
Step number

Function number

Function name

1.

106

Begin

2.
3.

64
42

18 To waste
18 To column

3.0
10.0

4.
5.
6.

2
1
101

Reverse flush
Block flush
Phos Prep

10.0
4.0
3.0




Step time

7.
8.

142
111

Column 2 on
Block vent

2.0

9.
10.

58
33

Tet to waste
B+Tet to column

1.7
2.5

11.
12.
13.

34
33
43

Tet to column
B+Tet to column
Push to column

1.0
2.5

14.
15.

143
103

Column 2 off
wait

50.0

16.
17.

64
42

18 To waste
18 To column

3.0
10.0

18.

4

Flush to waste

5.0

19.
20.

42
2

18 To column
Reverse flush

10.0
10.0

21.
22.

1
101

Block flush
Phos Prep

4.0
3.0

23.
24.
25.

142
111
58

Column 2 on
Block vent
Tet to waste

2.0
1.7

26.
27.

35
34

5+Tet to column
Tet to column

2.5
1.0

28.
29.
30.

103
35
103

Wait
5+Tet to column
Wait

30.0
2.5
30.0

31.
32.

35
103

5+Tet to column
Wait

2.5
30.0

33.
34.
35.

43
103
64

Push to column
Wait
18 To waste

30.0
4.0

36.
37.

42
4

18 To column
Flush to waste

10.0
6.0

38.
39.

42
4

18 To column
Flush to waste

10.0
6.0

40.

42

18 To column

10.0




41.
42.

2
1

Reverse flush
Block flush

7.0
3.0

43.
44.

41
64

15 To column
18 To waste

8.0
4.0

45.
46.
47.

1
103
41

Block flush
Wait
15 To column

3.0
15.0
8.0

48.
49.

64
1

18 To waste
Block flush

4.0
3.0

50.
51.

103
42

Wait
18 To column

15.0
15.0

52.

4

Flush to waste

6.0

53.
54.

42
4

18 To column
Flush to waste

10.0
6.0

55.
56.

42
2

18 To column
Reverse flush

10.0
7.0

57.
58.
59.

1
105
64

Block flush
Start detrityl
18 To waste

3.0

60.
61.

42
2

18 To column
Reverse flush

10.0
5.0

62.
63.
64.

1
167
44

Block flush
If monitoring
19 To column

3.0

65.
66.

40
135

14 To column
Monitor triyls

3.0

67.
68.
69.

40
136
40

14 To column
Monitor noise
14 To column

25.0

70.
71.

137
42

Stop monitor
18 To column

72.
73.

2
168

Reverse flush
If not monitoring

8.0

74.

40

14 To column

6.0




4.0

25.0

10.0
10.0

75.
76.

3
40

Trityl flush
14 To column

5.0
6.0

77.
78.

103
3

Wait
Trityl flush

5.0
5.0

79.
80.
81.

40
103
3

14 To column
Wait
Trityl flush

6.0
5.0
5.0

82.
83.

40
103

14 To column
Wait

6.0
5.0

84.
85.

3
42

Trityl flush
18 To column

5.0
10.0

86.

3

Trityl flush

8.0

87.
88.

169
42

End monitoring
18 To column

8.0

89.
90.

2
1

Reverse flush
Block flush

5.0
4.0

91.

107

End

Note: Bottle 5—polymerizable capping phosphoramidite; bottle 14—detritylation
solution; bottle 15—oxidation solution; bottle 18—acetonitrile; bottle 19—
dichloromethane; B—base or phosphoramidite; Tet—tetrazole or other activator.
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A Highly Convenient Procedure for Oligodeoxynucleotide Purification




Recipes for Preparation of Polymerization Solutions
3.7 M of N,N-Dimethylacrylamide and 0.37 M N,N-methylenebis(acrylamide)
solution (cross-linking ratio 10:1): To 103 μL N,N-dimethylacrylamide (MW 99.13
mg/mmol, density 962 μg/μL, 100 mg, 1 mmol) and 15.5 mg N,Nmethylenebis(acrylamide) (MW 154.17 mg/mmol, 0.1 mmol), add 103 μL water. Mix
to dissolve. The final volume of the solutions is 272 μL.

5% (NH4)2S2O8 Solution: To 5 mg (NH4)2S2O8 (MW 228.18 mg/mmol), add 95 μL
water. Mix well (5 μL solution contains 1.1 μmol (NH4)2S2O8).

0.66 M TMEDA solution: To 49 μL TMEDA (MW 116.24 mg/mmol, density 0.777
mg/μL, 38.1 mg, 0.33 mmol), add water until the total volume reaches 500 μL. Mix
well (5 μL solution contains 3.3 μmol TMEDA).
HPLC conditions
Column: C-18, 5 μm, 100 Å, 250 × 3.20 mm; solvent A: 0.1 M triethylammonium
acetate, 5% acetonitrile; solvent B: 90% acetonitrile; flow rate: 0.5 mL/min;
detection: 260 nm; faster gradient: solvent B (0%-45%) in solvent A over 60 min;
slower gradient: solvent B (0%-15%) in solvent A over 60 min.




Figure B.1. HPLC of crude ODN 3.2, faster gradient. The enlarged version of the
profile shown in trace a in Figure 3.2. Failure sequences were capped with
polymerizable phosphoramidite during synthesis, and thus have longer retention times
than the full-length sequence. ODN 3.2 is 5-TCA TTG CTG CTT AGA CCG CT-3.

Figure B.2. HPLC of pure ODN 3.2, faster gradient. The enlarged version of the
profile shown in trace b in Figure 3.2. The ODN was purified by catching failure
sequences by polymerization.



Figure B.3. HPLC of crude 19-mer ODN 3.3, faster gradient. The 19-mer ODN 3 (5CAT TGC TGC TTA GAC CGC T-3), which is the same as 3.2 except that there is
one less base at the 5-end, was synthesized using the same procedure for 3.2.

Figure B.4. HPLC of pure 19-mer ODN 3.3, faster gradient. The 19-mer ODN 3.3
(5-CAT TGC TGC TTA GAC CGC T-3) was purified using the same procedure for
3.2.
 


Figure B.5. HPLC of ODNs 3.2 and 3.3, faster gradient. ODN 3.2 and 3.3 were coinjected into HPLC. A broadened peak was observed indicating that HPLC can
resolve the 19-mer failure sequence from 20-mer full-length sequence.

Figure B.6. HPLC of pure ODN 3.2, slower gradient

!


Figure B.7. HPLC of pure 19-mer ODN 3.3, slower gradient

Figure B.8. HPLC of ODNs 3.2 and 3.3, slower gradient ODNs 3.2 and 3.3 (~1:1
ratio) were co-injected into HPLC. With slower gradient, the two were better
resolved. Under the same conditions, pure ODN 3.2 does not show a shoulder at the
left side of the peak.
"


Figure B.9. HPLC of 20-mer ODN 3.4 containing 8-oxo-dG treated with ammonia.
The 20-mer ODN (3.4) that contains an 8-oxo-dG [5-TCA TTG CT(8-oxo-dG) CTT
AGA CCG CT-3] was synthesized and purified with reversed-phase HPLC (RSC
Adv. 2014, 4, 8746). The product was heated in concentrated NH4OH at 80 °C for 15
min. After cooling to room temperature, nBuOH was added. The precipitate was
analyzed with HPLC. The fast gradient was used. The multiple peaks in the profile
indicate that the ODN is not stable under such conditions. Because ODN 3.2 was also
processed under the same conditions during purification and only showed a single
peak, we infer that 3.2 does not contain damaged dG. This experiment gives
additional proof that ODN is stable under radical acrylamide polymerization
conditions.




Figure B.10. HPLC of residue from 4th extraction of gel. During purification of ODN
3.2 using the catching by polymerization approach, after extraction of full-length
sequence with water for three times, the gel was extracted for an another time. The 4th
extract was processed using the same nBuOH precipitation procedure and analyzed
with HPLC. No UV active material is detectable indicating that three extractions are
sufficient.




Figure B.11. HPLC of blank control experiment. The catching failure sequences by
polymerization ODN purification procedure was followed except that crude ODN
was not added. After nBuOH precipitation and removal of supernatant, no solid
residue was observable in the tube. The tube was washed with 30 μL water, and 20
μL was injected into HPLC to generate the profile, which showed no UV active
material.
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Figure C.1. Crude RP HPLC profile of the 31-mer ODN 4.9
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Figure C.2. Pure RP HPLC profile of the 31-mer ODN 4.9 purified on a 0.2 jmol
scale
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Figure C.3. Crude RP HPLC profile of 37-mer ODN 4.10
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Figure C.4. Pure RP HPLC profile of 37-mer ODN 4.10 purified on a 1 jmol scale
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Figure C.5. Crude RP HPLC profile of the 61-mer ODN 4.11
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Figure C.6. Pure RP HPLC profile of the 61-mer ODN 4.11 purified on a 0.2 jmol
scale




Figure C.7. The 37-mer ODN 4.10 purified with the catching by polymerization
technology

 


Figure C.8. 1H NMR of compound 4.3
!


Figure C.9. 13C NMR of compound 4.3
"


Figure C.10. 1H NMR of compound 4.4




Figure C.11. 13C NMR of compound 4.4



Figure C.12. 1H NMR of compound 4.5



Figure C.13. 13C NMR of compound 4.5



Figure C.14. 1H NMR of compound 4.6



Figure C.15. 13C NMR of compound 4.6




Figure C.16. 1H NMR of compound 4.7



Figure C.17. 13C NMR of compound 4.7
 


Figure C.18. 1H NMR of compound 4.1
!


Figure C.19. 13C NMR of compound 4.1
"


Figure C.20. 31P NMR of compound 4.1



Figure C.21. 1H NMR of ODN 4.10




Figure C.22. 31P NMR of ODN 4.10



Figure C.23. ESI MS of compound 4.4




Figure C.24. ESI MS of compound 4.5






Figure C.25. ESI MS of compound 4.6






Figure C.26. ESI MS of compound 4.7
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Figure C.27. ESI MS of compound 4.1
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Figure D.1. RP HPLC profile of crude peptide 6.11 (16-amino acid) with side chain
protecting groups and methacrylamide tag on
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Figure D.2. RP HPLC profile of crude peptide 6.11 (16-amino acid) with side chain
protecting groups and methacrylamide tag off

"


Abs (214 nm)

80
60
40
20
0
0

10

20

30

40

50

60

[min.]

Time

Figure D.3. RP HPLC profile of peptide 6.11 (16-amino acid) purified by catching
full-length sequences by polymerization




Figure D.4. ESI MS of compound 6.3




Figure D.5. ESI MS of compound 6.4




Figure D.6. ESI MS of compound 6.1
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Figure D.7. ESI MS of the 6-amino acid peptide 6.5
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Figure D.8. ESI MS of the 16-amino acid peptide 6.11
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Figure D.9. 1H NMR of compound 6.3



Figure D.10. 13C NMR of compound 6.3

 


Figure D.11. 1H NMR of compound 6.4
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Figure D.12. 13C NMR of compound 6.4
"


Figure D.13. 1H NMR of compound 6.1
 


Figure D.14. 13C NMR of compound 6.1
 


Figure D.15. 1H NMR of 6-aa peptide 6.5
 


Figure D.16. 1H NMR of 6-aa peptide 6.11
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